Substituted N-cyanopyrrolidines with activity as USP30 inhibitors

N-cyanopyrrolidines are developed to selectively inhibit USP30, addressing mitochondrial dysfunction and related conditions by enhancing mitophagy, offering therapeutic benefits for diseases like Parkinson's, cancer, and fibrosis.

JP2024544660APending Publication Date: 2024-12-03MISSION THERAPEUTICS LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024532713
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-04-27
Filing Date
2022-11-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a need for safe, alternative, and/or improved methods and compositions for treating or preventing conditions involving mitochondrial dysfunction, cancer, and fibrosis, as existing treatments are limited by toxicity, drug resistance, and lack of specificity in targeting deubiquitinating enzymes like USP30.

Method used

Development of N-cyanopyrrolidines that act as selective inhibitors of the deubiquitinase ubiquitin C-terminal hydrolase 30 (USP30) to upregulate Parkin-induced mitophagy, thereby addressing mitochondrial dysfunction and related conditions.

Benefits of technology

The N-cyanopyrrolidines effectively inhibit USP30, enhancing mitophagy and providing therapeutic benefits for conditions such as Parkinson's disease, cancer, fibrosis, and kidney diseases by improving mitochondrial function and reducing oxidative stress.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544660000001_ABST
    Figure 2024544660000001_ABST
Patent Text Reader

Abstract

The present invention relates to a class of substituted N-cyanopyrrolidines that have activity as inhibitors of the deubiquitinase USP30, which have utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis. JPEG2024544660000133.jpg41128
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a class of N-cyanopyrrolidines that have activity as inhibitors of the deubiquitinating enzyme ubiquitin C-terminal hydrolase 30, also known as ubiquitin-specific peptidase 30 (USP30), their uses, processes for their preparation, and compositions containing the inhibitors. These inhibitors have utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer, and fibrosis.

[0002] All documents cited or relied upon below are expressly incorporated herein by reference. [Background technology]

[0003] Ubiquitin is a small 76-amino acid protein important for regulating protein function in cells. Ubiquitination and deubiquitination are enzymatically mediated processes in which ubiquitin is covalently attached to or cleaved from target proteins by deubiquitinating enzymes (DUBs). In human cells, there are approximately 100 DUBs, classified into subfamilies based on sequence homology. The USP family is characterized by a common Cys and His box, which contains Cys and His residues important for DUB activity. The ubiquitination and deubiquitination processes are involved in regulating many cellular functions, including cell cycle progression, apoptosis, cell surface receptor modification, DNA transcription, and DNA repair. Therefore, the ubiquitin system is involved in the pathogenesis of numerous disease states, including inflammation, viral infection, metabolic dysfunction, CNS disorders, and tumorigenesis.

[0004] Ubiquitin is a key regulator of mitochondrial dynamics. Mitochondria are dynamic organelles whose biogenesis, fusion, and fission events are regulated by post-translational regulation via many key ubiquitination factors, such as mitofusins. In humans, USP30 is a 517-amino acid protein found in the outer mitochondrial membrane (Nakamura et al., 2008, Mol Biol 19:1903-11). It is the only deubiquitinating enzyme with a mitochondrial addressing signal and has been shown to deubiquitinate many mitochondrial proteins. It has been demonstrated that USP30 counteracts Parkin-mediated mitophagy and that reducing USP30 activity can rescue Parkin-mediated defects in mitophagy (Bingol et al., 2015, Nature 510:370-5; Gersch et al., 2017, Nat Struct Mol Biol 24(11):920-930; Cunningham et al., 2015, Nat Cell Biol 17(2):160-169). Inactivation of USP30 can also increase mitochondrial protein import, potentially via ubiquitination of TOM proteins (Jacoupy et al., 2019, Sci Rep 9(1):11829). A small proportion of USP30 is localized to peroxisomes, which are generated by the fusion of mitochondria with ER vesicles, and USP30 potentially antagonizes the Pex2 / pexophagy pathway (Riccio et al., 2019, J Cell Biol 218(3):798-807). The E3 Ub ligase March5 and the deubiquitinating enzyme USP30 associate with translocase and regulate mitochondrial import; March5 opposes mitochondrial import and directs substrate degradation, while USP30 deubiquitinates substrates to promote their import (Phu et al., 2020, Molecular Cell 77, 1107-1123).

[0005] Mitochondrial dysfunction can be defined as a decrease in mitochondrial content (mitophagy or mitochondrial biogenesis), a decrease in mitochondrial activity and oxidative phosphorylation, and also as a regulation of reactive oxygen species (ROS) production. Thus, mitochondrial dysfunction is thought to play a role in numerous aging processes and pathologies.

[0006] For example, Parkinson's disease, which affects approximately 10 million people worldwide (Parkinson's Disease Foundation), is characterized by the loss of dopaminergic neurons in the substantia nigra. While the exact mechanisms underlying PD are unknown, mitochondrial dysfunction is increasingly recognized as a key determinant of dopaminergic neuron susceptibility in PD, characterizing both familial and sporadic forms of the disease, as well as toxin-induced parkinsonism. Parkin is one of many proteins implicated in early-onset PD. While most PD cases are associated with alpha-synuclein deficiency, 10% of Parkinson's disease cases are associated with specific genetic defects, one of which is in the ubiquitin E3 ligase parkin. Parkin and the protein kinase PTEN-induced putative kinase 1 (PINK1) cooperate to ubiquitinate mitochondrial membrane proteins in damaged mitochondria, leading to mitophagy. Dysregulation of mitophagy increases oxidative stress, which has been described as a hallmark of PD. Therefore, inhibition of USP30 may be a potential strategy for the treatment of PD. For example, PD patients with parkin mutations that result in reduced activity may be therapeutically compensated for by inhibiting USP30.

[0007] It has been reported that USP30 depletion enhances mitophagy clearance of mitochondria and Parkin-induced cell death. USP30 has also been shown to regulate BAX / BAK-dependent apoptosis independently of Parkin overexpression. USP30 depletion sensitizes cancer cells to BH-3 mimetics, such as ABT-737, without requiring Parkin overexpression. Thus, an anti-apoptotic role has been demonstrated for USP30, making it a potential target for anticancer therapy.

[0008] The ubiquitin-proteasome system has attracted interest as a target for cancer therapy following the approval of the proteasome inhibitor bortezomib (Velcade®) for the treatment of multiple myeloma. Long-term treatment with bortezomib is limited by associated toxicity and drug resistance. However, therapeutic strategies targeting specific aspects of the ubiquitin-proteasome pathway upstream of the proteasome, such as DUBs, are predicted to be better tolerated (Bedford et al., 2011, Nature Rev 10:29-46).

[0009] Fibrotic diseases, including renal, hepatic, and pulmonary fibrosis, are major causes of morbidity and mortality and can affect all tissues and organ systems. Fibrosis is thought to be the result of acute or chronic stress on a tissue or organ and is characterized by extracellular matrix deposition, decreased vascular / tubular / ductal / airway patency, and dysfunction that ultimately leads to organ failure. While many fibrotic conditions are precipitated by lifestyle or environmental factors, some fibrotic conditions may be initiated by genetic triggers or are actually considered idiopathic (i.e., lacking a known cause). Certain fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), can be treated with nonspecific kinase inhibitors (nintedanib) or drugs without a well-characterized mechanism of action (pirfenidone). Other treatments for organ fibrosis, such as renal or hepatic fibrosis, relieve pressure on the organ itself (e.g., beta-blockers for cirrhosis, angiotensin receptor blockers for chronic kidney disease). Attention to lifestyle factors, such as glucose and dietary management, can also influence the course and severity of the disease.

[0010] Mitochondrial dysfunction is implicated in numerous fibrotic diseases, and oxidative stress downstream of the dysfunction, along with reduced ATP production, is a key pathogenic mediator. In preclinical models, disruption of the mitophagy pathway (by mutation or knockout of either Parkin or PINK1) exacerbates pulmonary and renal fibrosis, with evidence of increased oxidative stress.

[0011] Kurita et al., 2017, Respiratory Research 18:114, disclosed that the accumulation of profibrotic myofibroblasts is a key process for fibrotic remodeling in IPF. Recent findings have implicated autophagy / mitophagy, part of the lysosomal degradation mechanism, in the pathogenesis of IPF, and have suggested that mitophagy is involved in myofibroblast differentiation through the regulation of mitochondrial reactive oxygen species (ROS)-mediated platelet-derived growth factor receptor (PDGFR) activation. Kurita's results suggest that pirfenidone induces PARK 2-mediated mitophagy and also inhibits the development of pulmonary fibrosis in conditions of insufficient mitophagy, which may at least partially explain its antifibrotic mechanism for the treatment of IPF.

[0012] Williams et al., 2015, Pharmacol Res. December; 102:264-269, discussed the role of PINK1-Parkin-mediated autophagy in protecting against alcohol- and acetaminophen-induced liver injury by removing damaged mitochondria via mitophagy. It was suggested that pharmacological stabilization of USP8 or inactivation of USP15 and USP30 may be potential therapeutic targets for upregulating Parkin-induced mitophagy, which could then prevent drug-induced liver injury. However, it was noted that DUBs are regulated both transcriptionally and post-translationally, which can make drug development challenging for targeting these specific enzymes. Furthermore, phosphorylated ubiquitin has been shown to be resistant to DUBs. The authors concluded that stabilizing PINK1 or upregulating its kinase activity may be a more effective target than inhibiting DUBs.

[0013] Williams et al, 2015, Biomolecules 5, 2619-2642 and Williams et al, 2015, Am J Physiol Gastrointest Liver Physiol 309:G324 G340 review the mechanisms involved in regulating mitochondrial homeostasis in the liver and how these mechanisms may prevent alcohol-induced liver disease.

[0014] Luciani et al., 2020, Nat. Commun. 11, 970, reported that deregulation of the mitochondrial network in terminally differentiated cells contributes to a wide range of disorders, including methylmalonic acidemia (MMA). MMA is one of the most common inherited metabolic disorders caused by deficiency of mitochondrial methylmalonyl coenzyme A mutase (MMUT). MMUT deficiency induces metabolic and mitochondrial changes that are exacerbated by abnormalities in PINK1 / Parkin-mediated mitophagy, leading to the accumulation of dysfunctional mitochondria that induce epithelial stress and ultimately cellular damage. A link between primary MMUT deficiency, affected mitochondria, mitophagy dysfunction, and epithelial stress has been suggested, providing potential therapeutic perspectives for MMA.

[0015] Kluge et al., Bioorganic & Medicinal Chemistry Letters, 2018, 28 2655-2659, reported that selective inhibitors of USP30 accelerate mitophagy.

[0016] A series of N-cyano substituted heterocyclic derivatives have been disclosed as deubiquitinase inhibitors in WO 2016 / 046530 (US15 / 513125, US15 / 894025, US16 / 448066), WO 2016 / 156816 (US15 / 558632, US16 / 297937, US16 / 419558, US16 / 419747, US16 / 788446), WO 2017 / 009650 (US15 / 738900), WO 2018 / 0100906 (US15 / 0100906), WO 2018 / 0100908 (US15 / 0100908), WO 2018 / 0100909 (US15 / 0100908), WO 2018 / 0100909 (US15 / 0100909), WO 2018 / 0100910 (US15 / 0100910), WO 2018 / 0100920 (US15 / 0100920), WO 2018 / 0100930 (US15 / 0100930), WO 2018 / 0100940 (US15 / 01009400), WO 2018 / 0100950 (US15 / 0100950), WO 2018 / 0100960 (US15 / 0100960), WO 2018 / 01009700 (US15 / 01009700), WO 2018 / 010098 (US15 / 010098), WO 20 International Publication No. 2017 / 093718 (US15 / 776149), International Publication No. 2017 / 103614 (US15 / 781615), International Publication No. 2017 / 149313 (US16 / 078518), International Publication No. 2017 / 109488 (US16 / 060299), International Publication No. 2017 / 141036 (US16 / 070936), International Publication No. 2017 / 163078 (US16 / 087515), International Publication No. 2017 / 158381 (US 16 / 080229), International Publication No. 2017 / 158388 (US16 / 080506), International Publication No. 2018 / 065768 (US16 / 336685), International Publication No. 2018 / 060742 (US16 / 336202), International Publication No. 2018 / 060689 (US16 / 334836), International Publication No. 2018 / 060691 (US16 / 336363), International Publication No. 2018 / 220355 (US16 / 615040), International Publication No. and WO 2022 / 084479, each of which is expressly incorporated herein by reference. WO 2019 / 171042 (US 16 / 977019), which is expressly incorporated herein by reference, discloses the use of N-cyanopyrrolidines as inhibitors of USP30 for the treatment of fibrotic diseases.

[0017] Falgueyret et al., 2001, J. Med. Chem. 44, 94-104 and WO 01 / 77073 refer to cyanopyrrolidines as inhibitors of cathepsins K and L, which have potential utility in the treatment of osteoporosis and other bone resorption-related conditions. WO 2015 / 179190 refers to N-acylethanolamine-hydrolyzing acid amidase inhibitors, which have potential utility in the treatment of ulcerative colitis and Crohn's disease. WO 2013 / 030218 refers to quinazolin-4-one compounds as inhibitors of ubiquitin-specific proteases, such as USP7, which have potential utility in the treatment of cancer, neurodegenerative diseases, inflammatory disorders, and viral infections. WO 2015 / 017502 and WO 2016 / 019237 refer to inhibitors of Bruton's tyrosine kinase, which have potential utility in the treatment of diseases such as autoimmune diseases, inflammatory diseases, and cancer. WO 2009 / 026197, WO 2009 / 129365, WO 2009 / 129370, and WO 2009 / 129371 refer to cyanopyrrolidines as inhibitors of cathepsin C, which have potential utility in the treatment of COPD. U.S. Patent Application Publication No. 2008 / 0300268 refers to polyaromatic compounds as inhibitors of the tyrosine kinase receptor PDGFR. WO 2019 / 222468, WO 2019 / 071073, WO 2020 / 036940, and WO 2020 / 072964, Rusilowicz-Jones et al., 2020, bioRxiv 2020.04.16.044206 (20 April 2020), and Tsefou et al., bioRxiv 2021.02.02.429344 (2 February 2021) mention cyanamide-containing compounds as USP30 inhibitors. Yue et al., 2014, Cell Research, 24, 482-496 mention the diterpenoid derivative 15-oxospiramilactone as a USP30 inhibitor that induced mitochondrial fusion.

[0018] WO 2015 / 183987 refers to a pharmaceutical composition comprising a deubiquitinase inhibitor and human serum albumin in a method for treating cancer, fibrosis, an autoimmune disease or condition, an inflammatory disease or condition, a neurodegenerative disease or condition, or an infectious disease. It is noted that deubiquitinases, including UCHL5 / UCH37, USP4, USP9X, USP11, and USP15, are said to be involved in regulating the TGF-β signaling pathway, the disruption of which leads to neurodegenerative and fibrotic diseases, autoimmune dysfunction, and cancer.

[0019] International Publication No. WO 2006 / 067165 refers to a method for treating fibrotic diseases using indolinone kinase inhibitors. International Publication No. WO 2007 / 119214 refers to a method for treating early pulmonary fibrosis using endothelin receptor antagonists. International Publication No. WO 2012 / 170290 refers to a method for treating fibrotic diseases using THC acid. International Publication No. WO 2018 / 213150 refers to sulfonamide USP30 inhibitors with potential utility in treating conditions involving mitochondrial defects. Larson-Casey et al., 2016, Immunity 44, 582-596, relates to macrophage Akt1 kinase-mediated mitophagy, apoptosis resistance, and pulmonary fibrosis. Tang et al., 2015, Kidney Diseases 1, 71-79, reviews the potential role of mitophagy in renal pathophysiology.

[0020] There is a need for safe, alternative, and / or improved methods and compositions for treating or preventing conditions involving mitochondrial dysfunction, cancer, and fibrosis, as well as various symptoms and conditions associated therewith.Without being bound by any particular theory or mechanism, it is believed that the compounds of the present invention act to inhibit the enzyme USP30, thereby upregulating parkin-induced mitophagy.

[0021] Acute kidney injury (AKI) is defined as a sudden decline in kidney function occurring within 7 days. The severity of the injury is graded based on an increase in serum creatinine (SCr) and a decrease in urine output, as described in the Kidney Disease Improving Global Outcomes (KDIGO) guidelines. AKI occurs in approximately 13.3 million people annually, 85% of whom live in developing countries, and is thought to contribute to approximately 1.7 million deaths annually (Mehta et al., 2015, Lancet 385(9987):2616-2643). AKI increases the likelihood of developing permanent kidney damage (i.e., chronic kidney disease; CKD) and can lead to non-renal organ damage. AKI is a significant public health concern, especially considering the sheer number of patients who develop incident CKD, progressive CKD, end-stage renal disease, and cardiovascular events. AKI has been found to be prevalent in patients hospitalized with COVID-19 and is strongly associated with in-hospital mortality, with mitochondrial damage and dysfunction reported as a potential pathophysiological mechanism and therapeutic target (Kellum et al., Nephrol Dial Transplant (2020) 35:1652-1662).

[0022] AKI and CKD are considered to be on the same disease spectrum and continuum (Chawla et al., 2017, Nat Rev Nephrol 13(4):241-257). Patients undergoing coronary artery bypass grafting (CABG) are at high risk for kidney damage. There is a clear unmet medical need in the development of pharmaceuticals for the treatment and / or prevention of AKI.

[0023] The kidney is a site of high metabolic demand, and high mitophagy rates have been demonstrated in vivo (McWilliams et al., 2018, Cell Metab 27(2):439-449 e435). Renal proximal tubular epithelial cells (RPTECs), a cell type that requires significant ATP for solute / ion exchange, are rich in mitochondria and are the primary effector cells of acute kidney injury (AKI). Mitochondrial dysfunction has been implicated in the AKI / CKD mechanism, with multiple lines of evidence from preclinical AKI and CKD models and data demonstrating abnormal mitochondrial phenotypes in patient biopsies (Emma et al., 2016, Nat Rev Nephrol 12(5):267-280; Eirin et al., 2017, Handb Exp Pharmacol 240:229-250). Furthermore, primary mitochondrial diseases often manifest as renal manifestations such as focal glomerulosclerosis in patients with MELAS / MIDD (Kawakami et al., 2015, J Am Soc Nephrol 26(5):1040-1052) and primary tubular lesions in patients with coenzyme Q deficiency. Mutations in mtDNA can cause maternally inherited tubulointerstitial disease (Connor et al., 2017, PLoS Genet 13(3):e1006620).

[0024] Regarding mitochondrial quality control in renal injury (Tang et al., 2018, Autophagy 14(5):880-897), it was demonstrated that renal injury was exacerbated after ischemic AKI in both PINK1 KO and PARK2 KO mice, suggesting that PINK1 / Parkin-mediated mitophagy plays a protective role after renal IRI. Furthermore, Parkin / PINK1 mitophagy prevents cisplatin-induced renal injury (Wang et al., 2018, Cell Death Dis 9(11):1113). While limited models of CKD are available for investigating mitophagy, supporting evidence for mitochondrial quality control in fibrosis comes from studies on fibrotic lung conditions such as COPD and IPF. Parkin knockout animals exhibit exacerbated pulmonary fibrosis in response to bleomycin (Kobayashi et al., 2016, J Immunol, 197:504-516). Similarly, airway epithelial cells from parkin knockout (KO) animals exhibit exacerbated fibrotic and senescent responses to cigarette smoke (Araya et al., 2019, Autophagy 15(3):510-526).

[0025] Preclinical models can be used to study potential novel therapeutic agents through their ability to model fibrosis pathology (e.g., collagen deposition) consistent with the human condition. Preclinical models can be toxin-mediated (e.g., bleomycin for lung and skin fibrosis), surgical (e.g., ischemia / reperfusion injury and unilateral ureteral obstruction models for acute tubulointerstitial fibrosis), and genetic (e.g., diabetic (db / db) mice for diabetic nephropathy). For example, both examples given previously for indicated IPF treatments (nintedanib and pirfenidone) show efficacy in the bleomycin lung fibrosis model.

[0026] Leigh syndrome is a rare inherited neurometabolic disorder affecting the central nervous system. This progressive disorder begins in infants between 3 months and 2 years of age. Rarely, it occurs in people aged 13 to 19 years and in adults. Leigh syndrome can be caused by mutations in nuclear DNA encoding mitochondrial proteins, mutations in mitochondrial DNA (maternally inherited Leigh syndrome - MILS), or a deficiency of an enzyme called pyruvate dehydrogenase, located on the short arm of the X chromosome (X-linked Leigh syndrome). Symptoms of Leigh syndrome usually progress rapidly. The earliest signs may be poor suckling and loss of head control and motor skills. These symptoms may be accompanied by anorexia, vomiting, irritability, persistent crying, and seizures. As the disorder progresses, symptoms may also include generalized weakness, lack of muscle tone, and the development of lactic acidosis, which can lead to impaired respiratory and renal function.

[0027] In maternally inherited Leigh syndrome (MILS), genetic mutations in mitochondrial DNA (high prevalence >90%) disrupt the energy source that powers cells in areas of the brain that play a role in motor movement. Genetic mutations in mitochondrial DNA lead to a chronic lack of energy in these cells, which then affects the central nervous system and causes progressive degeneration of motor function. When genetic mutations in mitochondrial DNA that cause MILS are less prevalent (less than 90%), the condition is known as neuropathic ataxia and retinitis pigmentosa (NARP). There is also a form of Leigh disease (called X-linked Leigh disease) that results from mutations in genes that produce another group of substances important for cellular metabolism. There is an additional variant of Leigh syndrome, called the French-Canadian variant, characterized by mutations in a gene called LRPPRC. Similar neurological symptoms are manifested as those of Leigh syndrome, but fatty liver is also commonly observed in the French-Canadian variant.

[0028] Muscular dystrophies are characterized by specific abnormalities in muscle biopsies from patients (e.g., variations in muscle fiber size, muscle fiber necrosis, scar tissue formation, and inflammation). Approximately 30 different genetic conditions constitute muscular dystrophies. Duchenne muscular dystrophy (DMD) is classified as a dystrophinopathy, one of a range of muscle diseases, each caused by alterations in the dystrophin gene. Clinical features of DMD include weakness and wasting of various voluntary muscles in the body. In the most advanced stages of the disease, cardiac and intestinal muscles are affected, and cardiomyopathy and subsequent heart failure are the main causes of death.

[0029] Reid, et al., "The Interplay of Mitophagy and Inflammation in Duchenne Muscular Dystrophy." Life 2021, 11, 648, reported that mitochondrial dysfunction is one of the first features visible in dystrophic muscle before overt muscle breakdown, suggesting that mitochondrial dysfunction may significantly contribute to the pathology of this disease rather than being a later consequence of muscle necrosis. In healthy tissue, these damaged mitochondria are marked by mitophagy, but mitophagy has been shown to be significantly impaired in DMD.

[0030] Vila et al., Cell Death and Differentiation (2017) 24, 330-342, revealed that active mitochondria are required for repair of sarcolemma damage in healthy muscle fibers, and that proteins promoting mitochondrial function, calcium homeostasis, and sarcolemma stability are significantly altered during disease onset in dystrophin-deficient mdx mice. They hypothesized that increased calcium overload in dystrophic muscle fibers and mitochondria causes mitochondrial dysfunction, which in turn reduces the repair capacity of dystrophic muscle fibers and leads to their death. Therefore, enhancing autophagy may help remove these mitochondria.

[0031] Luan et al., Science Translational Medicine (2021) 13, 1-12, demonstrated that animal DMD models and DMD patient tissues contain reduced expression of genes involved in mitophagy, which contributes to mitochondrial dysfunction. Administration of urolithin A, a natural compound that can stimulate mitophagy, increased muscle metabolism and stem cell regenerative capacity, leading to recovery of muscle function in an mdx mouse model of DMD. Urolithin A also reduced CD45-positive inflammatory cells in TA muscle, suggesting a potential anti-inflammatory mechanism may contribute to the benefits in the mdx mouse model.

[0032] Thus, there is a need for compounds that are inhibitors of USP30 for treating or preventing conditions where inhibition of USP30 is indicated. In particular, there is a need for USP30 inhibitors with suitable and / or improved properties to maximize efficacy against target diseases. Summary of the Invention

[0033] The present invention provides compounds of formula (I): [ka] a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein (a)X 1 is N; X 2 , X 3 and X 4 is CR 6 is; or (b)X 1 is N; X 2 , X 3 and X 4 One of them is N; X 2 , X 3 and X 4 Two of them are CR 6 is; or (c)X 1 and X 4 is CR6 and; X 2 and X 3 is N; or Ring A is (i) a 5-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N and O; (ii) a 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N, O, and S; (iii) a 4- to 6-membered saturated or partially saturated monocyclic heterocyclyl ring containing 1 to 3 heteroatoms each independently selected from N, O, and S; and (iv) selected from phenyl or naphthyl; Ring A is unsubstituted or contains one or two R 7 is substituted by a substituent; Ring B is (i) phenyl or naphthyl; (ii) a 5- to 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N, O, and S; and (iii) a 9- to 10-membered bicyclic heteroaryl ring containing 1 to 4 heteroatoms each independently selected from N, O, and S; Ring B is unsubstituted or each independently represents halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6)cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, piperidinyl, NH(C1-C6)alkyl, N((C1-C6) substituted by 1 to 5 substituents selected from: C(O)NH(C1-C6)alkyl, C(O)N((C1-C6)alkyl), NHC(O)(C1-C6)alkyl, N(C1-C6)alkyl)C(O)(C1-C6)alkyl), C(O)(C1-C6)alkyl, C(O)O(C1-C6)alkyl, CO2H, CONH2, SON2NH(C1-C6)alkyl and SON((C1-C6)alkyl); R 1 is selected from hydrogen, (C1-C6) alkyl, and (C3-C6) cycloalkyl; R 2 and R 3 are each independently selected from hydrogen, halo, (C1-C4) alkyl, and (C1-C4) alkoxy; R 4 and R 5 are each independently selected from hydrogen and (C1-C4) alkyl; R 6 is hydrogen or (C1-C4) alkyl; Each R 7 are independently selected from halo, (C1-C6) alkyl, and (C1-C6) alkoxy; provided that ring A is unsubstituted oxazolyl or oxadiazolyl, ring B is phenyl, and R 1 , R 2 , R 3 , R 4 and R 5 are each hydrogen, and X 1 , X 2 , X 3 and X 4When two of are N, ring B is not substituted with CF3 in the meta position relative to ring A. The present invention relates to a compound, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.

[0034] The present invention also relates to the use of compounds of formula (I), especially in the treatment of conditions involving mitochondrial dysfunction, cancer and fibrosis, as well as processes for their preparation and pharmaceutical compositions containing said compounds. DETAILED DESCRIPTION OF THE INVENTION

[0035] The present invention relates to USP30 inhibitors with suitable and / or improved properties for maximizing efficacy against target diseases, such as potency, selectivity, physicochemical properties, ADME (absorption, distribution, metabolism and excretion) properties including PK (pharmacokinetic) profiles, and safety profiles.

[0036] Generally, it is desirable to maximize the potency of a drug molecule against a target enzyme in a relevant assay in order to reduce the effective / effective dose administered to a patient. Compounds of the present invention can be tested for USP30 affinity using the in vitro biochemical fluorescence polarization (FP) assay described herein.

[0037] USP30 is a transmembrane protein located in the outer membrane of mitochondria, an energy-producing organelle present in cells. Therefore, being able to demonstrate cellular activity in vitro is advantageous because it is one of many components that may exhibit greater target binding ability in its physiological context, i.e., when USP30 inhibitor compounds can penetrate cells. The USP30 cellular Western blot (WB) assay aims to test the activity of compounds against USP30 in cells using an irreversible activity probe to monitor USP30 activity. Similar to the cellular Western blot assay, target binding assessment (ex vivo) may be performed on either brain or kidney tissue samples from animals administered the compound.

[0038] To extend knowledge of target binding to downstream pharmacodynamics, assessment of TOM20 (mitochondrial outer membrane protein) ubiquitination may be performed.

[0039] In general, it is important that a drug be as selective as possible for its desired target enzyme, as additional activity may result in potential side effects. The precise physiological roles of many DUBs have yet to be fully determined, but regardless of what role these DUBs may play, ensuring that any drug has selectivity for a relevant mechanistic target of unknown physiological function is a principle of sound medicinal chemistry. Representative examples of DUB enzymes for which the compounds of the present invention may be screened include UCHL1, UCHL3, UCHL5, YOD1, SENP2, SENP6, TRABID, BAP1, Cezanne, MINDY2 / FAM63B, OTUD1, OTUD3, OTUD5, OTUD6A, OTUD6B, OTUB1 / UBCH5B, OTUB2, CYLD, VCPIP, AMSH-LP, JOSD1, JOSD2, USP1 / UAF1, USP2, USP4, USP5, USP6, USP7, USP8, USP9x, USP10, USP11, USP12 / UAF1, USP13, USP14, USP15, USP16, USP19, USP20, USP21, USP22, USP24, USP25, USP28, USP32, USP34, USP35, USP36, USP45, USP46 / UAF1, USP47 and USP48. Preferably, the compounds of the invention have better selectivity for USP30 over one or more of these DUB enzymes.

[0040] Apart from selectivity for other DUB enzymes, it is important that the drug has low affinity for other targets, and pharmacological profiling can be performed on a panel of targets to evaluate and minimize potential off-target effects. Examples of targets for which the compounds of the present invention can be screened are those in the industry-standard Eurofins-Cerep SafetyScreen 44 panel, which includes 44 targets as a representative selection of GPCR receptors, transporters, ion channels, nuclear receptors, and kinase and non-kinase enzymes. Preferably, compounds of the present invention have insignificant affinity for the targets in this screening panel. Another example of targets for which the compounds of the present invention can be screened is the kinases in the Thermo Fisher SelectScreen Kinase Profiling Panel, which includes 39 targets as a representative selection of kinase enzymes. Preferably, compounds of the present invention have insignificant affinity for the targets in this screening panel. Furthermore, an example of a specific enzyme class for which the compounds of the present invention can be screened is cathepsins (e.g., cathepsins A, B, C, H, K, L, S, V, and Z). Preferably, the compounds of the present invention have good selectivity for USP30 over one or more of these enzymes.

[0041] There is also a need for compounds with favorable pharmacokinetic properties that make them suitable for oral administration. Orally administered drugs should have good bioavailability, i.e., the ability to easily pass through the gastrointestinal (GI) tract and not undergo extensive metabolism when entering the systemic circulation from the GI tract. Once a drug enters the systemic circulation, the rate of metabolism is also important in determining the residence time of the drug in the body.

[0042] Therefore, it is clearly preferable that a drug molecule has the properties of being able to easily pass through the GI tract and being slowly metabolized in the body. The Caco-2 assay is a widely accepted model for predicting the ability of a given molecule to pass through the GI tract. The majority of the metabolism of drug molecules generally occurs in the liver, and in vitro assays using whole cell hepatocytes (animal or human) are widely accepted methods for measuring the susceptibility of a given molecule to metabolism in the liver. Such assays aim to predict in vivo clearance from calculated hepatocyte clearance.

[0043] Compounds that have good Caco-2 fluidity and are stable to hepatocytes are predicted to have good oral bioavailability (good absorption across the GI tract and minimal extraction of the compound as it passes through the liver) and a long enough residence time in the body for the drug to be effective.

[0044] The solubility of a compound is an important factor in achieving the desired drug concentration in the systemic circulation for the expected pharmacological response.Low water solubility is a problem encountered in the formulation development of new chemical substances, and in order to be absorbed, the drug must be present in the form of a solution at the absorption site.The kinetic solubility of a compound can be measured using turbidimetric solubility assays, and this data can also be used in conjunction with Caco-2 permeability data to predict dose-dependent human intestinal absorption.

[0045] Other parameters that can be measured using standard assays that indicate the exposure profile of a compound include, for example, plasma stability (half-life measurements), blood AUC, C max , C min and T max Values ​​include:

[0046] The treatment of CNS disorders, including Alzheimer's disease, Parkinson's disease, and other disorders described herein, requires drug molecules to target the brain, which requires sufficient penetration of the blood-brain barrier. Therefore, there is a need for USP30 inhibitors that have effective blood-brain penetration properties and provide a suitable residence time in the brain to be effective. The probability that a compound can cross the blood-brain barrier can be measured by an in vitro flux assay using MDR1-MDCK cell monolayers (Madin-Darby canine kidney cells transfected with MDR-1, which results in overexpression of the human efflux transporter P-glycoprotein). Furthermore, exposure can also be measured directly in the brain and plasma using in vivo animal models.

[0047] There is also a need for compounds with favorable safety profiles that can be measured by a variety of standard in vitro and in vivo methods. A cytotoxicity counterscreen can be used to assay antiproliferative / cytotoxic effects in specific cell lines (e.g., HCT116) by fluorescent detection of resofurin alamarBlue™ against resofurin in response to mitochondrial activity.

[0048] Toxicology and safety studies may also be conducted to identify potential target organs of adverse effects and to define the therapeutic index for setting an initial starting dose in clinical trials. Regulatory requirements generally require studies to be conducted in at least two experimental animal species, one rodent (rat or mouse) and one non-rodent (rabbit, dog, non-human primate, or other suitable species).

[0049] A bacterial reverse mutation assay (Ames test) may be used to assess the mutagenic properties of compounds of the present invention, commonly using the bacterial strain Salmonella typhimurium, which is mutant in the biosynthesis of the amino acid histidine.

[0050] The micronucleus assay may be used to determine whether a compound is genotoxic by assessing the presence or absence of micronuclei, which may contain chromosome fragments produced from DNA breaks (clastogens) or whole chromosomes produced by disruption of the mitotic apparatus (aneuploidogens).

[0051] The hERG predictive assay provides useful information about the test compound's potential binding to potassium channels and potential QT prolongation on echocardiograms. Inhibition of hERG current causes QT interval prolongation, resulting in potentially fatal ventricular tachyarrhythmias (Torsades de Pointes). Typically, assay data can be generated from an automated patch clamp assay platform.

[0052] According to a first aspect, the present invention provides a compound of formula (I): [ka] a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein (a)X 1 is N; X 2 , X 3 and X 4 is CR 6 is; or (b)X 1 is N; X 2 , X 3 and X 4 One of them is N; X 2 , X 3 and X 4 Two of them are CR 6 is; or (c)X 1 and X 4 is CR 6 and; X 2 and X 3 is N; or Ring A is (i) a 5-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N and O; (ii) a 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N, O, and S; (iii) a 4- to 6-membered saturated or partially saturated monocyclic heterocyclyl ring containing 1 to 3 heteroatoms each independently selected from N, O, and S; and (iv) selected from phenyl or naphthyl; Ring A is unsubstituted or contains one or two R 7 is substituted by a substituent; Ring B is (i) phenyl or naphthyl; (ii) a 5- to 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N, O, and S; and (iii) a 9- to 10-membered bicyclic heteroaryl ring containing 1 to 4 heteroatoms each independently selected from N, O, and S; Ring B is unsubstituted or independently selected from halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6)cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, piperidinyl, NH(C1-C6)alkyl, N((C1-C6)alkyl) 2, substituted by 1 to 5 substituents selected from C(O)NH(C1-C6)alkyl, C(O)N((C1-C6)alkyl)2, NHC(O)(C1-C6)alkyl, N(C1-C6)alkyl)C(O)(C1-C6)alkyl), C(O)(C1-C6)alkyl, C(O)O(C1-C6)alkyl, CO2H, CONH2, SON2NH(C1-C6)alkyl and SON((C1-C6)alkyl)2; R 1 is selected from hydrogen, (C1-C6) alkyl, and (C3-C6) cycloalkyl; R 2 and R3 are each independently selected from hydrogen, halo, (C1-C4) alkyl, and (C1-C4) alkoxy; R 4 and R 5 are each independently selected from hydrogen and (C1-C4) alkyl; R 6 is hydrogen or (C1-C4) alkyl; Each R 7 are independently selected from halo, (C1-C6) alkyl, and (C1-C6) alkoxy; provided that ring A is unsubstituted oxazolyl or oxadiazolyl, ring B is phenyl, and R 1 , R 2 , R 3 , R 4 and R 5 are each hydrogen, and X 1 , X 2 , X 3 and X 4 When two of are N, ring B is not substituted with CF3 in the meta position relative to ring A. Provided are compounds, tautomers thereof, or pharmaceutically acceptable salts of the compounds or tautomers.

[0053] The disclaimer relates to WO 2021 / 239863, which includes Example 4, an N-cyanopyrrolidine substituted with CH2-triazolyl.

[0054] Unless otherwise specified, alkyl and alkoxy groups may be straight or branched and contain 1 to 6 carbon atoms, more typically 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, pentyl, and hexyl. Examples of alkoxy include methoxy, ethoxy, n-propoxy, isobutoxy, and n-butoxy. Examples of alkoxyalkyl include methoxymethyl, methoxyethoxy, and ethoxymethoxy.

[0055] Unless otherwise specified, cycloalkyl and cycloalkoxy (O-cycloalkyl) groups contain 3 to 6 carbon atoms, more typically 3 to 4 carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of cycloalkoxy include cyclopropoxy and cyclobutoxy.

[0056] Halo means fluoro, chloro, bromo or iodo, especially fluoro or chloro. Haloalkyl and haloalkoxy groups may contain one or more halo substituents. Examples are fluoromethyl, difluoromethyl, trifluoromethyl and trifluoromethoxy.

[0057] Heterocyclyl rings may be either saturated or partially saturated and contain 1 to 4 heteroatoms, preferably 1, 2, or 3, each independently selected from nitrogen, oxygen, and sulfur, and may be monocyclic or fused bicyclic rings. Examples of heterocyclyl groups include azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, pyrrolinyl, dihydrofuranyl, dihydrothiophenyl, dihydrooxazolyl, thiazolinyl, dioxolanyl, oxathiolanyl, dithiolanyl, imidazolidinyl, imidazolinyl, pyrazolinyl, thiazolidinyl, pyranyl, piperidinyl, dioxanyl, morpholino, dithianyl, thiomorpholino, piperazinyl, and tetrahydropyrazolopyrazinyl.

[0058] Heteroaryl rings may be monocyclic or bicyclic and may contain 1 to 4 heteroatoms, preferably 1, 2, or 3 heteroatoms, each independently selected from nitrogen, oxygen, and sulfur, except that for Ring A, each heteroatom is independently selected (singly) from nitrogen and oxygen. Monocyclic heteroaryl rings are aromatic, and bicyclic heteroaryl rings are either fused rings in which both rings are aromatic and one of the rings is aromatic and the other is saturated or partially saturated. Examples of heteroaryl groups include furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl (especially 1,3,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl and 1,2,5-oxadiazolyl), thiazolyl, isothiazolyl, thiadiazolyl (especially 1,3,4-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl and 1,2,5-thiadiazolyl), imidazolyl, pyrazolyl, triazolyl (especially 1,2,3-triazolyl and 1,2,4-triazolyl), tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl (especially 1,2,3-triazinyl and 1,2,4-triazinyl). and 1,3,4-triazinyl), indazolyl, indolyl, indolinyl, indolizinyl, isoindolyl, isoindolinyl, purinyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzotriazolyl, imidazopyridinyl, pyrazolopyridinyl, thiazolopyridinyl, dihydropyrrolopyridinyl, oxazolopyridinyl, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, benzothiazinyl, dihydrobenzoxazinyl, dihydroquinazolinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.

[0059] Unless otherwise specified, the term "substituted" means substituted by one or more defined groups. When groups may be selected from two or more options, the selected groups may be the same or different. The term "independently" means that when two or more substituents are selected from two or more possible substituents, the substituents may be the same or different.

[0060] Preferred aspects and embodiments of compounds of formula (I) are defined below.

[0061] In one preferred embodiment of the present invention, (a), X 1 is N and X 2 , X 3 and X 4 is CR 6 is.

[0062] In another preferred embodiment of the present invention, (b) X 1 is N and X 2 , X 3 and X 4 One of them is N and the other is X 2 , X 3 and X 4 Two of them are CR 6 is.

[0063] In another preferred embodiment of the present invention, (c), X 1 and X 4 is CR 6 and X 2 and X 3 is N.

[0064] In a preferred embodiment of the present invention, ring B is (i) phenyl or naphthyl; (ii) 5- to 6-membered monocyclic heteroaryl rings selected from furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl (especially 1,3,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl and 1,2,5-oxadiazolyl), thiazolyl, isothiazolyl, thiadiazolyl (especially 1,3,4-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl and 1,2,5-thiadiazolyl), imidazolyl, pyrazolyl, triazolyl (especially 1,2,3-triazolyl and 1,2,4-triazolyl), pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl; and (iii) A 9- to 10-membered bicyclic heteroaryl ring selected from indazolyl, indolyl, indolinyl, indolizinyl, isoindolyl, isoindolinyl, purinyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzotriazolyl, imidazopyridinyl, pyrazolopyridinyl, thiazolopyridinyl, dihydropyrrolopyridinyl, oxazolopyridinyl, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, benzothiazinyl, dihydrobenzoxazinyl, dihydroquinazolinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.

[0065] More preferably, Ring B is selected from phenyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indazolyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl and dihydroquinazolinyl.

[0066] Even more preferably, Ring B is selected from phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indazolyl, indolyl and isoindolyl.

[0067] Most preferably, Ring B is selected from phenyl, pyridinyl and indazolyl.

[0068] In a preferred embodiment of the invention, Ring B is either unsubstituted or substituted with 1 to 5 substituents, more preferably 1 to 3 substituents, and most preferably 1 to 2 substituents, each independently selected from halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6)cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, and piperidinyl.

[0069] More preferably, Ring B is either unsubstituted or substituted with 1 to 5 substituents, preferably 1 to 3 substituents, and most preferably 1 to 2 substituents, each independently selected from halo, CN, hydroxy, oxo, (C1-C3)alkyl, (C1-C3)alkoxy, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, (C3-C4)cycloalkyl, O(C3-C4 cycloalkyl, (C1-C3)alkoxy(C1-C3)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, and piperidinyl.

[0070] Even more preferably, Ring B is either unsubstituted or substituted with 1 to 5 substituents, preferably 1 to 3 substituents, and most preferably 1 to 2 substituents, each independently selected from halo, CN, (C1-C3)alkyl, (C1-C3)alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3, and oxetanyloxy.

[0071] Even more preferably, Ring B is either unsubstituted or substituted with 1 to 5 substituents, preferably 1 to 3 substituents, and most preferably 1 to 2 substituents, each independently selected from chloro, fluoro, CN, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclopropoxy, CF3, OCF3, and oxetan-3-yloxy.

[0072] Most preferably, Ring B is either unsubstituted or substituted with 1 to 5 substituents, preferably 1 to 3 substituents, most preferably 1 to 2 substituents, each independently selected from chloro, fluoro, CN, methyl, ethyl, methoxy, cyclopropyl, cyclopropoxy, CF3, OCF3, and oxetan-3-yloxy.

[0073] In one preferred embodiment, the present invention provides a compound of formula (I) having the formula (I)(A): [ka] a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein Z is N or CR 11 and; R 8 , R 11 and R 12 are each independently selected from hydrogen, halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6 cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, and piperidinyl; R 9 and R 10are each independently selected from hydrogen, halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, O(C3-C6 cycloalkyl, (C1-C6)alkoxy(C1-C6)alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, and piperidinyl; or R 9 and R 10 are joined to form a 5-6 membered saturated, partially saturated or aromatic ring containing 1-2 heteroatoms each independently selected from N, O and S, which ring is either unsubstituted or substituted with 1-2 substituents each independently selected from halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl and halo(C1-C6)alkoxy; provided that ring A is unsubstituted oxazolyl or oxadiazolyl, and R 1 , R 2 , R 3 , R 4 and R 5 are each hydrogen, and X 1 , X 2 , X 3 and X 4 Two of them are N and Z is CR 11 and R 11 is hydrogen or halo, R 9 is not CF3, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.

[0074] In one embodiment, Z is CR 11 which is a compound of formula (I) having the formula (I)(B): [ka] The present invention provides a compound having a tautomer thereof, or a pharmaceutically acceptable salt of the compound or tautomer, wherein ring B is phenyl or a 9-10 membered bicyclic heteroaryl ring (R 9 and R 10together form a heterocyclyl or heteroaryl ring).

[0075] In another embodiment, Z is N, which is a compound of formula (I) having the formula (I)(C): [ka] Provided are tautomers thereof, or pharmaceutically acceptable salts of the compounds or tautomers, which correspond to compounds of formula (I) wherein Ring B is pyridinyl (a 6-membered monocyclic heteroaryl ring).

[0076] In another preferred embodiment of the present invention, ring A is a 5-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms, each independently selected from N and O. More preferably, ring A is a heteroaryl ring selected from furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl (particularly 1,3,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, and 1,2,5-oxadiazolyl), imidazolyl, pyrazolyl, and triazolyl (particularly 1,2,3-triazolyl and 1,2,4-triazolyl). Even more preferably, ring A is selected from oxazolyl and oxadiazolyl. Most preferably, ring A is selected from oxazolyl and 1,3,4-oxadiazolyl.

[0077] In another preferred embodiment, when Ring A is selected from oxazolyl and oxadiazolyl, the present invention provides compounds of formula (I) having formula (I)(D): [ka] a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein X 5 are N, CH and CR 7 In one preferred embodiment, X is selected from the group consisting of: 5 CH and CR 7Z is selected from CR 11 In another preferred embodiment, X 5 is N and Z is CR 11 In another preferred embodiment, X 5 CH and CR 7 and Z is N. In another preferred embodiment, X 5 is N and Z is N. Most preferably, in each embodiment, X 5 is CH.

[0078] In another preferred embodiment of the present invention, ring A is a 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms, each independently selected from N, O, and S. More preferably, ring A is a heteroaryl ring selected from pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, and triazinyl. Most preferably, ring A is pyridinyl.

[0079] In another preferred embodiment, when Ring A is pyridinyl, the present invention provides compounds of formula (I) having formula (I)(E): [ka] In one preferred embodiment, Z is CR. 11 In another preferred embodiment, Z is N. The pyridinyl ring is unsubstituted or contains one or two R 7 The pyridinyl ring is either substituted or unsubstituted by a substituent.

[0080] In another preferred embodiment of the present invention, ring A is a 4-6 membered saturated or partially saturated monocyclic heterocyclyl ring containing 1-3 heteroatoms, each independently selected from N, O, and S. More preferably, ring A is a heterocyclyl ring selected from azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, pyrrolinyl, dihydrofuranyl, dihydrothiophenyl, dihydrooxazolyl, thiazolinyl, dioxolanyl, oxathiolanyl, dithiolanyl, imidazolidinyl, imidazolinyl, pyrazolinyl, thiazolidinyl, pyranyl, piperidinyl, dioxanyl, morpholino, dithianyl, thiomorpholino, and piperazinyl. Most preferably, ring A is pyrrolidinyl.

[0081] In another preferred embodiment, when Ring A is pyrrolidinyl, the present invention provides compounds of formula (I) having formula (I)(F): [ka] In one preferred embodiment, Z is CR. 11 In another preferred embodiment, Z is N. The pyrrolidinyl ring is unsubstituted or contains one or two R 7 The pyrrolidinyl ring is either substituted or unsubstituted by a substituent. Preferably, the pyrrolidinyl ring is unsubstituted.

[0082] In another preferred embodiment of the present invention, ring A is phenyl.

[0083] In another preferred embodiment, when ring A is phenyl, the present invention provides compounds of formula (I) having formula (I)(G): [ka] In one preferred embodiment, Z is CR. 11In another preferred embodiment, Z is N. The phenyl ring is unsubstituted or contains one or two R 7 Preferably, the phenyl ring is unsubstituted or substituted with fluoro.

[0084] In preferred embodiments of all aspects of the invention, R 1 is selected from hydrogen, methyl and cyclopropyl. Most preferably, R 1 is selected from hydrogen and cyclopropyl.

[0085] In preferred embodiments of all aspects of the invention, R 2 , R 3 , R 4 and R 5 are each hydrogen.

[0086] In preferred embodiments of all aspects of the invention, R 6 is hydrogen or methyl. Most preferably, R 6 is hydrogen.

[0087] In one preferred embodiment of all aspects of the invention, ring A is unsubstituted.

[0088] In another preferred embodiment of all aspects of the invention, ring A contains one or two R independently selected from fluoro, chloro, methyl and methoxy. 7 Preferably, ring A is substituted with one R selected from fluoro, chloro, methyl and methoxy. 7 is substituted with a group.

[0089] In preferred embodiments of all aspects of the invention, R 8 and R 11 are each independently selected from hydrogen, halo, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, CF3, and OCF3. More preferably, R 8 and R 11are each independently selected from hydrogen, halo, and CN. Even more preferably, R 8 and R 11 are each independently selected from hydrogen, fluoro and CN. Most preferably, R 8 and R 11 are each hydrogen.

[0090] In preferred embodiments of all aspects of the invention, R 9 is selected from hydrogen, halo, CN, hydroxy, oxo, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, (C3-C4)cycloalkyl, O(C3-C4)cycloalkyl and oxetanyloxy. More preferably, R 9 is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy. Even more preferably, R 9 is selected from hydrogen, fluoro, chloro, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, CF3 and OCF3. Most preferably, R 9 is selected from hydrogen, chloro, CN, ethyl, cyclopropyl, CF3 and OCF3.

[0091] In preferred embodiments of all aspects of the invention, R 10 is selected from hydrogen, halo, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, CF3 and OCF3. More preferably, R 10 is selected from hydrogen, fluoro, chloro and CN. Most preferably, R 10 is hydrogen.

[0092] Alternatively, in preferred embodiments of all aspects of the invention, R 9 and R 10together form a 5-6 membered partially saturated or aromatic ring containing 1-2 heteroatoms each independently selected from N, O and S. More preferably, R 9 and R 10 together form a 5-6 membered partially saturated or aromatic ring containing 1-2 nitrogen atoms. Most preferably, R 9 and R 10 together form a 5-membered partially saturated or aromatic ring containing 1 to 2 nitrogen atoms. In particularly preferred embodiments of all aspects of the invention, R 9 and R 10 taken together with the phenyl ring to which they are attached form an indazolyl ring.

[0093] Preferably, R 9 and R 10 The ring formed by R is either unsubstituted or substituted with 1 to 2 substituents each independently selected from halo, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, CF3, and OCF3. More preferably, R 9 and R 10 The ring formed by R is either unsubstituted or substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl and methoxy. 9 and R 10 The ring formed by R is either unsubstituted or substituted with one substituent. 9 and R 10 When taken together with the phenyl ring to which they are attached form an indazolyl ring, the ring is preferably 1-methyl-1H-indazolyl.

[0094] In preferred embodiments of all aspects of the invention, R 12is selected from hydrogen, halo, CN, hydroxy, oxo, (C1-C3)alkyl, (C1-C3)alkoxy, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, (C3-C4)cycloalkyl, O(C3-C4)cycloalkyl and oxetanyloxy. More preferably, R 12 is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy. Even more preferably, R 12 is selected from hydrogen, fluoro, chloro, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy. 12 is selected from hydrogen, methoxy, cyclopropyl, cyclopropoxy, OCF3 and oxetan-3-yloxy.

[0095] In one preferred embodiment, the compound of formula (I) is a compound of formula (I)(D): R 8 is selected from hydrogen, halo, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, CF3, and OCF3; R 9 is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, OCF3, and oxetan-3-yloxy; R 10 is selected from hydrogen, halo, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, CF3, and OCF3; R 11 is selected from hydrogen, halo, CN, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclopropoxy, and OCF3; R 12is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy.

[0096] In preferred embodiments of all aspects of the invention, R 8 , R 9 , R 10 , R 11 and R 12 Two of the substituents are hydrogen and the remaining three substituents are as defined in the embodiments herein. Most preferably, R 8 , R 9 , R 10 , R 11 and R 12 Three of the substituents are hydrogen, and the remaining two substituents are as defined in the embodiments herein.

[0097] In preferred embodiments of all aspects of the invention, R 8 and R 11 is hydrogen and R 9 , R 10 and R 12 is as defined in the embodiments herein. More preferably, R 8 and R 11 is hydrogen and R 10 is selected from hydrogen, fluoro and CN; R 9 and R 12 is as defined in the embodiments herein. Most preferably, R 8 , R 10 and R 11 is hydrogen and R 9 and R 12 is as defined in the embodiments of this specification.

[0098] For example, in one preferred embodiment of all aspects of the invention: R 8 , R 10 and R 11 is hydrogen; R 9 and R 12are each independently selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3, and oxetan-3-yloxy.

[0099] The compounds of formula (I) contain two or more asymmetric carbon atoms (chiral centers) and can exist as four or more stereoisomers.

[0100] The compound of formula (I) is NR 1 C(O) and CR 4 R 5 The pyrrolidine ring carbon atoms substituted by the ring groups contain two chiral centers, which may be present in either the (R) or (S) configuration. The designation of the absolute configuration (R) and (S) of stereoisomers according to IUPAC nomenclature depends on the nature of the substituents and the application of sequence rules. Compounds of formula (I) may, for example, be 2 or R 3 is other than hydrogen, or R 4 and R 5 When is different, it may contain other chiral centers. All stereoisomers of the compounds of formula (I) and combinations thereof are included within the scope of the present invention.

[0101] Therefore, NR 1 C(O) and CR 4 R 5 With respect to the chiral centres of the ring groups, the compounds of formula (I) may exist in any of the following configurations: [ka]

[0102] The compounds of formula (I) of the present invention, and all aspects and preferred embodiments thereof, preferably exist as single stereoisomers having the following absolute configuration: [ka]

[0103] base R 2 , R3 , R 4 and R 5 When are all hydrogen, the compounds of formula (I) of the present invention, and all aspects and preferred embodiments thereof, preferably exist as a single stereoisomer having the following absolute configuration (3R,5S): [ka]

[0104] When the compound of formula (I) is a single stereoisomer, it is preferably present in a stereoisomeric excess of at least 60%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95%, for example 96%, 97%, 98%, 99% or 100%.

[0105] Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative), for example, using chiral high-performance liquid chromatography (HPLC). Alternatively, the racemate (or racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, if the compound of formula (I) contains an acidic or basic moiety, with a base or acid, such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and / or fractional crystallization, and one or both diastereoisomers may be converted to the corresponding pure enantiomer by means well known to those skilled in the art. The chiral compounds of the present invention (and their chiral precursors) may be obtained in enantiomerically enriched form using chromatography, typically HPLC, on an asymmetric resin using a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing 0-50% by volume, typically 2%-20% propan-2-ol, and 0-5% by volume of an alkylamine, typically 0.1% diethylamine. The eluate is concentrated to provide the enriched mixture. The present invention includes all crystalline forms of the compound of formula (I), including the racemate and racemic mixtures thereof (conglomerates). Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art. See, for example, "Stereochemistry of Organic Compounds" by EL Eliel and SH Wilen (Wiley, New York, 1994).

[0106] Where the present invention relates to a compound of formula (I), preferably this compound has the absolute stereochemical configuration of formula (I)(i): [ka]

[0107] Where the present invention relates to a compound of formula (I)(A), preferably the compound has the absolute stereochemical configuration of formula (I)(A)(i): [ka]

[0108] Where the present invention relates to a compound of formula (I)(B), preferably the compound has the absolute stereochemical configuration of formula (I)(B)(i): [ka]

[0109] Where the present invention relates to a compound of formula (I)(C), preferably the compound has the absolute stereochemical configuration of formula (I)(C)(i): [ka]

[0110] Where the present invention relates to a compound of formula (I)(D), preferably the compound has the absolute stereochemical configuration of formula (I)(D)(i): [ka]

[0111] Where the present invention relates to a compound of formula (I)(E), preferably the compound has the absolute stereochemical configuration of formula (I)(E)(i): [ka]

[0112] Where the present invention relates to a compound of formula (I)(F), preferably the compound has the absolute stereochemical configuration of formula (I)(F)(i): [ka]

[0113] Where the present invention relates to a compound of formula (I)(G), preferably the compound has the absolute stereochemical configuration of formula (I)(G)(i): [ka]

[0114] In one particularly preferred embodiment of each compound of formula (I) and formula (I)(i) of the present invention: Ring B is selected from phenyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indazolyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl and dihydroquinazolinyl, preferably selected from phenyl, pyridinyl and indazolyl; Ring B is either unsubstituted or substituted with 1 to 2 substituents each independently selected from halo, CN, (C1-C3)alkyl, (C1-C3)alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3, and oxetanyloxy; Ring A is selected from furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolidinyl and phenyl, preferably selected from oxazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrrolidinyl and phenyl; Ring A is unsubstituted or contains one R selected from fluoro, chloro, methyl and methoxy. 7 substituted with a group; R 1 is selected from hydrogen, methyl and cyclopropyl; R 2 , R 3 , R 4 and R 5 are each hydrogen; R 6 is hydrogen or methyl.

[0115] In a more particularly preferred embodiment of each compound of formula (I) and formula (I)(i) of the present invention, Ring B is selected from phenyl, pyridinyl and indazolyl; Ring B is either unsubstituted or substituted with 1 to 2 substituents each independently selected from halo, CN, (C1-C3)alkyl, (C1-C3)alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3, and oxetanyloxy; Ring A is selected from oxazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrrolidinyl, and phenyl; Ring A is either unsubstituted or substituted with methyl; R 1 is selected from hydrogen and cyclopropyl; R 2 , R 3 , R 4 and R 5 are each hydrogen; R 6 is hydrogen or methyl.

[0116] In one particularly preferred embodiment of each of the compounds of formula (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen, methyl and cyclopropyl; R 2 , R 3 , R 4 and R 5 are each hydrogen; R 6 is hydrogen or methyl, Ring A is unsubstituted or contains one or two R independently selected from fluoro, chloro, methyl, and methoxy. 7 substituted by a group; R 8 and R 11 are each hydrogen; R 9is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy; R 10 is selected from hydrogen, fluoro and CN, preferably hydrogen; R 12 is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy.

[0117] In particularly more preferred embodiments of each of the compounds of formula (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen and cyclopropyl; R 2 , R 3 , R 4 , R 5 , R 8 , R 10 and R 11 are each hydrogen; R 6 is hydrogen or methyl, Ring A is either unsubstituted or substituted with methyl; R 9 is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy; R 12 is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy.

[0118] In another particularly preferred embodiment of each of the compounds of formula (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen, methyl and cyclopropyl; R 2 , R 3 , R 4 , R 5 , R 8 and R 11 are each hydrogen; R 6 is hydrogen or methyl, Ring A is unsubstituted or contains one or two R independently selected from fluoro, chloro, methyl, and methoxy. 7 substituted by a group; R 9 and R 10 are taken together to form a 5-6 membered partially saturated or aromatic ring containing 1-2 nitrogen atoms, which is either unsubstituted or substituted with 1-2 substituents each independently selected from fluoro, chloro, methyl and methoxy; R 12 is selected from hydrogen, halo, CN, (C1-C3) alkyl, (C1-C3) alkoxy, cyclopropyl, cyclopropoxy, CF3, OCF3 and oxetan-3-yloxy, preferably hydrogen.

[0119] In particularly more preferred embodiments of each of the compounds of formula (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F), (I)(G), (I)(A)(i), (I)(B)(i), (I)(C)(i), (I)(D)(i), (I)(E)(i), (I)(F)(i) and (I)(G)(i) of the present invention: R 1 is selected from hydrogen and cyclopropyl; R 2 , R 3 , R4 , R 5 , R 8 , R 11 and R 12 are each hydrogen; R 6 is hydrogen or methyl, Ring A is either unsubstituted or substituted with methyl; R 9 and R 10 taken together with the phenyl ring to which they are attached form an indazole ring, which is either unsubstituted or substituted with 1 to 2 substituents each independently selected from fluoro and methyl, preferably substituted with methyl.

[0120] Preferred compounds of formula (I) for use in the present invention are N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyclopropylphenyl)oxazole 2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)picolinamide; N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)(3(trifluoromethyl)phenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide; N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; SN-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (R)—N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-propyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide; N-((3R,5S-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide; and N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-6-(1H-indazol-4-yl)nicotinamide; or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.

[0121] Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts (including disalts) thereof.

[0122] Suitable acid addition salts are formed from acids which form non-toxic salts, and examples include acetate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulfate, camsylate, citrate, edisylate, esylate, fumarate, gluceptate, gluconate, glucuronate, hybenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide, hydrogen phosphate, isethionate, D- and L-lactate, malate, maleate, malonate, mesylate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, palmate, phosphate, saccharate, stearate, succinate, sulfate, D- and L-tartrate, and tosylate salts.

[0123] Suitable base salts are formed from bases which form non-toxic salts, examples of which include aluminum, ammonium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

[0124] For a review of suitable salts, see Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim, Germany (2002).

[0125] Pharmaceutically acceptable salts of compounds of formula (I) may be readily prepared by combining solutions of the compound of formula (I) with the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

[0126] Pharmaceutically acceptable solvates in accordance with the present invention include hydrates and solvates wherein the solvent of crystallization may be isotopically substituted, e.g., DO, acetone-d, DMSO-d.

[0127] Also within the scope of the present invention are clathrates, drug-host inclusion complexes in which, in contrast to the aforementioned solvates, the drug and host are present in non-stoichiometric amounts. For a review of such complexes, see Haleblian, J. Pharm Sci, 64(8), 1269-1288 (August 1975).

[0128] Hereinafter all references to compounds of formula (I) include references to salts thereof and to solvates and clathrates of compounds of formula (I) and salts thereof.

[0129] The present invention includes all polymorphic forms of the compounds of formula (I) as defined above.

[0130] Also within the scope of the present invention are so-called "prodrugs" of compounds of formula (I). Thus, certain derivatives of compounds of formula (I), which themselves have little or no pharmacological activity, can be metabolized upon administration into or to the body to yield compounds of formula (I) with the desired activity. Such derivatives are referred to as "prodrugs."

[0131] Prodrugs according to the invention can be produced, for example, by replacing appropriate functional groups present in compounds of formula (I) with certain moieties known to those skilled in the art as "promoieties," for example, as described in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985). Finally, certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I).

[0132] Also within the scope of the present invention are metabolites of compounds of formula (I), i.e., compounds formed in vivo upon administration of compounds of formula (I). Such metabolites may themselves be compounds of formula (I), and are specifically included within the scope of the present invention.

[0133] All tautomeric forms of the compounds of formula (I) are included within the scope of the invention.

[0134] Certain derivatives of the compounds of formula (I) containing nitrogen atoms may also form the corresponding N-oxides and such compounds are also within the scope of the invention.

[0135] The present invention also includes all pharmaceutically acceptable isotopic variations of the compounds of formula (I). An isotopic variation is defined as a variation in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.

[0136] Examples of isotopes suitable for inclusion in compounds of the invention include: 2 H and 3 Hydrogen such as H 13 C and 14 Carbon, such as C 15 Nitrogen such as N 17 O and 18 Oxygen, such as O 32 Phosphorus such as P 35 Sulfur such as S 18 Fluorine such as F, 36 Examples include isotopes of chlorine such as Cl.

[0137] Substitution of compounds of the invention with isotopes such as deuterium can afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and therefore may be undesirable in some circumstances.

[0138] Certain isotopic variations of the compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. 14 C is particularly useful for this purpose in view of its ease of incorporation and ready means of detection.

[0139] Isotopic variations of compounds of formula (I) may generally be prepared by conventional techniques known to those skilled in the art, or by preparation using processes analogous to those described in the accompanying examples and appropriate isotopic variations of suitable reagents.

[0140] The compounds of formula (I) are inhibitors of the deubiquitinase USP30.

[0141] According to a further aspect, the present invention provides a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, for use in inhibiting USP30 either in vitro or in vivo.

[0142] According to a further aspect, the present invention provides a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of the compound or tautomer, for use as a medicament.

[0143] According to a further aspect, the present invention provides a method for the treatment or prevention of a disorder or condition in which inhibition of USP30 is known or can be shown to have a beneficial effect in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer. In a preferred embodiment of all aspects of the invention, the disorder or condition is a CNS indication. In a further preferred embodiment of all aspects of the invention, the disorder or condition is a peripheral indication.

[0144] According to a further aspect, the present invention provides the use of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, in the manufacture of a medicament for the treatment or prevention of a disorder or condition in which inhibition of USP30 is known or can be shown to have a beneficial effect. The manufacture of a medicament may include, inter alia, chemical synthesis of a compound of formula (I) or a salt thereof, or preparation of a composition or formulation comprising the compound or salt, or packaging of any medicament comprising the compound. In a preferred embodiment of all aspects of the invention, the disorder or condition is a CNS indication. In a further preferred embodiment of all aspects of the invention, the disorder or condition is a peripheral indication.

[0145] According to a further aspect, the present invention provides a method of inhibiting USP30 in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of formula (I) as defined herein, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.

[0146] The disorder or condition that would benefit from USP30 activity may be selected from conditions involving mitochondrial dysfunction, cancer and fibrosis.

[0147] In one preferred embodiment of all aspects of the invention, the disorder or condition that would benefit from USP30 activity is a condition associated with mitochondrial dysfunction. The condition associated with mitochondrial dysfunction may be a CNS indication or a peripheral indication.

[0148] Mitochondrial dysfunction is caused by the defect of mitochondria, which is a specialized compartment that exists in all cells of the body except red blood cells.When mitochondria stops functioning, less energy is produced in cells, which then leads to cell damage or even cell death.When this process is repeated throughout the body, the life of the subject that this occurs will be seriously impaired.Mitochondrial disease is most often manifested in the organs that require a lot of energy, such as the brain, heart, liver, skeletal muscle, kidney, and endocrine and respiratory system.

[0149] The condition associated with mitochondrial dysfunction may be selected from a condition associated with mitophagy deficiency, a condition associated with mutations in mitochondrial DNA, a condition associated with mitochondrial oxidative stress, a condition associated with defects in mitochondrial membrane potential, mitochondrial biogenesis, a condition associated with defects in mitochondrial shape or morphology, and a condition associated with lysosomal storage defects.

[0150] In particular, conditions involving mitochondrial dysfunction include neurodegenerative diseases; multiple sclerosis (MS); mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome; maternally inherited diabetes and deafness (MIDD); Leber's hereditary optic neuropathy (LHON); cancer (e.g., breast cancer, ovarian cancer, prostate cancer, lung cancer, kidney cancer, stomach cancer, colon cancer, testicular cancer, head and neck cancer, pancreatic cancer, brain cancer, melanoma, bone cancer, or other tissue organ cancers and lymphomas) and Cancers of blood cells such as leukemia, multiple myeloma, metastatic cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, nasopharyngeal carcinoma, colorectal cancer, and non-small cell lung cancer; neuropathy, ataxia, retinitis pigmentosa, maternally inherited Leigh syndrome (NARP-MILS); Danon disease; diabetes; diabetic nephropathy; metabolic disorders; heart failure; ischemic heart disease leading to myocardial infarction; psychiatric disorders, such as schizophrenia; multiple sulfatase deficiency (MSD); mucolipidosis II (ML) II); Mucolibidosis III (ML III); Mucolibidosis IV (ML IV); GM1-gangliosidosis (GM1); Neuronal ceroid lipofuscinosis (NCL1); Alpers disease; Barth syndrome; β-oxidation defects; Carnitine-acyl-carnitine deficiency; Carnitine deficiency; Creatine deficiency syndrome; Coenzyme Q10 deficiency; Complex I deficiency; Complex II deficiency; Complex III deficiency; Complex IV deficiency; Complex V deficiency; COX deficiency; Chronic Progressive External Ophthalmoplegia Syndrome (CPEO); CPT I deficiency; CPT II deficiency; glutaric acidemia type II; Kearns-Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency (LCHAD); Leigh's disease or syndrome; Leigh syndrome French-Canadian (LSFC) variant; lethal infantile cardiomyopathy (LIC); Luft's disease; medium-chain acyl-CoA dehydrogenase deficiency (MCAD); myoclonic epilepsy with ragged-red fibers (MERRF); mitochondrial cytopathy; mitochondrial recessive ataxia syndrome; mitochondrial DNA depletion syndrome; myoneurogastrointestinal disorders and encephalopathy; Pearson syndrome; pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG gene mutations; medium / short-chain 3-hydroxyacyl-CoA dehydrogenase (M / SCHAD) deficiency; very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency; peroxisomal disorders; methylmalonic acidemia; mevalonate kinase deficiencyThe cognitive impairment may be selected from age-related decline in cognitive function and muscle strength; impaired muscle structure; and cognitive impairment associated with neurodegenerative and neuropsychiatric disorders.

[0151] The condition involving mitochondrial dysfunction can be a CNS disorder, for example, a neurodegenerative disease.

[0152] Neurodegenerative diseases include, but are not limited to, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, ischemia, stroke, dementia with Lewy bodies, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia.

[0153] In particular, the compounds of the present invention may be useful for the treatment or prevention of, but not limited to, PD associated with mutations in alpha-synuclein, parkin, PINK1, GBA, and LRRK2, as well as autosomal recessive juvenile Parkinson's disease (AR-JP) or early-onset Parkinson's disease (EOPD) in which parkin or PINK1 is mutated, truncated, or deleted.

[0154] In particular, the compounds of the invention may be useful in the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric disorders, including, for example, cognitive impairment associated with Alzheimer's disease and Parkinson's disease, pre-symptomatic or prodromal forms of AD and PD, Huntington's disease, dementia with Lewy bodies, schizophrenia, mood disorders, bipolar and major depressive disorder.

[0155] In a preferred embodiment, the present invention relates to the treatment or prevention of Leigh syndrome or disease, including, for example, X-linked Leigh disease, French-Canadian variant of Leigh syndrome, and / or symptoms associated with Leigh disease. In particular, the compounds of the present invention may be useful in the treatment of a muscle structure disorder selected from muscular dystrophy, Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Bethlem myopathy, central core disease, congenital fiber type imbalance, vitreous myopathy, muscle sodium channelopathy, myotonic chondrodystrophy, myotubular myopathy, nemaline body disease, and stress urinary incontinence.

[0156] When the compounds of the present invention or pharmaceutical compositions thereof described herein are used for the treatment or prevention of conditions involving mitochondrial dysfunction, they may be combined with one or more additional drugs. The compounds may be combined with one or more additional drugs selected from levodopa, dopamine agonists, monoamine oxidase (MAO) B inhibitors, catechol O-methyltransferase (COMT) inhibitors, anticholinergics, riluzole, amantadine, cholinesterase inhibitors, memantine, tetrabenazine, antipsychotics, diazepam, clonazepam, antidepressants, and anticonvulsants. The compounds may be combined with drugs that reduce / remove pathogenic protein aggregates in neurodegenerative diseases, such as drugs that reduce / remove α-synuclein in Parkinson's disease, multiple system atrophy, or dementia with Lewy bodies; drugs that reduce / remove tau in Alzheimer's disease or progressive supranuclear palsy; or drugs that reduce / remove TDP-43 in ALS or frontotemporal dementia.

[0157] The compounds may be combined with novel agents that may be used as treatments for mitochondrial diseases, including, but not limited to, nicotinamide riboside.

[0158] The compounds may also be combined with corticosteroids (e.g., prednisone and deflazacort), drugs used to treat muscular dystrophies such as DMD, including ataluren, eteplirsen, golodirsen, casimersen, viltepso, and other exon skipping / nonsense readthrough / gene therapies, gibinostat, pamrevlumab, and vamorolone, as well as cardiac medications such as angiotensin-converting enzyme inhibitors and beta-blockers.

[0159] In another preferred embodiment of all aspects of the present invention, the disorder or condition that would benefit from USP30 activity is cancer. The cancer may be associated with mitochondrial dysfunction. Preferred cancers include, for example, breast cancer, ovarian cancer, prostate cancer, lung cancer, kidney cancer, stomach cancer, colon cancer, testicular cancer, head and neck cancer, pancreatic cancer, brain cancer, melanoma, bone cancer, or other tissue and organ cancers and cancers of blood cells such as lymphoma and leukemia, multiple myeloma, metastatic cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, nasopharyngeal carcinoma, colorectal cancer, and non-small cell lung cancer.

[0160] In particular, the compounds of the present invention may be useful in the treatment or prevention of cancers in which the apoptotic pathway is dysregulated, more particularly cancers in which proteins of the BCL-2 family are mutated or over- or under-expressed.

[0161] Fibrosis refers to the accumulation of extracellular matrix components that occurs after trauma, inflammation, tissue repair, immune response, cellular hyperplasia, and neoplasia. Fibrotic disorders that can be treated by the compounds and compositions of the present invention include, among others, fibrosis associated with major organ diseases, such as interstitial lung disease (ILD), cirrhosis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) (liver fibrosis), kidney disease (renal fibrosis), acute kidney injury (AKI), acute kidney disease (AKD), chronic kidney disease (CKD), delayed kidney graft function, cardiac or vascular diseases (cardiac fibrosis, hypertrophic cardiomyopathy (HCM)), and eye diseases. These include fibrosis / fibrotic disorders; fibroproliferative disorders, such as systemic and localized scleroderma, keloids and hypertrophic scars, atherosclerosis, restenosis, and Dupuytren's contracture; trauma-related scars, such as surgical complications, chemotherapy-induced fibrosis (e.g., bleomycin-induced fibrosis), radiation-induced fibrosis, accidental injury, and burns; retroperitoneal fibrosis (Ormond's disease); and peritoneal fibrosis / scarring in patients undergoing peritoneal dialysis, usually after kidney transplantation. See, e.g., Wynn et al., 2004, Nat Rev Immunol. August;4(8):583-594. Accordingly, the present invention relates to methods for treating or preventing fibrosis / fibrotic disorders of and / or associated with major organs, including, for example, the lung, liver, kidney, heart, skin, eye, gastrointestinal tract, peritoneum, and bone marrow, as well as other diseases / disorders described herein, and compounds and compositions for use in such methods.

[0162] The compounds may be combined with drugs used to treat kidney disease, including anti-diabetic drugs, cardiovascular disease drugs, and novel drugs that target disease-related pathways such as oxidative stress (including but not limited to the nrf2 / keap-1 pathway) and anti-apoptotic pathways (including but not limited to anti-p53 drugs).

[0163] Interstitial lung diseases (ILDs) include disorders in which pulmonary inflammation and fibrosis are the final common pathway of pathology, such as sarcoidosis, silicosis, drug reactions, infections, and collagen vascular diseases such as rheumatoid arthritis and systemic sclerosis (scleroderma). Fibrotic disorders of the lung include, for example, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia (UIP), interstitial lung disease, idiopathic fibrosing alveolitis (CFA), bronchiolitis obliterans, and bronchiectasis.

[0164] Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD and has no known cause.

[0165] The compounds may be combined with drugs for the treatment of IPF and potentially ILD, including nintedanib and pirfenidone.

[0166] Cirrhosis of the liver has similar causes to ILD and includes, for example, cirrhosis associated with viral hepatitis, schistosomiasis, and chronic alcoholism.

[0167] Kidney disease can be associated with diabetes, which can damage and scar the kidneys, leading to progressive loss of function and similar hypertensive disorders. Renal fibrosis can occur at any stage of kidney disease, from acute kidney disease (AKD) after injury and chronic kidney disease (CKD), such as incident CKD and progressive CKD, to end-stage renal disease (ESRD). Renal fibrosis can develop as a result of cardiovascular diseases such as hypertension or diabetes, both of which place a tremendous strain on kidney function and promote fibrosis. However, renal fibrosis can also be idiopathic (of unknown cause), and certain inherited mitochondrial diseases also exhibit the manifestation of renal fibrosis and associated symptoms.

[0168] Heart disease can result in scar tissue that can impair the heart's ability to pump.

[0169] Eye diseases include, for example, macular degeneration and retinal and vitreous retinopathies, which can impair vision.

[0170] In a preferred embodiment, the present invention relates to the treatment or prevention of idiopathic pulmonary fibrosis (IPF).

[0171] In another preferred embodiment, the present invention relates to the treatment or prevention of renal fibrosis.

[0172] In another preferred embodiment, the present invention relates to the treatment or prevention of acute kidney injury (AKI), particularly in high-risk patients. Examples include postoperative AKI, such as ischemia-reperfusion injury and delayed graft function in organ transplants, oncology, such as chemotherapy-induced AKI; contrast-induced nephropathy, such as direct tubular cytotoxicity, hemodynamic ischemia, and osmotic effects; acute interstitial nephritis, such as that caused by drugs or infections; AKI due to obstruction, such as kidney stones; and COVID-19-induced AKI. A particular high-risk patient subgroup is one undergoing cardiac surgery, such as coronary artery bypass grafting and / or valve surgery. There are established static risk factors for AKI, such as age 65 or older, insulin-dependent diabetes mellitus, CKD (adults with an estimated glomerular filtration rate [eGFR] below 60 mL / min / 1.73 m2 are particularly at risk), heart failure, liver disease, and a history of AKI.

[0173] In another preferred embodiment, the present invention relates to the treatment or prevention of such AKI or chronic kidney disease (CKD) due to acute kidney disease (AKD), including, for example, tubulointerstitial fibrosis and diabetic nephropathy.

[0174] In another preferred embodiment, the present invention relates to the treatment or prevention of liver diseases, including, for example, NAFLD, NASH, cirrhosis, portal hypertension, acute liver failure, and hepatocellular carcinoma. Liver diseases such as NAFLD and NASH can be associated with various metabolic conditions, such as metabolic syndrome and type II diabetes, which also increase the risk of various diabetes-related conditions, including diabetic retinopathy and peripheral neuropathy.

[0175] The compounds of the invention described herein or pharmaceutical compositions thereof, when used for the treatment or prevention of conditions associated with liver disease and metabolic dysfunction, may be combined with one or more additional agents, including metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, PPAR agonists, SGLT2 inhibitors, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs).

[0176] Reference to "treatment" includes measures to improve or alleviate the symptoms, either temporarily or permanently, or to eliminate the cause of the symptoms. The compounds of the present invention are useful in treating the diseases disclosed herein in humans and other mammals.

[0177] In another embodiment, the present invention encompasses prophylactic therapy of the diseases disclosed herein, including means for preventing or delaying the onset of symptoms of the named disorder or condition. The compounds of the present invention are useful for the prevention of the diseases disclosed herein in humans and other mammals.

[0178] A patient in need of treatment or prevention can be, for example, a human or other mammal suffering from or at risk of suffering from the condition.

[0179] According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as defined herein or a pharmaceutically acceptable salt of said compound or tautomer, together with a pharmaceutically acceptable diluent or carrier.

[0180] The pharmaceutical composition of the present invention comprises any of the compounds of the present invention combined with any pharmaceutically acceptable carrier, adjuvant or vehicle. Examples of pharmaceutically acceptable carriers are known to those skilled in the art and include, but are not limited to, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants and dispersing agents, depending on the mode of administration and the nature of the dosage form. The composition may be in the form of, for example, tablets, capsules, powders, granules, elixirs, lozenges, suppositories, syrups, and liquid preparations, including suspensions and solutions. In the context of the present invention, the term "pharmaceutical composition" refers to a composition comprising an active agent and further comprising one or more pharmaceutically acceptable carriers. The composition may further contain, depending on the mode of administration and the nature of the dosage form, ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preservatives, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants and dispersing agents.

[0181] The compounds of the present invention or pharmaceutical compositions thereof described herein may be used alone or in combination with one or more additional pharmaceutical agents. The compounds may be combined with an additional antitumor therapeutic agent, such as a chemotherapeutic agent or an inhibitor of another regulatory protein. In one embodiment, the additional antitumor therapeutic agent is a BH-3 mimetic. In a further embodiment, the BH-3 mimetic may be selected from, but is not limited to, one or more of ABT-737, ABT-199, ABT-263, and obatoclax. In a further embodiment, the additional antitumor agent is a chemotherapeutic agent. The chemotherapeutic agent may be selected from, but is not limited to, olaparib, mitomycin C, cisplatin, carboplatin, oxaliplatin, ionizing radiation (IR), camptothecin, irinotecan, topotecan, temozolomide, taxanes, 5-fluoropyrimidines, gemcitabine, and doxorubicin.

[0182] For the treatment or prevention of fibrotic disorders, for example, the compounds of the invention described herein or pharmaceutical compositions thereof may be used alone or in combination with one or more additional therapeutic agents selected from the group consisting of anticholinergics, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, LTD4 antagonists, EGFR inhibitors, and endothelin antagonists.

[0183] In particular, the compounds of the present invention described herein or pharmaceutical compositions thereof may be used alone or in combination with one or more additional therapeutic agents selected from the group consisting of general immunosuppressants such as corticosteroids, immunosuppressants or cytotoxic agents, or antifibrotic agents such as pirfenidone or nonspecific kinase inhibitors (e.g., nintedanib).

[0184] The pharmaceutical compositions of the present invention can be administered in any suitably effective manner, including orally, parenterally, topically, by inhalation, intranasally, rectally, intravaginally, ophthalmically, and auricularly. Pharmaceutical compositions suitable for the delivery of the compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation can be found, for example, in "Remington's Pharmaceutical Sciences," 19th Edition (Mack Publishing Company, 1995).

[0185] Oral administration The compounds of the present invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.

[0186] Formulations suitable for oral administration include solid formulations such as tablets, particulate, liquid, or powder containing capsules, lozenges (including liquid-filled), chewables, multiparticulates and nanoparticles, gels, films (including mucoadhesive), ovules, sprays, and liquid formulations.

[0187] Liquid preparations include suspensions, solutions, syrups and elixirs.Such preparations can be used as fillers in soft or hard capsules, and typically comprise carriers such as water, ethanol, propylene glycol, methylcellulose or suitable oils, and one or more emulsifiers and / or suspending agents.Liquid preparations can also be prepared by reconstituting solids, for example, from sachets.

[0188] The compounds of the present invention may also be used in fast dissolving, fast disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11(6), 981-986 by Liang and Chen (2001).

[0189] A typical tablet may be prepared using standard methods known to formulation chemists, for example, by direct compression, granulation (dry, wet, or melt), melt congealing, or extrusion. Tablet formulations may comprise one or more layers and may be coated or uncoated.

[0190] Examples of excipients suitable for oral administration include carriers such as cellulose, calcium carbonate, calcium hydrogen phosphate, mannitol, and sodium citrate, granulating binders such as polyvinylpyrrolidine, hydroxypropyl cellulose, hydroxypropylmethylcellulose, and gelatin, disintegrants such as sodium starch glycolate and sodium silicate, lubricants such as magnesium stearate and stearic acid, wetting agents such as sodium lauryl sulfate, preservatives, antioxidants, flavorings, and coloring agents.

[0191] Solid formulations for oral administration may be formulated for immediate release and / or controlled release. Controlled release formulations include delayed release, sustained release, pulsed release, controlled dual release, targeted release, and programmed release. Details of suitable controlled release technologies, such as high-energy dispersions, osmotic pressure, and coated particles, can be found in Verma et al., Pharmaceutical Technology Online, 25(2), 1-14 (2001). Other controlled release formulations are described in U.S. Patent No. 6,106,864.

[0192] Parenteral administration The compound of the present invention can also be administered directly into the bloodstream, intramuscularly, or into an internal organ.Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ​​intrasternal, intracranial, intramuscular, and subcutaneous.Suitable devices for parenteral administration include needles (including microneedles), syringes, needle-free syringes, and infusion techniques.

[0193] Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates, and buffering agents (preferably pH 3-9), although for some applications they may be more suitably formulated as sterile non-aqueous solutions or as a dry form for use with a suitable vehicle such as sterile pyrogen-free water.

[0194] The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well-known to those skilled in the art.

[0195] The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques such as suitable processing, e.g., the use of high-energy spray-dried dispersions and / or the use of solubility-enhancing agents.

[0196] Formulations for parenteral administration may be formulated to be immediate and / or controlled release, including delayed-, sustained-, pulsed-, controlled dual-, targeted-, and programmed-release formulations.

[0197] The pharmaceutical compositions of the present invention also include compositions and methods known in the art for bypassing the blood-brain barrier or can be injected directly into the brain. Suitable areas for injection include the cerebral cortex, cerebellum, midbrain, brainstem, hypothalamus, spinal cord and ventricular tissue, as well as areas of the peripheral nervous system, including the carotid body and adrenal medulla.

[0198] dose The magnitude of an effective dose of a compound will, of course, vary depending on the nature of the severity of the condition being treated and the route of administration. Selection of an appropriate dose (administration amount) is within the discretion of the physician. The daily dose range for humans and non-human animals is about 10 μg to about 100 mg per kg of body weight, and may generally be about 10 μg to 30 mg per kg of body weight per dose. The above doses may be administered 1 to 3 times per day.

[0199] For example, oral administration may require a total daily dose of 5 mg to 1000 mg, e.g., 5 to 500 mg, while intravenous administration may require only 0.01 to 30 mg / kg body weight, e.g., 0.1 to 10 mg / kg, more preferably 0.1 to 1 mg / kg body weight. The total daily dose may be administered in single or divided doses. Those skilled in the art will also appreciate that in treating or preventing a particular condition, the compounds of the present invention may be taken as a single dose "as needed" (i.e., as needed or desired).

[0200] Synthesis methodology Compounds of formula (I) may be prepared using the methods described below in the general reaction schemes and representative examples. Where appropriate, individual transformations within the schemes may be completed in different orders. The invention is illustrated by the following non-limiting examples, in which the following abbreviations and definitions are used. Compounds may be analyzed by liquid chromatography-mass spectrometry (LCMS) or 1 Characterized by 1 H NMR or both.

[0201] In a further aspect, the present invention provides a method for preparing a compound of formula (I), comprising reacting a compound of formula (IV) in which Y is OH with an amine of formula (V) in which PG is a protecting group such as BOC or Cbz to obtain an amide of formula (III) (Scheme 1). The amide coupling reaction can be carried out using standard methodology, such as by reaction with coupling reagents such as DCC, HATU, HBTU, EDC, or via a mixed anhydride. Alternatively, an acid (IV) in which Y is OH, or a carboxylate salt thereof, such as a lithium salt, can be converted to an acid chloride (IV) in which Y is Cl using SOCl, POCl, PCl, or PCl, and then reacted with an amine (V), preferably in a suitable solvent in the presence of a suitable base. Alternatively, a compound (IV) in which Y forms an ester can be directly reacted with an amine (V), preferably in a suitable solvent.

[0202] The compound of formula (IV) may be prepared according to the processes disclosed in WO 2016 / 156816, WO 2017 / 103614, WO 2018 / 234775, WO 2020 / 212350, WO 2020 / 212351, WO 2021 / 043870, WO 2021 / 204856, WO 2021 / 239863, WO 2021 / 245186, WO 2021 / 249909 and WO 2022 / 084479.

[0203] Compounds of formula (III) may be deprotected using standard methods to give amines (II), which may then be reacted with cyanogen bromide to give the corresponding compounds of formula (I). [ka]

[0204] In a further aspect, the present invention provides a compound selected from formula (II) and (III): [ka] In the formula, PG is a protecting group, and ring A, ring B, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 and R 5 provides a compound, a tautomer thereof, or a salt of said compound or tautomer, as defined herein for compounds of formula (I) and all preferred aspects and embodiments thereof.

[0205] For each of the synthetic intermediates of the compounds of formula (I), (I)(A), (I)(B), (I)(C), (I)(D), (I)(E), (I)(F) and (I)(G) of the present invention, the corresponding compounds of formula (II) and (III) [(II)(i) to (II)(G)(i) and (III)(i) to (III)(G)(i)] preferably exist as a single stereoisomer having the absolute configuration of formula (II)(i) and (III)(i): [ka]

[0206] When the compounds of formula (II) and (III) are present as single stereoisomers, they are preferably present in a stereoisomeric excess of at least 60%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95%, for example 96%, 97%, 98%, 99% or 100%.

[0207] The protecting group is preferably selected from tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), p-methoxybenzylcarbonyl (MeOZ), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl (Ac), benzoyl (Bz), benzyl (Bn), carbamate, p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts), trichloroethoxycarbonyl (Troc), 4-nitrobenzenesulfonyl (Nosyl), and 2-nitrophenylsulfenyl (Nps). Most preferred are BOC and Cbz. [Table 1]

[0208] LCMS method Method C [Table 2]

[0209] Method C1 [Table 3]

[0210] Method F [Table 4]

[0211] Method H [Table 5]

[0212] Method H1 [Table 6]

[0213] Method J [Table 7]

[0214] Method J1 [Table 8]

[0215] Method N [Table 9]

[0216] Method X1: A method used for reversed-phase preparative HPLC [Table 10]

[0217] Method X3: A method used for reversed-phase preparative HPLC [Table 11]

[0218] Method X4: A method used for reversed-phase preparative HPLC [Table 12]

[0219] Method X8: A method used for reversed-phase preparative HPLC [Table 13]

[0220] Method X9: A method used for reversed-phase preparative HPLC [Table 14]

[0221] Method X10: A method used for reversed-phase preparative HPLC [Table 15]

[0222] Method X11: A method used for reversed-phase preparative HPLC [Table 16]

[0223] Method X14: A method used for reversed-phase preparative HPLC [Table 17]

[0224] Method X15: A method used for reversed-phase preparative HPLC [Table 18]

[0225] Method X16: A method used for reversed-phase preparative HPLC [Table 19]

[0226] Method X17: A method used for reversed-phase preparative HPLC [Table 20]

[0227] Method Y4: Method used for analytical chiral SFC [Table 21]

[0228] Method Y8: Methods used for analytical chiral SFC [Table 22]

[0229] Method Y9: Methods used for analytical chiral HPLC [Table 23]

[0230] Method Y10: Methods used for analytical chiral HPLC [Table 24]

[0231] Method Y12A: Method used for analytical chiral SFC [Table 25]

[0232] Method Y14: Methods used for analytical chiral SFC [Table 26]

[0233] Method Y20: Methods used for analytical chiral SFC [Table 27]

[0234] Method Y21: Methods used for analytical chiral HPLC [Table 28]

[0235] Method Y28: Methods used for analytical chiral HPLC [Table 29]

[0236] Method Y30: Methods used for analytical chiral HPLC [Table 30]

[0237] Method Y31: Methods used for analytical chiral HPLC [Table 31]

[0238] Method Y32: Methods used for analytical chiral HPLC [Table 32]

[0239] Method Z1: A method used for preparative chiral HPLC [Table 33]

[0240] Method Z2: A method used for preparative chiral HPLC [Table 34]

[0241] Synthesis of intermediates Intermediate A tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate [ka]

[0242] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate To a stirred solution of 1H-1,2,3-triazole (CAS 288-36-8, Spectrochem, 0.76 g, 11.24 mmol) in DMF (30 mL) was added K2CO3 (3.88 g, 28.11 mmol) at 0 °C. tert-Butyl (2S,4R)-4-azido-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (3.0 g, 9.37 mmol) was added at 0 °C. The mixture was warmed to room temperature and stirred for 48 h, then poured into ice-cold water (700 mL) and extracted with EtOAc (5 × 100 mL). The combined organic phases were washed with ice-cold water (2 × 100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 15-20% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-azidopyrrolidine-1-carboxylate (top spot, 1.0 g, 3.41 mmol, 36% yield), followed by (40-50% EtOAc in n-hexane) tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (bottom spot, 1.0 g, 3.41 mmol, 36% yield).

[0243] For tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-azidopyrrolidine-1-carboxylate (upper spot, less polar): LCMS: Method C, 1.67 min, MS: ES+294.0; 1 H NMR(400MHz,DMSO-d6)δppm:7.83(s,2H),4.63-4.65(m,2H),4.02-4.19(m, 2H), 3.41-3.44 (m, 1H), 3.04-3.14 (m, 1H), 2.00-2.17 (m, 2H), 1.43 (s, 9H).

[0244] For tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (lower spot, more polar): LCMS: Method C, 1.52 min, MS: ES+294.2; 1 H NMR(400MHz,DMSO-d6)δppm:7.96-8.02(m,1H),7.77(s,1H),4.56-4.63(m,2H),4.01 -4.21(m,2H),3.41-3.49(m,1H),3.07-3.15(m,1H),1.95-2.08(m,2H),1.39(s,9H).

[0245] Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (bottom spot, 1.0 g, 3.41 mmol) in MeOH (20 mL) was added 10% Pd / C (50% water) (0.50 g, 0.5 w / w). The mixture was purged with H gas for 1 h, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.85 g, 3.18 mmol, 93% yield).

[0246] LCMS: Method C, 1.26 min, MS: ES+268.5.

[0247] Intermediate B tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamino)pyrrolidine-1-carboxylate [ka]

[0248] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamino)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (1.0 g, 3.74 mmol) and (1-ethoxycyclopropoxy)trimethylsilane (0.78 g, 4.49 mmol) in MeOH (5 mL) was added dropwise AcOH (0.5 mL) at 0 °C. After 5 min, NaBHCN (0.47 g, 7.48 mmol) was added portionwise at 0 °C, and the mixture was heated at 60 °C for 6 h. The mixture was combined with another identical batch and concentrated under reduced pressure. The crude product was then poured into water (100 mL) and extracted with EtOAc (2 × 100 mL). The combined organic phases were dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 4-5% MeOH in DCM) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamino)pyrrolidine-1-carboxylate (0.38 g, 1.23 mmol, 16% yield). LCMS: Method H1, 2.34 min, MS: ES+ 308.2.

[0249] Intermediate C tert-Butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-aminopyrrolidine-1-carboxylate [ka]

[0250] Step (i) tert-Butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-aminopyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-azidopyrrolidine-1-carboxylate (top spot, 1.0 g, 3.41 mmol) in MeOH (20 mL) was added 10% Pd / C (50% water) (0.50 g, 0.5 w / w). The mixture was purged with H gas for 1 h, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.98 g, 3.67 mmol, quantitative yield).

[0251] LCMS: Method C, 1.31 min, MS: ES+268.5.

[0252] Intermediate D tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate [ka]

[0253] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate To a stirred solution of 4H-1,2,4-triazole (CAS 288-88-0, Spectrochem, 0.17 g, 2.40 mmol) in DMF (14 mL) was added K2CO3 (0.90 g, 6.56 mmol) at 0 °C. tert-Butyl (2S,4R)-4-azido-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (0.70 g, 2.18 mmol) was added at 0 °C. The mixture was warmed to room temperature and stirred for 48 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (4 × 100 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30–35% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (0.22 g, 0.75 mmol, 34% yield).

[0254] LCMS: Method C, 1.53 min, MS: ES+294.6; 1 H NMR(400MHz,DMSO-d6)δppm:8.43(m,1H),8.01(s,1H),4.34-4.45(m,2H),4.08-4 .17(m,2H),3.40-3.49(m,1H),3.15-3.18(m,1H),1.95-2.01(m,2H),1.39(s,9H).

[0255] Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (0.22 g, 0.75 mmol) in MeOH (2.2 mL) was added 10% Pd / C (50% water) (0.11 g, 0.5 w / w). The mixture was purged with H gas for 2 h, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.16 g, 0.59 mmol, 80% yield).

[0256] LCMS: Method C, 1.23 min, MS: ES+268.2.

[0257] Intermediate E tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-aminopyrrolidine-1-carboxylate [ka]

[0258] Step (i) N'-Formylformohydrazide To hydrazine hydrate (99%) (5.00 g, 99.88 mmol) was added formic acid (8.29 mL, 219.73 mmol) dropwise at 0° C. and stirred at 0° C. for 15 minutes. The mixture was warmed to room temperature and heated at 120° C. for 6 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by trituration with diethyl ether (3×50 mL) and dried under reduced pressure to give N′-formylformohydrazide (3.0 g, 34.06 mmol, 34% yield).

[0259] 1 H NMR (400MHz, DMSO-d6) δppm: 9.84 (brs, 2H), 8.01 (s, 2H).

[0260] Step (ii) (E)-N'-((E)-(dimethylamino)methylene)-N,N-dimethylformohydrazonamide To a stirred solution of N'-formylformohydrazide (3.0 g, 34.06 mmol) in DMF (30 mL) was added SOCl (5.46 mL, 74.93 mmol) dropwise at 0 °C. The mixture was warmed to room temperature and stirred at room temperature for 48 h. The solid was filtered through a Buchner funnel, washed with diethyl ether (3 × 50 mL), and the filtrate was concentrated under reduced pressure. The residue was purified by trituration with diethyl ether (2 × 50 mL), n-hexane (2 × 50 mL), and dried under reduced pressure to give (E-N'-((E-(dimethylamino)methylene)-N,N-dimethylformohydrazonamide (4.0 g, 28.12 mmol, 82% yield).

[0261] 1 H NMR (400MHz, DMSO-d6) δppm: 8.30 (s, 2H), 2.99 (s, 12H).

[0262] Step (iii) tert-Butyl (2S,4R)-2-(aminomethyl)-4-azidopyrrolidine-1-carboxylate An autoclave charged with tert-butyl (2S,4R)-4-azido-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (4.0 g, 12.48 mmol) in MeOH (40 mL) was purged with NH gas at −78° C., and the mixture was then heated at 70° C. for 15 h. The resulting mixture was concentrated under reduced pressure to give tert-butyl (2S,4R)-2-(aminomethyl)-4-azidopyrrolidine-1-carboxylate (1.80 g, 7.45 mmol, 59% yield).

[0263] LCMS: Method C, 1.29 min, MS: ES+186.0 (M-56).

[0264] Step (iv) tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-azidopyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-(aminomethyl)-4-azidopyrrolidine-1-carboxylate (1.0 g, 4.14 mmol) and (E)-N'-(E-(dimethylamino)methylene)-N,N-dimethylformohydrazonamide (1.17 g, 4.14 mmol) in toluene (10 mL), p-TSA (0.08 g, 0.41 mmol) and 4 Å molecular sieves (0.5 g, 0.5 w / w) were added at room temperature, and the mixture was heated at 110 °C for 15 h. The mixture was poured into ice-cold water (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% MeOH in DCM) to give tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-azidopyrrolidine-1-carboxylate (0.49 g, 1.67 mmol, 40% yield).

[0265] 1 H NMR (400MHz, DMSO-d6) δppm: 8.42 (s, 2H), 4.11-4.31 (m, 4H), 3.12-3.18 (m, 1H), 1.85-2.12 (m, 3H), 1.42 (s, 9H).

[0266] Step (v) tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-aminopyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-azidopyrrolidine-1-carboxylate (0.49 g, 1.67 mmol) in MeOH (5 mL) was added 10% Pd / C (50% water) (0.24 g, 0.5 w / w). The mixture was purged with H gas for 2 h, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.25 g, 0.93 mmol, 56% yield).

[0267] 1 H NMR (400MHz, DMSO-d6) δppm: 8.39 (s, 2H), 4.06-4.21 (m, 3H), 3.12-3.28 (m, 2H), 2.89-3.02 (m, 1H), 1.61-1.81 (m, 4H), 1.43 (s, 9H).

[0268] Intermediate F tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate [ka]

[0269] Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate To a stirred solution of 1H-pyrazole (CAS288-13-1, Combi-Blocks, 1.05 g, 15.46 mmol) in DMF (45 mL) was added K2CO3 (5.82 g, 42.18 mmol) at 0 °C. tert-Butyl (2S,4R)-4-azido-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (4.50 g, 14.06 mmol) was added at 0 °C. The mixture was allowed to warm to room temperature and stirred for 48 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (2 × 150 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 15% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (2.42 g, 8.25 mmol, 58% yield).

[0270] LCMS: Method J1, 3.92 min, MS: ES+293.0.

[0271] Step (ii) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-azidopyrrolidine-1-carboxylate (0.42 g, 1.43 mmol) in MeOH (4.5 mL) was added 10% Pd / C (50% water) (0.21 g, 0.5 w / w). The mixture was purged with H gas for 2 hours, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.35 g, 1.31 mmol, 91% yield).

[0272] LCMS: Method J1, 2.64 min, MS: ES+267.0.

[0273] intermediate G tert-Butyl (2S,4R)-4-amino-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate and tert-Butyl (2S,4R)-4-amino-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate [ka]

[0274] Step (i) tert-Butyl (2S,4R)-4-azido-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate and tert-Butyl (2S,4R)-4-azido-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate To a stirred solution of 3-methyl-1H-pyrazole (CAS 1453-58-3, Combi-Blocks, 0.77 g, 9.4 mmol) in DMF (30 mL) was added NaH (60% in oil) (0.47 g, 9.8 mmol) portionwise at 0 °C. tert-Butyl (2S,4R)-4-azido-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (1.37 g, 4.27 mmol) was added at 0 °C. The mixture was allowed to warm to room temperature and stirred for 18 h, then poured into ice-cold water (200 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phases were washed with ice-cold water (2 × 100 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 15-20% EtOAc in n-hexane) to give a mixture of tert-butyl (2S,4R)-4-azido-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate and tert-butyl (2S,4R)-4-azido-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate (0.97 g, 3.18 mmol, 74% yield).

[0275] LCMS: Method H1, 3.17 min, MS: ES+307.0.

[0276] Step (ii) tert-Butyl (2S,4R)-4-amino-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate and tert-Butyl (2S,4R)-4-amino-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-4-azido-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate and tert-butyl (2S,4R)-4-azido-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate (0.97 g, 3.18 mmol) as a mixture in MeOH (20 mL) was added 10% Pd / C (50% water) (0.47 g, 0.5 w / w). The mixture was purged with H gas for 2 hours, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give a mixture of tert-butyl (2S,4R)-4-amino-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate and tert-butyl (2S,4R)-4-amino-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate (0.73 g, quantitative yield).

[0277] LCMS: Method H, 2.21 min, MS: ES+281.0.

[0278] Intermediate H Lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate [ka]

[0279] Step (i) 3-acetyl-4-aminobenzonitrile A stirred solution of 1-(2-amino-5-bromophenyl)ethan-1-one (CAS 29124-56-9, Combi-Blocks, 24.0 g, 112.68 mmol) in DMF (250 mL) was purged with N gas for 15 minutes, followed by the addition of CuCN (11.09 g, 123.94 mmol) and heating at 170 °C for 16 hours. The mixture was poured into water (500 mL) and extracted with EtOAc (2 × 500 mL). The combined organic phases were dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 12% EtOAc in n-hexane) to give 3-acetyl-4-aminobenzonitrile (10.5 g, 65.62 mmol, 58% yield). LCMS: Method H1, 2.39 min, MS: ES+ 161.0.

[0280] Step (ii) 3-Acetyl-4-iodobenzonitrile To a stirred solution of 3-acetyl-4-aminobenzonitrile (9.5 g, 59.37 mmol) in concentrated HCl (100 mL) was added NaNO (8.19 g, 118.75 mmol) portionwise at 0 °C and stirred for 10 min. A solution of KI (24.63 g, 148.42 mmol) in water (100 mL) was added dropwise at 0 °C and stirred for 0.5 h. The mixture was poured into water (200 mL) and extracted with EtOAc (2 × 100 mL). The combined organic phases were washed with 10% sodium thiosulfate solution (2 × 100 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc in n-hexane) to give 3-acetyl-4-iodobenzonitrile (12.5 g, 46.13 mmol, 77% yield).

[0281] 1 H NMR (400MHz, DMSO-d6) δppm: 8.18-8.21 (m, 2H), 7.67 (dd, J = 8.0, 2.0Hz, 1H), 2.61 (s, 3H).

[0282] Step (iii) 3-Acetyl-4-cyclopropylbenzonitrile To a stirred solution of 3-acetyl-4-iodobenzonitrile (12.5 g, 46.13 mmol) and cyclopropylboronic acid (CAS 411235-57-9, Combi-Blocks, 7.92 g, 92.26 mmol) in toluene:water (130 mL, 8:2) was added KPO (19.55 g, 92.26 mmol). The mixture was purged with N for 10 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (3.37 g, 4.61 mmol) and heating at 100 °C for 5 hours. The mixture was poured into water (400 mL) and extracted with EtOAc (2 × 400 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EtOAc in n-hexane) to give 3-acetyl-4-cyclopropylbenzonitrile (4.8 g, 25.94 mmol, 56% yield).

[0283] LCMS: Method H1, 3.01 min, MS: ES+186.0.

[0284] Step (iv) 3-(2-Bromoacetyl)-4-cyclopropylbenzonitrile To a stirred solution of 3-acetyl-4-cyclopropylbenzonitrile (4.8 g, 25.94 mmol) in THF (50 mL) was added phenyltrimethylammonium tribromide (10.72 g, 28.53 mmol) portionwise at room temperature and stirred for 16 h. The mixture was poured into water (200 mL) and extracted with EtOAc (2 × 200 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5% EtOAc in n-hexane) to give 3-(2-bromoacetyl)-4-cyclopropylbenzonitrile (4.5 g, 17.11 mmol, 65% yield).

[0285] LCMS: Method H1, 3.25 min, MS: ES-262.0, 264.0.

[0286] Step (v) 4-Cyclopropyl-3-glycylbenzonitrile HCl salt To a stirred solution of 3-(2-bromoacetyl)-4-cyclopropylbenzonitrile (4.5 g, 17.11 mmol) in MeCN (50 mL) was added sodium diformylamide (1.97 g, 20.53 mmol) and heated at 80° C. for 1 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (50 mL) and concentrated HCl (4.5 mL). The mixture was further stirred at 80° C. for 3 h and then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was stirred with diethyl ether (40 mL) to form a precipitate. The solid was collected by vacuum filtration to give 4-cyclopropyl-3-glycylbenzonitrile HCl salt (5.5 g, quantitative yield).

[0287] LCMS: Method H1, 2.31 min, MS: ES+201.0.

[0288] Step (vi) Ethyl 2-((2-(5-cyano-2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 4-cyclopropyl-3-glycylbenzonitrile HCl salt (5.5 g, 23.25 mmol) in DCM (60 mL) at 0 °C was added K2CO3 (12.83 g, 93.0 mmol). Ethyl oxalyl chloride (6.32 g, 5.17 mL, 46.5 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 1 h, then poured into water (200 mL) and extracted with EtOAc (2 × 200 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to give ethyl 2-((2-(5-cyano-2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate (3.3 g, 11.0 mmol, 64% yield over two steps).

[0289] LCMS: Method H1, 2.84 min, MS: ES+301.0.

[0290] Step (vii) Ethyl 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(5-cyano-2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate (3.3 g, 11.0 mmol) in POCl (33 mL, 10 vol) was heated at 100 °C for 5 h. The mixture was cooled to room temperature, poured slowly onto crushed ice, and extracted with EtOAc (2 × 100 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 15% EtOAc in n-hexane) to give ethyl 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (1.2 g, 4.25 mmol, 39% yield).

[0291] LCMS: Method H1, 3.38 min, MS: ES+283.0.

[0292] Step (viii) Lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 1.77 mmol) in THF (6 mL) was added dropwise a solution of LiOH.HO (0.15 g, 3.54 mmol) in water (1 mL) at 0° C. and stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure to give lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.50 g, quantitative yield).

[0293] LCMS: Method H1, 2.14 min, MS: ES+255.0.

[0294] Intermediate I Lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate [ka]

[0295] Step (i) Methyl 5-cyano-2-cyclopropylbenzoate To a stirred solution of methyl 2-bromo-5-cyanobenzoate (CAS 1031927-03-3, Reddy N Reddy, 1.5 g, 6.27 mmol) and cyclopropylboronic acid (CAS 411235-57-9, Combi-Blocks, 0.59 g, 6.90 mmol) in toluene:water (15 mL, 9:1) was added KPO (2.65 g, 12.54 mmol). The mixture was purged with N for 15 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.45 g, 0.627 mmol) and heating at 100 °C for 3 hours. The mixture was poured into water (30 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5% EtOAc in n-hexane) to give methyl 5-cyano-2-cyclopropylbenzoate (1.0 g, 4.97 mmol, 79% yield).

[0296] LCMS: Method H1, 3.19 min, MS: ES+219.0(M+18).

[0297] Step (ii) 5-Cyano-2-cyclopropylbenzohydrazide To a stirred solution of methyl 5-cyano-2-cyclopropylbenzoate (1.0 g, 4.97 mmol) in EtOH (10 mL) was added hydrazine hydrate (99%) (5 mL, 5 volumes) at 0 °C. The mixture was warmed to room temperature and stirred for 3 h. The mixture was concentrated under reduced pressure to give 5-cyano-2-cyclopropylbenzohydrazide (0.7 g, 3.48 mmol, 70% yield).

[0298] LCMS: Method H1, 1.96 min, MS: ES+202.0.

[0299] Step (iii) Ethyl 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of 5-cyano-2-cyclopropylbenzohydrazide (0.7 g, 3.48 mmol) in DCM (7 mL) was added TEA (2.11 g, 2.90 mL, 20.89 mmol) and ethyl oxalyl chloride (0.1 g, 0.85 mL, 7.66 mmol) dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 1 h. TsCl (0.79 g, 4.17 mmol) was added portionwise at 0 °C. The mixture was warmed to room temperature and stirred at room temperature for 2 h, then poured into water (30 mL) and extracted with DCM (3 × 100 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 40% EtOAc in n-hexane) to give ethyl 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.3 g, 1.05 mmol, 30% yield).

[0300] LCMS: Method H1, 3.20 min, MS: ES+284.0.

[0301] Step (vi) Lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of ethyl 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.24 g, 0.85 mmol) in THF (4 mL) at 0° C. was added dropwise a solution of lithium hydroxide monohydrate (0.03 g, 0.85 mmol) in water (1 mL) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure to give lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.25 g, quantitative yield).

[0302] LCMS: Method H1, 1.94 min, MS: ES+256.0.

[0303] Intermediate J 5-(3-chlorophenyl)oxazole-2-carboxylic acid [ka]

[0304] Step (i) 2-Bromo-1-(3-chlorophenyl)ethan-1-one To a stirred solution of 1-(3-chlorophenyl)ethan-1-one (CAS 99-02-5, Sigma-Aldrich, 2.0 g, 12.98 mmol) in DCM (40 mL) was added phenyltrimethylammonium tribromide (4.88 g, 12.98 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 2 h, then poured into water (50 mL) and extracted with DCM (2 × 50 mL). The combined organic phases were dried over NaSO and concentrated under reduced pressure to give 2-bromo-1-(3-chlorophenyl)ethan-1-one (1.1 g, 4.74 mmol, 36% yield). The crude product was used directly in the next step.

[0305] Step (ii) 2-Amino-1-(3-chlorophenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(3-chlorophenyl)ethan-1-one (1.0 g, 4.31 mmol) in MeCN (25 mL) was added sodium diformylamide (0.62 g, 6.46 mmol) and heated at 80° C. for 12 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (5 mL) and concentrated HCl (2 mL). The mixture was further stirred at 60° C. for 2 h and then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was stirred with n-hexane (25 mL) to form a precipitate. The solid was collected by vacuum filtration to give 2-amino-1-(3-chlorophenyl)ethan-1-one HCl salt (0.8 g, 3.89 mmol, 90% yield).

[0306] LCMS: Method C1, 0.89 min, MS: ES+: 170.2.

[0307] Step (iii) 2-((2-(3-chlorophenyl)-2-oxoethyl)amino)-2-oxoacetic acid ethyl ester To a stirred solution of 2-amino-1-(3-chlorophenyl)ethan-1-one HCl salt (0.8 g, 3.89 mmol) in DCM (20 mL) was added KCO (1.61 g, 11.67 mmol) at 0 °C. Ethyl oxalyl chloride (0.79 g, 0.65 mL, 5.83 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 2 h, then poured into ice-cold water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexane) to give ethyl 2-((2-(3-chlorophenyl)-2-oxoethyl)amino)-2-oxoacetate (0.7 g, 2.60 mmol, 66% yield).

[0308] LCMS: Method C1, 1.22 min, MS: ES+270.3.

[0309] Step (iv) Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(3-chlorophenyl)-2-oxoethyl)amino)-2-oxoacetate (0.7 g, 2.60 mmol) in POCl3 (15 mL, 20 vol) was heated at 100°C for 16 h. The mixture was cooled to room temperature, poured into ice-cold water (100 mL), and extracted with EtOAc (2 x 200 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was suspended in MeOH (10 mL) and stirred at -78°C for 15 min. The solid was collected by vacuum filtration to give ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate (0.4 g, 1.59 mmol, 61% yield).

[0310] LCMS: Method C1, 1.35 min, MS: ES+: 252.2.

[0311] Step (v) 5-(3-chlorophenyl)oxazole-2-carboxylic acid To a stirred solution of ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate (0.2 g, 0.79 mmol) in THF:water (3:1, 4 mL) was added lithium hydroxide monohydrate (0.17 g, 3.98 mmol) in portions at 0° C. The mixture was stirred at room temperature for 2 hours and then poured into water (20 mL) and acidified to approximately pH 2 with 1 N HCl to precipitate. The solid was collected by vacuum filtration to give 5-(3-chlorophenyl)oxazole-2-carboxylic acid (0.15 g, 0.67 mmol, 84% yield).

[0312] LCMS: Method H1, 1.93 min, MS: ES+224.0.

[0313] Intermediate K 5-(2-Methoxyphenyl)oxazole-2-carboxylic acid [ka]

[0314] Step (i) 2-Bromo-1-(2-methoxyphenyl)ethan-1-one To a stirred solution of 1-(2-methoxyphenyl)ethan-1-one (CAS 579-74-8, Spectrochem, 2.0 g, 13.31 mmol) in THF (40 mL) was added phenyltrimethylammonium tribromide (5.0 g, 13.31 mmol) portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 16 h, then poured into water (50 mL) and extracted with DCM (2 × 50 mL). The combined organic phase was washed with NaSO 4で乾燥させ、 Filtration and concentration in vacuo gave 2-bromo-1-(2-methoxyphenyl)ethan-1-one (2 g, 8.73 mmol, 65% yield).

[0315] LCMS: Method F, 6.41 min, MS: ES+: 229.0, 231.0.

[0316] Step (ii) 2-Amino-1-(2-methoxyphenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(2-methoxyphenyl)ethan-1-one (2.0 g, 8.73 mmol) in MeCN (50 mL) was added sodium diformylamide (1.25 g, 13.09 mmol) and heated at 80° C. for 12 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (20 mL) and concentrated HCl (10 mL). The mixture was further stirred at 80° C. for 3 h and then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was stirred with n-hexane (50 mL) to form a precipitate. The solid was collected by vacuum filtration to give 2-amino-1-(2-methoxyphenyl)ethan-1-one HCl salt (1.2 g, 7.26 mmol, 83% yield).

[0317] LCMS: Method H1, 1.80 min, MS: ES+: 166.0.

[0318] Step (iii) Ethyl 2-((2-(2-methoxyphenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(2-methoxyphenyl)ethan-1-one HCl salt (1.2 g, 7.26 mmol) in DCM (30 mL) was added KCO (3.0 g, 21.78 mmol) at 0 °C. Ethyl oxalyl chloride (1.48 g, 1.20 mL, 10.89 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 3 h, then poured into ice-cold water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phases were dried over NaSO and concentrated under reduced pressure to give ethyl 2-((2-(2-methoxyphenyl)-2-oxoethyl)amino)-2-oxoacetate (1.0 g, 3.76 mmol, 51% yield).

[0319] LCMS: Method H1, 2.64 min, MS: ES+266.0.

[0320] Step (iv) Ethyl 5-(2-methoxyphenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(2-methoxyphenyl)-2-oxoethyl)amino)-2-oxoacetate (1.0 g, 3.76 mmol) in POCl (20 mL, 20 vol) was heated at 100 °C for 3 h. The mixture was cooled to room temperature, poured into ice-cold water (100 mL), and extracted with EtOAc (2 × 200 mL). The combined organic phases were dried over NaSO and concentrated under reduced pressure to give ethyl 5-(2-methoxyphenyl)oxazole-2-carboxylate (0.8 g, 3.23 mmol, 85% yield).

[0321] LCMS: Method H1, 3.19 min, MS: ES+: 248.0.

[0322] Step (v) 5-(2-Methoxyphenyl)oxazole-2-carboxylic acid To a stirred solution of ethyl 5-(2-methoxyphenyl)oxazole-2-carboxylate (0.8 g, 3.23 mmol) in THF:water (6 mL, 2:1) was added LiOH·HO (0.81 g, 19.42 mmol) portionwise at 0 °C. The mixture was stirred at room temperature for 12 h, then poured into water (20 mL) and acidified to approximately pH 2 with 1 N HCl to form a precipitate. The solid was collected by vacuum filtration to give 5-(2-methoxyphenyl)oxazole-2-carboxylic acid (0.6 g, 2.73 mmol, 84% yield).

[0323] LCMS: Method C1, 1.00 min, MS: ES+220.1.

[0324] Intermediate L Ethyl 5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate [ka]

[0325] Step (i) Ethyl 2-cyclopropylbenzoate To a stirred solution of ethyl 2-bromobenzoate (CAS 6091-64-1, Combi-Blocks, 8.0 g, 35.09 mmol) and cyclopropylboronic acid (CAS 411235-57-9, Combi-Blocks, 3.01 g, 35.09 mmol) in toluene:water (80 mL, 9:1) was added KPO (14.89 g, 70.18 mmol). The mixture was purged with N for 20 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (2.56 g, 3.50 mmol) and heating at 120 °C for 3 hours. The mixture was poured into water (50 mL) and extracted with EtOAc (2 × 40 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 6% EtOAc in n-hexane) to give ethyl 2-cyclopropylbenzoate (5.7 g, 29.98 mmol, 85% yield).

[0326] LCMS: Method C1, 1.14 min, MS: ES+191.0.

[0327] Step (ii) 2-Cyclopropylbenzohydrazide To a stirred solution of ethyl 2-cyclopropylbenzoate (5.56 g, 29.24 mmol) in EtOH (28 mL) was added hydrazine hydrate (99%) (16.68 mL, 3 volumes) at 0° C. and the mixture was heated at 80° C. for 48 h. The mixture was concentrated under reduced pressure to give 2-cyclopropylbenzohydrazide (4.5 g, 25.55 mmol, 87% yield).

[0328] LCMS: Method C1, 0.97 min, MS: ES+177.2.

[0329] Step (iii) Ethyl 2-(2-(2-cyclopropylbenzoyl)hydrazinyl)-2-oxoacetate To a stirred solution of 2-cyclopropylbenzohydrazide (4.4 g, 24.98 mmol) in DCM (44 mL) was added TEA (7.57 g, 10.42 mL, 74.94 mmol) and ethyl oxalyl chloride (6.82 g, 5.59 mL, 49.96 mmol) dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 3 h, then poured into water (120 mL) and extracted with DCM (3 × 50 mL). The combined organic phases were dried over Na SO , filtered, and concentrated under reduced pressure to give ethyl 2-(2-(2-cyclopropylbenzoyl)hydrazinyl)-2-oxoacetate (13.0 g, quantitative yield).

[0330] LCMS: Method C1, 1.09 min, MS: ES+277.2.

[0331] Step (iv) Ethyl 5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of ethyl 2-(2-(2-cyclopropylbenzoyl)hydrazinyl)-2-oxoacetate (13 g, 47.08 mmol) in DCM (130 mL) was added TEA (14.26 g, 19.64 mL, 141.24 mmol) and TsCl (10.72 g, 56.49 mmol) portionwise at 0 °C. The mixture was warmed to room temperature and stirred for 3 h, then poured into water (100 mL) and extracted with DCM (3 × 100 mL). The combined organic phases were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 20% EtOAc in n-hexane) to give ethyl 5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (2.97 g, 11.49 mmol, 46% yield over two steps).

[0332] LCMS: Method C1, 1.36 min, MS: ES+259.16.

[0333] Intermediate M Lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate [ka]

[0334] Step (i) 1-(2-cyclopropylphenyl)ethan-1-one To a stirred solution of 1-(2-bromophenyl)ethan-1-one (CAS 2142-69-0, Combi-Blocks, 10.0 g, 50.51 mmol) and cyclopropylboronic acid (CAS 411235-57-9, Combi-Blocks, 8.67 g, 101.02 mmol) in toluene:water (100 mL, 8:2) was added KPO (21.41 g, 101.02 mmol). The mixture was purged with N for 10 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (3.69 g, 5.05 mmol) and heating at 100 °C for 5 hours. The mixture was poured into water (300 mL) and extracted with EtOAc (2 × 300 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 1-2% EtOAc in n-hexane) to give 1-(2-cyclopropylphenyl)ethan-1-one (6.0 g, 37.5 mmol, 74% yield).

[0335] LCMS: Method H1, 3.15 min, MS: ES+161.0.

[0336] Step (ii) 2-Bromo-1-(2-cyclopropylphenyl)ethan-1-one To a stirred solution of 1-(2-cyclopropylphenyl)ethan-1-one (6.0 g, 37.5 mmol) in THF (70 mL) was added phenyltrimethylammonium tribromide (15.50 g, 41.25 mmol) portionwise at 0 °C. The mixture was warmed to room temperature and stirred for 16 h, then poured into water (200 mL) and extracted with EtOAc (2 × 200 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 1% EtOAc in n-hexane) to give 2-bromo-1-(2-cyclopropylphenyl)ethan-1-one (6.2 g, 26.05 mmol, 69% yield).

[0337] LCMS: Method H1, 3.38 min, MS: ES+239.0, 240.9.

[0338] Step (iii) 2-Amino-1-(2-cyclopropylphenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(2-cyclopropylphenyl)ethan-1-one (6.2 g, 26.05 mmol) in MeCN (60 mL) was added sodium diformylamide (3.0 g, 31.26 mmol) and heated at 80° C. for 3 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (60 mL) and concentrated HCl (6.5 mL). The mixture was further stirred at 80° C. for 16 h and then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was stirred with diethyl ether (50 mL) to form a precipitate. The solid was collected by vacuum filtration to give 2-amino-1-(2-cyclopropylphenyl)ethan-1-one HCl salt (8.2 g, quantitative yield).

[0339] LCMS: Method H1, 2.36 min, MS: ES+176.0.

[0340] Step (iv) Ethyl 2-((2-(2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(2-cyclopropylphenyl)ethan-1-one HCl salt (8.2 g, 38.77 mmol) in DCM (85 mL) was added KCO (21.40 g, 155.08 mmol) at 0 °C. Ethyl oxalyl chloride (10.54 g, 8.63 mL, 77.54 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 1 h, then poured into water (200 mL) and extracted with EtOAc (2 × 200 mL). The combined organic phases were dried over NaSO and concentrated under reduced pressure to give ethyl 2-((2-(2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate (4.1 g, 14.90 mmol, 57% yield over two steps).

[0341] LCMS: Method H1, 3.09 min, MS: ES+276.0.

[0342] Step (v) Ethyl 5-(2-cyclopropylphenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(2-cyclopropylphenyl)-2-oxoethyl)amino)-2-oxoacetate (4.1 g, 14.90 mmol) in POCl (41 mL, 10 vol) was heated at 100 °C for 5 h. The mixture was cooled to room temperature, poured slowly onto crushed ice, and extracted with EtOAc (2 × 200 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexane) to give ethyl 5-(2-cyclopropylphenyl)oxazole-2-carboxylate (1.5 g, 5.83 mmol, 39% yield).

[0343] LCMS: Method H1, 3.58 min, MS: ES+: 258.0.

[0344] Step (vi) Lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 1.94 mmol) in THF (4 mL) was added dropwise a solution of lithium hydroxide monohydrate (0.16 g, 3.88 mmol) in water (1 mL) at 0° C. and stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate (0.51 g, quantitative yield).

[0345] LCMS: Method H1, 2.07 min, MS: ES+230.0.

[0346] Intermediate O Lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate [ka]

[0347] Step (i) 2-Bromo-1-(2-(trifluoromethoxy)phenyl)ethan-1-one To a stirred solution of 1-(2-(trifluoromethoxy)phenyl)ethan-1-one (CAS 220227-93-0, Sigma-Aldrich, 1.0 g, 4.89 mmol) in THF (40 mL) was added phenyltrimethylammonium tribromide (1.84 g, 4.89 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 16 h, then poured into water (50 mL) and extracted with DCM (3 × 50 mL). The combined organic phases were dried over NaSO, filtered, and concentrated under reduced pressure to give 2-bromo-1-(2-(trifluoromethoxy)phenyl)ethan-1-one (1.2 g, 4.25 mmol, 86% yield). The crude product was used directly in the next step.

[0348] Step (ii) 2-Amino-1-(2-(trifluoromethoxy)phenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(2-(trifluoromethoxy)phenyl)ethan-1-one (1.2 g, 4.23 mmol) in MeCN (30 mL) was added sodium diformylamide (0.61 g, 6.35 mmol) and heated at 80° C. for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (5 mL) and concentrated HCl (6 mL). The mixture was further stirred at 80° C. for 3 h and then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was stirred with n-hexane (25 mL) to form a precipitate. The solid was collected by vacuum filtration to give 2-amino-1-(2-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (1.2 g, quantitative yield).

[0349] LCMS: Method C1, 0.92 min, MS: ES+: 220.1.

[0350] Step (iii) Ethyl 2-oxo-2-((2-oxo-2-(2-(trifluoromethoxy)phenyl)ethyl)amino)acetate To a stirred solution of 2-amino-1-(2-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (1.2 g, 5.47 mmol) in DCM (30 mL) was added K2CO3 (2.26 g, 16.37 mmol) at 0 °C. Ethyl oxalyl chloride (1.11 g, 0.90 mL, 8.21 mmol) was added dropwise at 0 °C. The mixture was allowed to warm to room temperature and stirred at room temperature for 3 h, then poured into ice-cold water (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexane) to give ethyl 2-oxo-2-((2-oxo-2-(2-(trifluoromethoxy)phenyl)ethyl)amino)acetate (0.65 g, 2.30 mmol, 48% yield over two steps).

[0351] LCMS: Method C1, 1.30 min, MS: ES+320.2.

[0352] Step (iv) Ethyl 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-oxo-2-((2-oxo-2-(2-(trifluoromethoxy)phenyl)ethyl)amino)acetate (0.6 g, 2.03 mmol) in POCl (10 mL, 15 vol) was heated at 110 °C for 3 h. The mixture was cooled to room temperature, poured into ice-cold water (100 mL), and extracted with EtOAc (3 × 100 mL). The combined organic phases were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexane) to give ethyl 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.32 g, 1.06 mmol, 52% yield).

[0353] LCMS: Method C1, 1.47 min, MS: ES+: 302.2.

[0354] Step (v) Lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, 0.99 mmol) in THF:MeOH:water (1:1:1, 9 mL) was added LiOH·HO (0.12 g, 2.98 mmol) portionwise at 0 °C. The mixture was stirred at room temperature for 3 h, and the mixture was concentrated under reduced pressure. The residue was stirred with pentane (10 mL) to form a precipitate. The solid was collected by vacuum filtration to give lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, quantitative yield).

[0355] LCMS: Method C1, 1.13 min, MS: ES+274.0.

[0356] Intermediate P Lithium 5-(3-bromophenyl)oxazole-2-carboxylate [ka]

[0357] Step (i) 2-Amino-1-(3-bromophenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(3-bromophenyl)ethan-1-one (CAS 18523-22-3, Combi-Blocks, 6.0 g, 21.74 mmol) in MeCN (150 mL) was added sodium diformylamide (3.1 g, 32.62 mmol) and heated at 70° C. for 24 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (60 mL) and concentrated HCl (30 mL). The mixture was further stirred at 70° C. for 4 h and then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was stirred with IPA (25 mL) to form a precipitate. The solid was collected by vacuum filtration to give 2-amino-1-(3-bromophenyl)ethan-1-one HCl salt (7.2 g, quantitative yield).

[0358] LCMS: Method C1, 0.99 min, MS: ES+: 214.1, 216.1.

[0359] Step (ii) Ethyl 2-((2-(3-bromophenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(3-bromophenyl)ethan-1-one HCl salt (7.0 g, 28.11 mmol) in DCM (100 mL) was added K2CO3 (11.65 g, 84.34 mmol) at 0 °C. Ethyl oxalyl chloride (5.75 g, 4.71 mL, 42.17 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 3 h, then poured into water (100 mL) and extracted with DCM (2 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to give ethyl 2-((2-(3-bromophenyl)-2-oxoethyl)amino)-2-oxoacetate (3.0 g, 9.58 mmol, 44% yield over two steps).

[0360] LCMS: Method C1, 1.19 min, MS: ES+314.0, 316.1.

[0361] Step (iii) Ethyl 5-(3-bromophenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(3-bromophenyl)-2-oxoethyl)amino)-2-oxoacetate (3.0 g, 9.58 mmol) in POCl (9.0 mL, 3 volumes) was heated at 100° C. for 3 h. The mixture was cooled to room temperature, poured into ice-cold water (100 mL), and extracted with EtOAc (3×100 mL). The combined organic phases were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexane) to give ethyl 5-(3-bromophenyl)oxazole-2-carboxylate (1.2 g, 4.06 mmol, 42% yield).

[0362] LCMS: Method C1, 1.36 min, MS: ES+: 295.9, 297.9.

[0363] Step (iv) Lithium 5-(3-bromophenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(3-bromophenyl)oxazole-2-carboxylate (1.1 g, 3.72 mmol) in THF:MeOH:water (10 mL, 1:1:1) was added LiOH·HO (0.45 g, 11.18 mmol) portionwise at 0° C. The mixture was stirred at 0° C. for 3 h and then concentrated under reduced pressure to give lithium 5-(3-bromophenyl)oxazole-2-carboxylate (1.1 g, quantitative yield).

[0364] LCMS: Method C1, 1.04 min, MS: ES+268.1, 269.9.

[0365] Intermediate Q Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate [ka]

[0366] Step (i) Methyl 2-cyclopropyl-5-(trifluoromethoxy)benzoate To a stirred solution of methyl 2-bromo-5-(trifluoromethoxy)benzoate (CAS 1150114-81-0, Combi-Blocks, 1.30 g, 4.36 mmol) and cyclopropylboronic acid (CAS 411235-57-9, Angene, 0.37 g, 4.36 mmol) in toluene:water (13 mL, 7:3) was added KPO (1.84 g, 8.69 mmol). The mixture was purged with N for 10 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (0.31 g, 0.43 mmol) and heating at 100 °C for 3 hours. The mixture was poured into water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 2% EtOAc in n-hexane) to give methyl 2-cyclopropyl-5-(trifluoromethoxy)benzoate (0.85 g, 3.26 mmol, 75% yield).

[0367] 1 H NMR(400MHz,CDCl3)δ7.68(s,1H),7.26(d,J=11.6Hz,1H),7.05(d,J=8.8Hz ,1H),3.95(s,3H),2.65-2.69(m,1H),1.02-1.05(m,2H),0.68-0.70(m,2H).

[0368] Step (ii) 2-Cyclopropyl-5-(trifluoromethoxy)benzohydrazide To a stirred solution of methyl 2-cyclopropyl-5-(trifluoromethoxy)benzoate (1.1 g, 4.22 mmol) in MeOH (28 mL) was added hydrazine hydrate (99%) (3.3 mL, 3 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature and stirred for 2 hours. The mixture was concentrated under reduced pressure to give 2-cyclopropyl-5-(trifluoromethoxy)benzohydrazide (1.07 g, 4.13 mmol, 97% yield).

[0369] LCMS: Method C1, 1.11 min, MS: ES+261.5.

[0370] Step (iii) Ethyl 2-(2-(2-cyclopropyl-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate To a stirred solution of 2-cyclopropyl-5-(trifluoromethoxy)benzohydrazide (1.0 g, 3.84 mmol) in DCM (10 mL) was added TEA (1.16 g, 1.6 mL, 11.52 mmol) and ethyl oxalyl chloride (1.04 g, 0.85 mL, 7.68 mmol) dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 2 h, then poured into water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic phases were dried over Na SO , filtered, and concentrated under reduced pressure to give ethyl 2-(2-(2-cyclopropyl-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate (1.64 g, quantitative yield).

[0371] LCMS: Method C1, 1.20 min, MS: ES+361.1.

[0372] Step (iv) Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of ethyl 2-(2-(2-cyclopropyl-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate (1.6 g, 4.44 mmol) in DCM (16 mL) was added TEA (1.34 g, 1.85 mL, 13.32 mmol) and TsCl (1.01 g, 5.32 mmol) portionwise at 0 °C. The mixture was warmed to room temperature and stirred for 2 h, then poured into water (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic phases were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 20% EtOAc in n-hexane) to give ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate (0.6 g, 1.75 mmol, 39% yield over two steps). LCMS: Method C1, 1.43 min, MS: ES+343.1.

[0373] Intermediate R Ethyl 5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate [ka]

[0374] Step (i) tert-Butyl 2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazine-1-carboxylate To a stirred solution of 2-fluoro-5-(trifluoromethoxy)benzoic acid (CAS 886497-85-4, Combi-Blocks, 7.0 g, 31.23 mmol) in THF (70 mL) was added DIPEA (12.08 g, 16 mL, 105.25 mmol) and HATU (23.7 g, 62.46 mmol) in portions at 0 °C. After 30 min, tert-butyl hydrazine carboxylate (4.95 g, 37.48 mmol) was added at 0 °C. The mixture was slowly warmed to room temperature and stirred at room temperature for 16 h, then poured into ice-cold water (50 mL) and extracted with EtOAc (2 × 200 mL). The combined organic phase was dried over Na SO , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 25% EtOAc in n-hexane) to give tert-butyl 2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazine-1-carboxylate (9.0 g, 26.62 mmol, 85% yield).

[0375] LCMS: Method J1, 3.43 min, MS: ES+283.1 (M-56).

[0376] Step (ii) 2-Fluoro-5-(trifluoromethoxy)benzohydrazide TFA salt To a stirred solution of tert-butyl 2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazine-1-carboxylate (5.0 g, 14.78 mmol) in DCM (50 mL) was added TFA (25 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give 2-fluoro-5-(trifluoromethoxy)benzohydrazide TFA salt (5.0 g, quantitative yield).

[0377] LCMS: Method C1, 1.02 min, MS: ES+239.2.

[0378] Step (iii) Ethyl 2-(2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate To a stirred solution of 2-fluoro-5-(trifluoromethoxy)benzohydrazide TFA salt (10.0 g, 20.99 mmol) in DCM (100 mL) was added K2CO3 (17.38 g, 125.97 mmol) at 0 °C. Ethyl oxalyl chloride (8.59 g, 6.97 mL, 62.98 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 4 h. The mixture was poured into water (100 mL), and a precipitate formed. The solid was collected by vacuum filtration to give ethyl 2-(2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate (10.0 g, 29.56 mmol, 88% yield over two steps).

[0379] LCMS: Method C1, 1.13 min, MS: ES+339.2.

[0380] Step (iv) Ethyl 5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of ethyl 2-(2-(2-fluoro-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate (10 g, 29.56 mmol) in DCM (100 mL) was added TEA (12.2 mL, 8.85 g, 88.68 mmol) and TsCl (6.76 g, 35.48 mmol) portionwise at 0 °C. The mixture was warmed to room temperature and stirred for 4 h. The mixture was poured into water (100 mL) and extracted with DCM (2 × 250 mL). The combined organic phases were dried over Na SO , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 10% EtOAc in n-hexane) to give ethyl 5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate (2.6 g, 8.12 mmol, 27% yield).

[0381] LCMS: Method J1, 4.02 min, MS: ES+: 320.8.

[0382] Intermediate S Lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate [ka]

[0383] Step (i) tert-Butyl (2-(5-cyano-2-fluorophenyl)-2-oxoethyl)carbamate To a stirred solution of 3-bromo-4-fluorobenzonitrile (CAS 79630-23-2, Combi-Blocks) (20.0 g, 100.53 mmol) in dry THF (150 mL) was added isopropylmagnesium chloride (2 M in THF) (50.26 mL, 100.53 mmol) dropwise at room temperature under a N atmosphere. The resulting dark solution was stirred at room temperature for 1.5 h, during which time a precipitate formed. Meanwhile, to a stirred suspension of tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate (21.92 g, 100.53 mmol) in THF (50 mL) was added isopropylmagnesium chloride (2 M in THF) (50.26 mL, 100.53 mmol) dropwise at 0 °C. The resulting solution was stirred for 15 min and then added dropwise to the initially generated aryl Grignard at 0 °C. The mixture was stirred at room temperature for 16 hours. The resulting reaction mixture was poured into water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (25% EtOAc in n-hexane) to give tert-butyl (2-(5-cyano-2-fluorophenyl)-2-oxoethyl)carbamate (3.0 g, 10.78 mmol, 10% yield).

[0384] LCMS: Method H1, 3.01 min, MS: ES+179.0 (M-100).

[0385] Step (ii) 4-Fluoro-3-glycylbenzonitrile TFA salt To a stirred solution of tert-butyl (2-(5-cyano-2-fluorophenyl)-2-oxoethyl)carbamate (2.2 g, 7.9 mmol) in DCM (22 mL) was added TFA (6.6 mL, 3 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature and stirred for 3 h, then concentrated under reduced pressure to give 4-fluoro-3-glycylbenzonitrile TFA salt (4.0 g, quantitative yield).

[0386] LCMS: Method C1, 0.37 min, MS: ES+178.9.

[0387] Step (iii) Ethyl 2-((2-(5-cyano-2-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 4-fluoro-3-glycylbenzonitrile TFA salt (4.0 g, 13.6 mmol) in DCM (20 mL) was added TEA (4.1 g, 5.7 mL, 41.0 mmol) at 0 °C. Ethyl oxalyl chloride (3.73 g, 3.0 mL, 27.3 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 2 h, then poured into ice-cold water (150 mL) and extracted with EtOAc (2 × 100 mL). The combined organic phases were dried over NaSO, filtered, and concentrated under reduced pressure to give ethyl 2-((2-(5-cyano-2-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate (2.8 g, 10.07 mmol, 44% yield over two steps).

[0388] LCMS: Method C1, 1.08 min, MS: ES+279.1.

[0389] Step (iv) Ethyl 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(5-cyano-2-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate (2.8 g, 10.07 mmol) in POCl (14 mL, 5 vol) was heated at 100 °C for 3 h. The mixture was cooled to room temperature, poured into ice-cold water (100 mL), and extracted with EtOAc (2 × 200 mL). The combined organic phases were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexane) to give ethyl 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate (0.8 g, 3.07 mmol, 38% yield over two steps).

[0390] LCMS: Method C1, 1.19 min, MS: ES+261.1.

[0391] Step (v) Lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate (0.8 g, 3.07 mmol) in THF (8 mL) was added dropwise a solution of LiOH·HO (0.15 g, 3.69 mmol) in water (2 mL) at 0°C and stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure to give lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate (0.9 g, quantitative yield).

[0392] LCMS: Method C1, 0.92 min, MS: ES+232.9.

[0393] Intermediate Y 2-Fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid [ka] To a stirred solution of 4-bromo-2-fluorobenzoic acid (CAS 112704-79-7, Ark-Pharma, 2.5 g, 11.47 mmol) and (1-methyl-1H-indazol-5-yl)boronic acid (CAS 590418-08-9, BLD-Pharma, 2.22 g, 12.61 mmol) in 1,4-dioxane:water (25 mL, 9:1) was added KPO (4.86 g, 22.94 mmol). The mixture was purged with N for 15 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.83 g, 1.14 mmol) and heating at 100 °C for 3 hours. The mixture was poured into water (100 mL) and extracted with EtOAc (2 × 150 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexane) to give 2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid (1.7 g, 6.29 mmol, 54% yield).

[0394] LCMS: Method J1, 3.08 min, MS: ES+271.1.

[0395] Intermediate Z 3-(3-(trifluoromethoxy)phenyl)pyrrolidine TFA salt [ka]

[0396] Step (i) tert-Butyl 4-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-pyrrole-1-carboxylate To a stirred solution of NaHMDS (1 M in THF) (5.39 mL, 5.39 mmol) in THF (4 mL), tert-butyl 3-oxopyrrolidine-1-carboxylate (CAS 101385-93-7, Combi-Blocks, 0.50 g, 2.69 mmol) was added portionwise at −78° C. and stirred for 15 min at −78° C. A solution of 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (CAS 37595-74-7, TCI, 0.90 g, 2.69 mmol) in THF (4 mL) was added dropwise and stirred for 2 h at −78° C. Three more identical batches were carried out in the same manner, and all four reaction mixtures were combined, poured into water (100 mL), and extracted with EtOAc (3×100 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-pyrrole-1-carboxylate (3.3 g, 10.4 mmol, 96% yield). The crude product was carried on to the next step.

[0397] Step (ii) tert-Butyl 4-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-pyrrole-1-carboxylate (2.50 g, 7.88 mmol) and (3-(trifluoromethoxy)phenyl)boronic acid (CAS 179113-90-7, Combi-Blocks, 1.61 g, 7.88 mmol) in 1,4-dioxane:water (10 mL, 8:2) was added KPO (5.0 g, 2.36 mmol). The mixture was purged with N for 20 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.50 g, 0.78 mmol) and heating at 80 °C for 2 hours. The mixture was poured into water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 4% EtOAc in n-hexane) to give tert-butyl 4-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrole-1-carboxylate (1.1 g, 3.34 mmol, 42% yield). MS: ES+ 273.97 (M-56).

[0398] Step (iii) tert-Butyl 3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl 4-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-pyrrole-1-carboxylate (1.0 g, 3.03 mmol) in MeOH (5 mL) was added 10% Pd / C (50% water) (0.5 g, 0.5 w / w). The mixture was purged with H gas for 2 h, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give tert-butyl 3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxylate (0.5 g, 1.51 mmol, 49% yield).

[0399] LCMS: Method C1, 1.47 min, MS: ES+275.9 (M-56).

[0400] Step (iv) 3-(3-(trifluoromethoxy)phenyl)pyrrolidine TFA salt To a stirred solution of tert-butyl 3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxylate (0.45 g, 1.45 mmol) in DCM (4 mL) was added TFA (2.4 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give 3-(3-(trifluoromethoxy)phenyl)pyrrolidine TFA salt (0.65 g, quantitative yield).

[0401] LCMS: Method C1, 1.14 min, MS: ES+232.0.

[0402] Intermediate Z1 Ethyl 5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate [ka]

[0403] Step (i) 4-Fluoro-N-methoxy-N-methyl-3-(trifluoromethoxy)benzamide To a stirred solution of 4-fluoro-3-(trifluoromethoxy)benzoic acid (CAS 886496-49-7, Combi-Blocks, 5.0 g, 22.32 mmol) in THF (50 mL) was added DIPEA (8.63 g, 11.44 mL, 66.96 mmol) and HATU (12.72 g, 33.48 mmol) portionwise at 0 °C. After 30 min, N,O-dimethylhydroxylamine HCl (2.39 g, 24.55 mmol) was added at 0 °C. The mixture was allowed to warm to room temperature and stirred at room temperature for 16 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (2 × 150 mL). The combined organic phase was dried over Na SO , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 16% EtOAc in n-hexane) to give 4-fluoro-N-methoxy-N-methyl-3-(trifluoromethoxy)benzamide (4.80 g, 17.97 mmol, 81% yield).

[0404] LCMS: Method J1, 3.78 min, MS: ES+267.8.

[0405] Step (ii) 1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one To a stirred solution of 4-fluoro-N-methoxy-N-methyl-3-(trifluoromethoxy)benzamide (4.80 g, 17.97 mmol) in THF (48 mL) was added methylmagnesium bromide (3 M in diethyl ether) (17.97 mL, 53.91 mmol) dropwise at 0 °C. The mixture was warmed to room temperature and stirred at room temperature for 16 h, then poured into water (150 mL), 1 N HCl (10 mL) was added, and extracted with EtOAc (2 × 150 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 12% EtOAc in n-hexane) to give 1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (3.0 g, 13.51 mmol, 75% yield).

[0406] 1H NMR (400MHz, DMSO-d6) δppm: 8.06-8.12 (m, 2H), 7.70 (t, J = 8.8Hz, 1H), 2.62 (s, 3H).

[0407] Step (iii) 2-Bromo-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one To a stirred solution of 1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (3.0 g, 13.51 mmol) in THF (30 mL) was added pyridinium tribromide (4.75 g, 14.86 mmol) portionwise at room temperature and stirred at room temperature for 16 hours. The mixture was poured into water (150 mL) and extracted with EtOAc (2×200 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% n-hexane) to give 2-bromo-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (2.0 g, 6.66 mmol, 49% yield). The material was carried on to the next step.

[0408] Step (iv) 2-Amino-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one HCl salt To a stirred solution of 2-bromo-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one (2.0 g, 6.66 mmol) in MeCN (20 mL) was added sodium diformylamide (0.76 g, 7.99 mmol) and heated at 80° C. for 16 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with MeOH (20 mL) and concentrated HCl (2 mL). The mixture was further stirred at 80° C. for 16 h and then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was stirred with diethyl ether (20 mL) to form a precipitate. The solid was collected by vacuum filtration to give 2-amino-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (2.9 g, quantitative yield).

[0409] LCMS: Method J1, 2.47 min, MS: ES+238.0.

[0410] Step (v) Ethyl 2-((2-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-oxoethyl)amino)-2-oxoacetate To a stirred solution of 2-amino-1-(4-fluoro-3-(trifluoromethoxy)phenyl)ethan-1-one HCl salt (2.90 g, 10.60 mmol) in DCM (30 mL) at 0 °C was added K2CO3 (4.39 g, 31.8 mmol). Ethyl oxalyl chloride (2.17 g, 1.77 mL, 15.9 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 4 h, then poured into water (50 mL) and extracted with DCM (2 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to give ethyl 2-((2-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-oxoethyl)amino)-2-oxoacetate (1.70 g, 5.04 mmol, 75% yield over two steps).

[0411] LCMS: Method J1, 3.80 min, MS: ES+337.8.

[0412] Step (vi) Ethyl 5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-oxoethyl)amino)-2-oxoacetate (1.70 g, 5.04 mmol) in POCl (9 mL, 5.3 vol) was heated at 120 °C for 16 h. The mixture was cooled to room temperature, poured slowly onto crushed ice, and extracted with EtOAc (2 × 100 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexane) to give ethyl 5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.96 g, 3.01 mmol, 60% yield).

[0413] LCMS: Method J1, 3.86 min, MS: ES+320.1.

[0414] Intermediate Z2 Ethyl 5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate [ka]

[0415] Step (i) Methyl 2-(azetidin-1-yl)-5-bromonicotinate To a stirred solution of azetidine hydrochloride (CAS 36520-39-5, Combi-Blocks, 1.79 g, 19.27 mmol) in DMSO (40 mL), K2CO3 (6.64 g, 48.18 mmol) was added at room temperature and stirred for 5 minutes. Methyl 5-bromo-2-chloronicotinate (CAS 78686-79-0, Combi-Blocks, 4.0 g, 16.06 mmol) was added at room temperature, and the mixture was heated at 80 °C for 2 hours. The mixture was poured into ice-cold water (100 mL), forming a precipitate. The solid was collected by vacuum filtration to give methyl 2-(azetidin-1-yl)-5-bromonicotinate (3.8 g, 14.07 mmol, 87% yield).

[0416] LCMS: Method C1, 1.35 min, MS: ES+271.1, 273.1.

[0417] Step (ii) Methyl 2-(azetidin-1-yl)-5-cyanonicotinate To a stirred solution of methyl 2-(azetidin-1-yl)-5-bromonicotinate (1.90 g, 7.03 mmol) in DMF (19 mL) was added zinc cyanide (2.46 g, 21.09 mmol) and zinc dust (0.23 g, 3.51 mmol) at room temperature. The mixture was degassed with N gas for 10 minutes, followed by the addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II] (0.26 g, 0.35 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (0.39 g, 0.70 mmol). The mixture was heated at 130° C. for 2 hours. Another identical batch was carried out in the same manner, and both reaction mixtures were mixed. The resulting mixture was poured into ice-cold water (50 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 14% EtOAc in n-hexane) to give methyl 2-(azetidin-1-yl)-5-cyanonicotinate (1.3 g, 5.99 mmol, 42% yield).

[0418] LCMS: Method C1, 1.14 min, MS: ES+: 218.1.

[0419] Step (iii) 2-(azetidin-1-yl)-5-cyanonicotinohydrazide Methyl 2-(azetidin-1-yl)-5-cyanonicotinate (1.2 g, 5.52 mmol) was added to hydrazine hydrate (99%) (31.2 mL, 26 volumes) at 0° C. The mixture was stirred at room temperature for 8 hours and then poured into water (20 mL), forming a precipitate. The solid was collected by vacuum filtration to give 2-(azetidin-1-yl)-5-cyanonicotinohydrazide (0.90 g, 4.14 mmol, 75% yield).

[0420] LCMS: Method C1, 0.79 min, MS: ES+218.2.

[0421] Step (iv) Ethyl 5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of 2-(azetidin-1-yl)-5-cyanonicotinohydrazide (0.9 g, 4.14 mmol) in DCM (10 mL) was added TEA (1.25 g, 1.72 mL, 12.42 mmol) and ethyl oxalyl chloride (0.85 g, 0.69 mL, 6.21 mmol) dropwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h. TEA (1.25 g, 1.72 mL, 12.42 mmol) and TsCl (0.94 g, 4.96 mmol) were added portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h. The resulting mixture was poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 27% EtOAc in n-hexane) to give ethyl 5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate (0.55 g, 1.83 mmol, 44% yield).

[0422] LCMS: Method C1, 1.20 min, MS: ES+300.2.

[0423] Intermediate Z3 Ethyl 5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate [ka]

[0424] Step (i) Methyl 5-bromo-2-(pyrrolidin-1-yl)nicotinate To a stirred solution of pyrrolidine (3.56 g, 50.2 mmol) in DMSO (50 mL), K2CO3 (8.31 g, 60.24 mmol) was added at room temperature and stirred for 5 minutes. Methyl 5-bromo-2-chloronicotinate (CAS 78686-79-0, Combi-Blocks, 5.0 g, 20.08 mmol) was added to the reaction mixture at room temperature and heated at 80 °C for 2 hours. The mixture was poured into ice-cold water (100 mL), forming a precipitate. The solid was collected by vacuum filtration to give methyl 5-bromo-2-(pyrrolidin-1-yl)nicotinate (4.8 g, 16.90 mmol, 84% yield). LCMS: Method C1, 1.37 min, MS: ES+ 285.1, 287.0.

[0425] Step (ii) Methyl 5-cyano-2-(pyrrolidin-1-yl)nicotinate To a stirred solution of methyl 5-bromo-2-(pyrrolidin-1-yl)nicotinate (0.50 g, 1.76 mmol) in DMF (5 mL) was added zinc cyanide (0.62 g, 5.28 mmol) and zinc dust (0.06 g, 0.88 mmol) at room temperature. The reaction mixture was degassed with N gas for 10 minutes, followed by the addition of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II] (0.06 g, 0.09 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (0.14 g, 0.26 mmol). The reaction mixture was heated at 130° C. for 2 hours. Eight more identical batches were carried out in the same manner, and all nine reaction mixtures were combined for workup. The resulting mixture was poured into ice-cold water (100 mL) and extracted with EtOAc (2 × 100 mL). The combined organic phase was washed with ice-cold water (4 × 100 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 34% EtOAc in n-hexane) to give methyl 5-cyano-2-(pyrrolidin-1-yl)nicotinate (2.0 g, 8.65 mmol, 54% yield).

[0426] LCMS: Method C1, 1.20 min, MS: ES+: 232.1.

[0427] Step (iii) 5-Cyano-2-(pyrrolidin-1-yl)nicotinohydrazide To a stirred solution of methyl 5-cyano-2-(pyrrolidin-1-yl)nicotinate (2.0 g, 8.65 mmol) in ethanol (20 mL) was added hydrazine hydrate (99%) (20 mL, 10 volumes) at room temperature. The mixture was heated at 80° C. for 16 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was suspended in water (20 mL) to form a precipitate. The solid was collected by vacuum filtration to give 5-cyano-2-(pyrrolidin-1-yl)nicotinohydrazide (0.72 g, 3.11 mmol, 36% yield).

[0428] LCMS: Method C1, 0.90 min, MS: ES+232.1.

[0429] Step (iv) Ethyl 5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of 5-cyano-2-(pyrrolidin-1-yl)nicotinohydrazide (0.72 g, 3.11 mmol) in DCM (7 mL) was added TEA (0.94 g, 1.29 mL, 9.33 mmol) and ethyl oxalyl chloride (0.46 g, 0.38 mL, 3.42 mmol) dropwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h. TEA (0.94 g, 1.29 mL, 9.33 mmol) and TsCl (0.71 g, 3.73 mmol) were added portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h, then poured into water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 30% EtOAc in n-hexane) to give ethyl 5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate (0.23 g, 0.73 mmol, 23% yield).

[0430] LCMS: Method C1, 1.25 min, MS: ES+314.1.

[0431] Intermediate Z4 Ethyl 5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate [ka]

[0432] Step (i) Methyl 2-chloro-5-(trifluoromethoxy)benzoate To an autoclave charged with a solution of 2-bromo-1-chloro-4-(trifluoromethoxy)benzene (CAS 468075-00-5, Combi-Blocks, 5.0 g, 18.25 mmol) in MeOH (100 mL) was added TEA (5.54 g, 7.63 mL, 54.76 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.33 g, 1.82 mmol). The mixture was heated at 80 °C for 16 h under CO gas (50 psi). The mixture was filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure. The residue was poured into water (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5% EtOAc in n-hexane) to give methyl 2-chloro-5-(trifluoromethoxy)benzoate (3.0 g, 11.81 mmol, 65% yield).

[0433] 1 H NMR (400MHz, DMSO-d6) δppm: 7.79 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H), 3.88 (s, 3H).

[0434] Step (ii) 2-Chloro-5-(trifluoromethoxy)benzohydrazide To a stirred solution of methyl 2-chloro-5-(trifluoromethoxy)benzoate (3.0 g, 3.81 mmol) in MeOH (30 mL) was added hydrazine hydrate (99%) (15 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to provide 2-chloro-5-(trifluoromethoxy)benzohydrazide (2.50 g, 9.84 mmol, 83% yield).

[0435] LCMS: Method H1, 2.37 min, MS: ES+254.9.

[0436] Step (iii) Ethyl 5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of 2-chloro-5-(trifluoromethoxy)benzohydrazide (2.50 g, 9.84 mmol) in DCM (25 mL) was added TEA (2.98 g, 4.11 mL, 29.52 mmol) and ethyl oxalyl chloride (1.47 g, 1.56 mL, 10.82 mmol) dropwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h. TsCl (2.24 g, 11.81 mmol) was added portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred at room temperature for 2 h, then poured into water (50 mL) and extracted with DCM (3 × 50 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 5% EtOAc in n-hexane) to give ethyl 5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate (1.5 g, 4.46 mmol, 45% yield).

[0437] LCMS: Method C1, 1.34 min, MS: ES+337.0.

[0438] Intermediate Z5 Ethyl 5-(2-bromo-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate Step (i) 2-Bromo-5-(trifluoromethoxy)benzohydrazide To a stirred solution of methyl 2-bromo-5-(trifluoromethoxy)benzoate (CAS 1150114-81-0, Enamine, 7.0 g, 23.49 mmol) in MeOH (70 mL) was added hydrazine hydrate (99%) (21 mL, 3 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 2 hours, and then concentrated under reduced pressure to give 2-bromo-5-(trifluoromethoxy)benzohydrazide (5.10 g, 17.11 mmol, 73% yield). LCMS: Method C, 1.39 min, MS: ES+ 299.0, 301.0.

[0439] Step (ii) Ethyl 2-(2-(2-bromo-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate To a stirred solution of 2-bromo-5-(trifluoromethoxy)benzohydrazide (5.10 g, 17.11 mmol) in DCM (51 mL) was added TEA (5.19 g, 7.2 mL, 51.34 mmol) and ethyl oxalyl chloride (2.80 g, 2.29 mL, 20.53 mmol) dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 2 h, then poured into water (50 mL) and extracted with DCM (3 × 30 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give ethyl 2-(2-(2-bromo-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate (8.0 g, quantitative yield).

[0440] LCMS: Method C1, 1.12 min, MS: ES+399.0, 401.0.

[0441] Step (iii) Ethyl 5-(2-bromo-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate To a stirred solution of ethyl 2-(2-(2-bromo-5-(trifluoromethoxy)benzoyl)hydrazinyl)-2-oxoacetate (8.0 g, 20.10 mmol) in DCM (80 mL) was added TEA (6.10 g, 8.40 mL, 60.30 mmol) and TsCl (3.81 g, 20.10 mmol) portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 2 h, then poured into water (50 mL) and extracted with DCM (3 × 30 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 12% EtOAc in n-hexane) to give ethyl 5-(2-bromo-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate (3.63 g, 9.55 mmol, 56% yield over two steps). LCMS: Method C1, 1.35 min, MS: ES+ 380.9, 382.9.

[0442] Intermediate Z6 Ethyl 3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxylate [ka]

[0443] Step (i) 2-Amino-5-(trifluoromethoxy)benzonitrile To a stirred solution of 2-bromo-4-(trifluoromethoxy)aniline (CAS 175278-17-8, BLDpharm, 20.0 g, 78.44 mmol) in NMP (150 mL) was added CuCN (14.0 g, 156.80 mmol) and heated at 165 °C for 18 h. The mixture was poured into aqueous ammonia (300 mL) and extracted with EtOAc (3 × 300 mL). The combined organic phases were dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 8% EtOAc in n-hexane) to give 2-amino-5-(trifluoromethoxy)benzonitrile (11.2 g, 55.43 mmol, 70% yield).

[0444] LCMS: Method H1, 3.04 min, MS: ES-201.0.

[0445] Step (ii) 2-Iodo-5-(trifluoromethoxy)benzonitrile To a stirred solution of 2-amino-5-(trifluoromethoxy)benzonitrile (6.0 g, 29.69 mmol) in concentrated HCl (60 mL) was added NaNO (4.0 g, 57.97 mmol) portionwise at 0 °C and stirred for 10 min at 0 °C. A solution of KI (24.63 g, 74.09 mmol) in water (60 mL) was added dropwise at 0 °C and stirred for 0.5 h. The mixture was poured into water (300 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phases were washed with 10% sodium thiosulfate solution (2 × 150 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 6% EtOAc in n-hexane) to give 2-iodo-5-(trifluoromethoxy)benzonitrile (7.79 g, 24.89 mmol, 84% yield).

[0446] 1 H NMR (400MHz, DMSO-d6) δppm: 8.13-8.16 (m, 1H), 8.01 (s, 1H), 7.48 (d, J = 8.4Hz, 1H).

[0447] Step (iii) 2-Cyclopropyl-5-(trifluoromethoxy)benzonitrile To a stirred solution of 2-iodo-5-(trifluoromethoxy)benzonitrile (2.6 g, 8.30 mmol) and cyclopropylboronic acid (CAS 411235-57-9, Combi-Blocks, 1.42 g, 16.53 mmol) in toluene:water (10 mL, 4:1) was added KPO (3.52 g, 16.60 mmol). The mixture was purged with N for 10 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.67 g, 0.91 mmol) and heating at 100 °C for 1 hour. Two more identical batches were performed in the same manner, and all three reaction mixtures were combined, poured into water (500 mL), and extracted with EtOAc (3 × 200 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 0.5% EtOAc in n-hexane) to give 2-cyclopropyl-5-(trifluoromethoxy)benzonitrile (8.2 g, quantitative yield).

[0448] 1 H NMR(400MHz,DMSO-d6)δppm:7.90(s,1H),7.60(d,J=8.4Hz,1H),7.21(d,J=8.8Hz,1H),2.16-2.19(m,1H),1.12-1.14(m,2H),0.84-0.85(m,2H).

[0449] Step (iv) (Z)-2-Cyclopropyl-N'-hydroxy-5-(trifluoromethoxy)benzimidamide To a stirred solution of 2-cyclopropyl-5-(trifluoromethoxy)benzonitrile (4.0 g, 17.62 mmol) and sodium hydroxide (2.11 g, 52.75 mmol) in EtOH:water (23 mL, 2:1) was added hydroxylamine HCl (3.67 g, 52.81 mmol) and heated at 40 °C for 48 h. The mixture was concentrated under reduced pressure, poured into water (100 mL), and extracted with EtOAc (3 × 100 mL). The combined organic phases were dried over anhydrous NaSO and concentrated under reduced pressure to give (Z)-2-cyclopropyl-N'-hydroxy-5-(trifluoromethoxy)benzimidamide (4.40 g, 16.92 mmol, 96% yield).

[0450] LCMS: Method H1, 2.79 min, MS: ES+261.0.

[0451] Step (v) Ethyl 3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxylate To a stirred solution of (Z)-2-cyclopropyl-N'-hydroxy-5-(trifluoromethoxy)benzimidamide (1.50 g, 5.76 mmol) in pyridine (5 mL) was added oxalylethyl chloride (1.18 g, 0.98 mL, 8.64 mmol) dropwise at 0 °C. The mixture was heated at 80 °C for 3 h, then cooled to room temperature and concentrated under reduced pressure. The resulting crude product was diluted with water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phases were dried over anhydrous NaSO and concentrated under reduced pressure to give ethyl 3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxylate (1.44 g, 4.20 mmol, 73% yield). LCMS: Method C, 2.05 min, MS: ES+ 343.1.

[0452] Intermediate Z7 Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxylate [ka]

[0453] Step (i) 2-Cyclopropyl-5-(trifluoromethoxy)benzoic acid To a stirred solution of methyl 2-cyclopropyl-5-(trifluoromethoxy)benzoate (1.10 g, 4.23 mmol) in THF:water (10 mL, 1:1), LiOH.HO (0.35 g, 8.46 mmol) was added portionwise at room temperature and stirred for 4 hours. The mixture was then poured into water (30 mL), acidified to approximately pH 4 with citric acid, and extracted with EtOAc (2 × 70 mL). The combined organic phases were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give 2-cyclopropyl-5-(trifluoromethoxy)benzoic acid (1.08 g, quantitative yield). LCMS: Method J1, 3.91 min, MS: ES+ 244.8.

[0454] Step (ii) Ethyl (Z)-2-(2-cyclopropyl-5-(trifluoromethoxy)benzamido)-2-(hydroxyimino)acetate To a stirred solution of 2-cyclopropyl-5-(trifluoromethoxy)benzoic acid (1.20 g, 4.87 mmol) in THF (12 mL) were added DIPEA (1.88 g, 2.5 mL, 14.63 mmol) and HATU (2.78 g, 7.31 mmol) in portions at 0° C. After 30 min, ethyl (Z)-2-amino-2-(hydroxyimino)acetate (CAS 10489-74-4, Combi-Blocks, 0.77 g, 5.85 mmol) was added at 0° C. The mixture was allowed to warm slowly to room temperature and stirred at room temperature for 4 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (2×70 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure to give ethyl (Z)-2-(2-cyclopropyl-5-(trifluoromethoxy)benzamido)-2-(hydroxyimino)acetate (0.90 g, 2.50 mmol, 59% yield over two steps). LCMS: Method J1, 3.71 min, MS: ES+361.2.

[0455] Step (iii) Ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxylate A solution of ethyl (Z-2-(2-cyclopropyl-5-(trifluoromethoxy)benzamido)-2-(hydroxyimino)acetate (0.90 g, 2.50 mmol) in pyridine (5 mL) was heated at 110° C. for 16 h. The mixture was warmed to room temperature, poured into water (30 mL), and extracted with EtOAc (2×50 mL). The combined organic phases were dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 12% EtOAc in n-hexane) to give ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxylate (0.17 g, 0.49 mmol, 20% yield over two steps). LCMS: Method J1, 4.50 min, MS: ES+ 342.9.

[0456] Synthesis of Examples Example 1 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide [ka]

[0457] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.3 g, 1.15 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamino)pyrrolidine-1-carboxylate (0.35 g, 1.13 mmol) in pyridine (5 mL) at 0 °C was added POCl (0.53 g, 0.3 mL, 3.45 mmol) dropwise. The mixture was stirred at room temperature for 2 h, then poured into water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.22 g, 0.41 mmol, 36% yield).

[0458] LCMS: Method H1, 3.24 min, MS: ES+544.2.

[0459] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.22 g, 0.40 mmol) in DCM (5 mL) was added TFA (1.1 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt (0.25 g, quantitative yield).

[0460] LCMS: Method H1, 2.62 min, MS: ES+444.2.

[0461] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt (0.25 g, 0.45 mmol) in THF (5 mL) was added K2CO3 (0.18 g, 1.34 mmol) at room temperature and stirred for 5 min. The mixture was cooled to 0 °C, and then cyanogen bromide (0.05 g, 0.45 mmol) was added. The mixture was allowed to warm to room temperature, stirred for 1 h, then poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80–90% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide (0.02 g, 0.05 mmol, 13% yield over two steps).

[0462] LCMS: Method H1, 2.88 min, MS: ES+469.2; 1 H NMR(400MHz,DMSO-d6)δppm:8.23(s,1H),8.13(s,1H),7.92(s,1H),7.83(d,J=8 .4Hz,1H),7.79(s,1H),7.41(d,J=8.4Hz,1H),4.61-4.62(m,2H),4.30-4.45(m, 2H),3.76-3.79(m,1H),3.62-3.66(m,1H),2.90-2.31(m,1H),2.19-2.20(m,3H) ,1.14-1.16(m,2H),0.83-0.85(m,2H),0.57-0.70(m,4H); Chiral SFC: Method Y21, 9.34 min.

[0463] Example 2 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide [ka]

[0464] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.3 g, 1.14 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(cyclopropylamino)pyrrolidine-1-carboxylate (0.35 g, 1.14 mmol) in pyridine (3 mL) at 0 °C was added POCl (0.52 g, 0.32 mL, 3.42 mmol) dropwise. The mixture was stirred at room temperature for 20 min, then poured into water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 65% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.30 g, 0.55 mmol, 48% yield).

[0465] LCMS: Method H1, 3.96 min, MS: ES+545.2.

[0466] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.30 g, 0.55 mmol) in DCM (3 mL) was added TFA (1.5 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamide TFA salt (0.40 g, quantitative yield).

[0467] LCMS: Method J1, 2.75 min, MS: ES+445.3.

[0468] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamide TFA salt (0.40 g, 0.71 mmol) in THF (4 mL) was added K2CO3 (0.29 g, 2.15 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.07 g, 0.71 mmol) was added at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (30 mL) and extracted with EtOAc (2 × 30 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyl-1,3,4-oxadiazole-2-carboxamide (0.09 g, 0.18 mmol, 35% yield over two steps).

[0469] LCMS: Method H1, 2.77 min, MS: ES+470.2; 1 H NMR(400MHz,DMSO-d6)δppm:8.34(s,1H),8.24(s,1H),8.0(d,J=8.0Hz,1H),7.80(s,1 H),7.36(d,J=8.0Hz,1H),4.62-4.63(m,2H),4.35-4.42(m,2H),3.78-3.82(m,1H),3. 65-3.69(m,1H),3.05-3.17(m,1H),2.80-2.91(m,1H),2.59-2.64(m,1H),2.17-2.25( m,1H),1.14-1.23(m,2H),0.9-1.0(m,2H),0.60-0.83(m,4H); Chiral SFC: Method Y28, 14.39 min.

[0470] Example 3 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide [ka]

[0471] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-cyanophenyl)oxazole-2-carboxylate (0.54 g, 2.24 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.30 g, 1.12 mmol) in THF (6 mL) was added TBD (0.31 g, 2.24 mmol) in portions at 0 °C. The mixture was allowed to warm to room temperature, stirred for 24 h, and heated at 70 °C for 24 h. The mixture was poured into water (100 mL) and extracted with EtOAc (4 × 100 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 3.5% MeOH in DCM) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.14 g, 0.30 mmol, 27% yield).

[0472] LCMS: Method C, 1.52 min, MS: ES+464.5.

[0473] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.14 g, 0.30 mmol) in DCM (2.8 mL) was added TFA (0.7 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.15 g, quantitative yield).

[0474] LCMS: Method C, 1.33 min, MS: ES+364.5.

[0475] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol) in THF (3 mL) was added K2CO3 (0.13 g, 0.94 mmol) at room temperature and stirred for 5 min. Cyanogen bromide (0.03 g, 0.31 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 h and then poured into ice-cold water (100 mL), and the solid was filtered through a Buchner funnel and washed with n-hexane (2 × 100 mL). The solid residue was purified by trituration with diethyl ether (2 × 5 mL) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.07 g, 0.18 mmol, 59% yield over two steps).

[0476] LCMS: Method H, 2.27 min, MS: ES+389.1;1 H NMR(400MHz,DMSO-d6)δppm:9.39(d,J=6.8Hz,1H),8.34(s,1H),8.20(s,1H), 8.14(d,J=8.0Hz,1H),8.10(s,1H),7.92(d,J=7.6Hz,1H),7.78(s,1H),7.75( t,J=8.0Hz,1H),4.61-4.63(m,2H),4.33-4.38(m,2H),3.65-3.69(m,1H),3.3 9-3.43(m,1H),2.16-2.25(m,1H),1.95-2.03(m,1H); Chiral SFC: Method Y12A, 4.55 minutes.

[0477] Example 4 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide [ka]

[0478] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.20 g, 0.66 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.18 g, 0.66 mmol) in THF (10 mL) was added DBU (1 mL, 5 vol) at room temperature and stirred for 16 h. The mixture was poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.08 g, 0.15 mmol, 23% yield).

[0479] LCMS: Method C1, 1.28 min, MS: ES+523.4.

[0480] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.08 g, 0.15 mmol) in DCM (3 mL) was added TFA (0.4 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.14 g, quantitative yield).

[0481] LCMS: Method C1, 1.07 min, MS: ES+423.3.

[0482] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.14 g, 0.25 mmol) in THF (3 mL) was added K2CO3 (0.07 g, 0.51 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.04 g, 0.38 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 68% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.03 g, 0.08 mmol, 51% yield over two steps).

[0483] LCMS: Method H1, 2.80 min, MS: ES+448.2; 1H NMR(400MHz,DMSO-d6)δppm:9.38(d,J=6.4Hz,1H),8.20(s,1H),8.10(s,1H), 7.88(d,J=7.6Hz,1H),7.83(s,1H),7.79(s,1H),7.69(t,J=8.0Hz,1H),7.47( d,J=8.0Hz,1H),4.62-4.65(m,2H),4.33-4.41(m,2H),3.66-3.70(m,1H),3.4 0-3.44(m,1H),2.18-2.25(m,1H),1.97-2.03(m,1H); Chiral SFC: Method Y12A, 3.77 minutes.

[0484] Example 5 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide [ka]

[0485] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-chlorophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of 5-(3-chlorophenyl)oxazole-2-carboxylic acid (0.1 g, 0.44 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.10 g, 0.37 mmol) in THF (5 mL) was added DIPEA (0.14 g, 0.19 mL, 1.11 mmol) and HATU (0.35 g, 0.92 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (2 × 30 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-chlorophenyl)-oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol, 84% yield).

[0486] LCMS: Method C1, 1.27 min, MS: ES+473.4.

[0487] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-chlorophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol) in DCM (3 mL) was added TFA (2.25 mL, 15 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide TFA salt (0.10 g, 0.20 mmol, 64% yield).

[0488] LCMS: Method C1, 1.04 min, MS: ES+373.3.

[0489] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide TFA salt (0.10 g, 0.20 mmol) in MeCN (3 mL) was added K2CO3 (0.08 g, 0.62 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.03 g, 0.24 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (20 mL) and extracted with EtOAc (2 × 20 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide (0.04 g, 0.10 mmol, 49% yield), which was further purified by reverse-phase preparative HPLC (Method X1) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide (0.02 g, 0.05 mmol, 23% yield).

[0490] LCMS: Method H1, 2.64 min, MS: ES+398.0; 1H NMR(400MHz,DMSO-d6)δppm:9.37(d,J=6.8Hz,1H),8.20(s,1H),8.06(s,1H),7.93(s,1H),7.79-7.81(m,2H),7.51-7.59(m,2H),4.6 2-4.64(m,2H),4.34-4.38(m,2H),3.66-3.70(m,1H),3.40-3.44(m,1H),2.18-2.24(m,1H),1.96-2.03(m,1H);Chiral SFC: Method Y20, 5.44 min.

[0491] Example 6 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide [ka]

[0492] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-methoxyphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of 5-(2-methoxyphenyl)oxazole-2-carboxylic acid (0.2 g, 0.91 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.21 g, 1.01 mmol) in THF (5 mL) was added DIPEA (0.35 g, 0.49 mL, 1.11 mmol) and HATU (0.52 g, 1.36 mmol) at 0 °C. The mixture was stirred at room temperature for 12 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (2 × 30 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 50% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-methoxyphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.18 g, 0.38 mmol, 42% yield).

[0493] LCMS: Method C1, 1.22 min, MS: ES+469.8.

[0494] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-methoxyphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.18 g, 0.38 mmol) in DCM (3 mL) was added TFA (1.08 mL, 6 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide TFA salt (0.15 g, quantitative yield).

[0495] LCMS: Method C1, 1.00 min, MS: ES+369.4.

[0496] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol) in THF (5 mL) was added K2CO3 (0.12 g, 0.93 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.03 g, 0.34 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (20 mL) and extracted with EtOAc (2 × 20 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide (0.09 g, 0.22 mmol, 59% yield over two steps).

[0497] LCMS: Method H1, 2.47 min, MS: ES+394.2; 1H NMR(400MHz,DMSO-d6)δppm:9.33(d,J=6.4Hz,1H),8.19(s,1H),7.82(dd,J=1.2,7 .6Hz,1H),7.78(s,1H),7.71(s,1H),7.42-7.47(m,1H),7.21(d,J=8.4,Hz1H),7.13 (t,J=7.6Hz,1H),4.61-4.62(m,2H),4.34-4.39(m,2H),3.97(s,3H),3.64-3.68(m, 1H),3.38-3.43(m,1H),2.17-2.24(m,1H),1.95-2.01(m,1H); Chiral SFC: Method Y4, 5.36 minutes.

[0498] Example 7 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide [ka]

[0499] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate A stirred solution of ethyl 5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.7 g, 2.71 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.76 g, 2.84 mmol) in THF (7 mL) was purged with N for 10 min. TBD (0.41 g, 2.98 mmol) was added portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred at room temperature for 16 h. The mixture was poured into water (50 mL) and the precipitated solid was collected by vacuum filtration, washed with water (2 × 10 mL), n-hexane (2 × 20 mL) and dried under reduced pressure to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.46 g, 0.97 mmol, 36% yield).

[0500] LCMS: Method C1, 1.29 min, MS: ES+480.41.

[0501] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.46 g, 0.95 mmol) in DCM (5 mL) was added TFA (2.3 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt. (0.48g, quantitative yield).

[0502] LCMS: Method C1, 1.03 min, MS: ES+380.2.

[0503] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.48 g, 0.97 mmol) in THF (5 mL) was added K2CO3 (0.40 g, 2.92 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.10 g, 0.97 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide (0.1 g, 0.24 mmol, 26% yield over two steps).

[0504] LCMS: Method H1, 2.72 min, MS: ES+405.2; 1H NMR(400MHz,DMSO-d6)δ9.77(d,J=6.4Hz,1H),8.21(s,1H),7.89(d,J=7.6Hz,1H),7.80(s ,1H),7.56(t,J=7.6Hz,1H),7.41(t,J=7.6Hz,1H),7.19(d,J=7.6Hz,1H),4.64-4.65(m,2H ),4.36-4.39(m,2H),3.67-3.71(m,1H),3.43-3.46(m,1H),2.69-2.71(m,1H),2.19-2.25 (m,1H),1.99-2.04(m,1H),1.03-1.04(m,2H),0.77-0.78(m,2H); Chiral HPLC: Method Y21, 10.58 min.

[0505] Example 8 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide [ka]

[0506] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 2.12 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.45 g, 1.70 mmol) in THF (10 mL) was added DIPEA (0.82 g, 1.09 mL, 6.38 mmol) at 0 °C. After 10 min, T3P (50% in EtOAc) (1.01 g, 2.02 mL, 3.19 mmol) was added dropwise at 0 °C. The mixture was stirred at room temperature for 5 h, then poured into water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.15 g, 0.31 mmol, 16% yield over two steps).

[0507] LCMS: Method H1, 3.32 min, MS: ES-477.2.

[0508] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropylphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.15 g, 0.31 mmol) in DCM (5 mL) was added TFA (1.5 mL, 10 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.17 g, quantitative yield). LCMS: Method H1, 3.00 min, MS: ES+ 379.0.

[0509] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.17 g, 0.34 mmol) in THF (5 mL) was added K2CO3 (0.14 g, 1.03 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.04 g, 0.34 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide (0.08 g, 0.19 mmol, 63% yield over two steps), which was further purified by reverse-phase preparative HPLC (Method X4) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide (0.04 g, 0.11 mmol, 35% yield over two steps).

[0510] LCMS: Method H1, 2.68 min, MS: ES+404.0; 1 H NMR(400MHz,DMSO-d6)δppm:9.38(d,J=6.8Hz,1H),8.21(s,1H),7.75-7.82(m, 3H),7.38-7.39(m,2H),7.24-7.26(m,1H),4.62-4.64(m,2H),4.34-4.39(m,2H) ,3.65-3.69(m,1H),3.41-3.45(m,1H),2.19-2.23(m,1H),2.11-2.15(m,1H),1 .98-2.02(m,1H),1.02-1.07(m,2H),0.69-0.73(m,2H); Chiral SFC: Method Y12A, 4.52 minutes.

[0511] Example 9 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide [ka]

[0512] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxylate (0.5 g, 1.92 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.36 g, 1.34 mmol) in pyridine (5 mL) was added POCl (0.88 g, 0.54 mL, 5.76 mmol) dropwise at 0 °C, and the mixture was stirred at room temperature for 2 h. The mixture was then poured into ice-cold water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phases were dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.07 g, 0.14 mmol, 8% yield over two steps).

[0513] LCMS: Method H1, 3.09 min, MS: ES-502.2.

[0514] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.07 g, 0.14 mmol) in DCM (5 mL) was added TFA (0.7 mL, 10 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.09 g, quantitative yield).

[0515] LCMS: Method H1, 2.50 min, MS: ES+404.2.

[0516] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.09 g, 0.17 mmol) in THF (5 mL) was added K2CO3 (0.07 g, 0.52 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.02 g, 0.17 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (50 mL) and extracted with EtOAc (2 × 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide (0.05 g, 0.10 mmol, 75% yield over two steps), which was further purified by reverse-phase preparative HPLC (Method X3) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide (0.02 g, 0.06 mmol, 42% yield over two steps).

[0517] LCMS: Method H1, 2.92 min, MS: ES+429.2; 1 H NMR(400MHz,DMSO-d6)δppm:9.42(d,J=5.6Hz,1H),8.21(s,1H),8.18(d,J=1.2Hz,1H ),7.93(s,1H),7.85(dd,J=8.0,1.2Hz,1H),7.79(s,1H),7.40(d,J=8.0Hz,1H),4.63 -4.64(m,2H),4.36-4.39(m,2H),3.67-3.71(m,1H),3.41-3.45(m,1H),2.21-2.26(m ,2H),1.98-2.04(m,1H),1.12-1.17(m,2H),0.82-0.86(m,2H);Chiral SFC: Method Y9, 5.54 minutes.

[0518] Example 10 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide [ka]

[0519] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, 1.09 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.33 g, 1.20 mmol) in THF (5 mL) was added DIPEA (0.42 g, 0.56 mL, 3.29 mmol) and T3P (50% in EtOAc) (0.69 g, 2.19 mmol) at 0 °C. The mixture was stirred at room temperature for 3 h, then poured into ice-cold water (30 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.18 g, 0.34 mmol, 34% yield).

[0520] LCMS: Method C1, 1.38 min, MS: ES+523.3.

[0521] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.18 g, 0.34 mmol) in DCM (5 mL) was added TFA (0.9 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.2 g, quantitative yield).

[0522] LCMS: Method C1, 1.13 min, MS: ES+423.3.

[0523] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.2 g, 0.37 mmol) in MeCN:THF (6 mL, 1:1) was added K2CO3 (0.15 g, 1.11 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.04 g, 0.41 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (20 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.12 g, 0.26 mmol, 77% yield over two steps).

[0524] LCMS: Method H1, 2.79 min, MS: ES+448.0; 1 H NMR(400MHz,DMSO-d6)δppm:9.42(d,J=6.4Hz,1H),8.20(s,1H),8.00(d,J=7.2Hz,1H),7.79(s,1H),7.71(s,1H),7.61(d,J=6.0Hz,3H), 4.62-4.64(m,2H),4.36-4.39(m,2H),3.66-3.70(m,1H),3.41-3.44(m,1H),2.18-2.25(m,1H),1.97-2.03(m,1H);Chiral SFC: Method Y9, 4.77 min.

[0525] Example 11 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide [ka]

[0526] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-bromophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-bromophenyl)oxazole-2-carboxylate (1.05 g, 3.92 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.7 g, 2.62 mmol) in THF (10 mL) was added DIPEA (1.01 g, 1.38 mL, 7.86 mmol) and T3P (50% in EtOAc) (1.66 g, 5.24 mmol) dropwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 2 h, then poured into water (50 mL) and extracted with EtOAc (2 × 100 mL). The combined organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-bromophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.6 g, 1.16 mmol, 29% yield over two steps).

[0527] LCMS: Method C1, 1.26 min, MS: ES+517.1, 519.1.

[0528] Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-vinylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-bromophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.30 g, 0.58 mmol) and potassium vinyltrifluoroborate (CAS 13682-77-4, Combi-Blocks, 0.10 g, 0.75 mmol) in EtOH (9 mL) was added TEA (0.076 g, 0.1 mL, 0.75 mmol). The mixture was purged with N gas for 20 min, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.04 g, 0.06 mmol) and heating at 80 °C for 3 h. The mixture was poured into water (50 mL) and extracted with EtOAc (2 × 40 mL). The combined organic phases were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-vinylphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.25 g, 0.53 mmol, 93% yield).

[0529] LCMS: Method C1, 1.25 min, MS: ES+465.3.

[0530] Step (iii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-ethylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-vinylphenyl)-oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.25 g, 0.53 mmol) in MeOH (10 mL) was added 10% Pd / C (50% water) (0.12 g, 0.5 w / w). The mixture was purged with H gas for 1 h, then filtered through Celite Hyflow®, and the filtrate was concentrated under reduced pressure to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-ethylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.22 g, 0.47 mmol, 88%).

[0531] LCMS: Method C1, 1.44 min, MS: ES+467.4.

[0532] Step (iv) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-ethylphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.22 g, 0.47 mmol) in DCM (10 mL) was added TFA (2.2 mL, 10 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide TFA salt (0.20 g, 0.41 mmol, 88% yield).

[0533] LCMS: Method C1, 1.07 min, MS: ES+367.2.

[0534] Step (v) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide TFA salt (0.20 g, 0.41 mmol) in THF (5 mL) was added K2CO3 (0.17 g, 1.24 mmol) at room temperature, and the mixture was stirred for 10 min. Cyanogen bromide (0.05 g, 0.45 mmol) was added at 0 °C, and the mixture was stirred at room temperature for 1 h, then poured into water (20 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 100% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide (0.08 g, 0.20 mmol, 43% yield over two steps).

[0535] LCMS: Method H, 2.81 min, MS: ES+392.0; 1 H NMR(400MHz,DMSO-d6)δppm:9.35(d,J=6.4Hz,1H),8.20(s,1H),7.94(s,1H),7.79(s,1 H),7.68(s,1H),7.65(d,J=7.6Hz,1H),7.45(t,J=7.6Hz,1H),7.31(d,J=7.6Hz,1H),4. 62-4.64(m,2H),4.35-4.37(m,2H),3.63-3.72(m,1H),3.42-3.44(m,1H),2.67-2.70(m ,2H),2.18-2.25(m,1H),1.97-2.02(m,1H),1.24(t,J=7.6Hz,3H);Chiral SFC: Method Y9, 5.71 minutes.

[0536] Example 12 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyclopropylphenyl)oxazole 2-carboxamide [ka]

[0537] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyclopropylphenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-bromophenyl)-oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.18 g, 0.34 mmol) and cyclopropylboronic acid (CAS 411235-57-9, Combi-Blocks, 0.044 g, 0.52 mmol) in toluene:water (8 mL, 9:1) was added KPO (0.22 g, 1.04 mmol). The mixture was purged with N2 gas for 20 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II] (0.025 g, 0.034 mmol) and heating at 100 °C for 3 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyclopropylphenyl)-oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.1 g, 0.20 mmol, 60% yield).

[0538] LCMS: Method C1, 1.30 min, MS: ES+479.3.

[0539] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyclopropylphenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(3-cyclopropylphenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.1 g, 0.20 mmol) in DCM (2.5 mL) was added TFA (0.5 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.08 g, 0.16 mmol, 78% yield).

[0540] LCMS: Method C1, 1.06 min, MS: ES+379.2.

[0541] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyclopropylphenyl)oxazole-2-carboxamide TFA salt (0.08 g, 0.16 mmol) in THF (5 mL) was added K2CO3 (0.07 g, 0.48 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.02 g, 0.17 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 97% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide (0.02 g, 0.06 mmol, 38% yield).

[0542] LCMS: Method H1, 2.81 min, MS: ES+404.2; 1 H NMR(400MHz,DMSO-d6)δ9.34(d,J=6.4Hz,1H),8.19(s,1H),7.94(s,1H),7.78(s,1H),7.58 (d,J=7.6Hz,1H),7.51(s,1H),7.39(t,J=7.6Hz,1H),7.15(d,J=8.0Hz,1H),4.61-4.62(m, 2H),4.32-4.41(m,2H),3.62-3.7(m,1H),3.40-3.41(m,1H),2.67-2.69(m,1H),2.18-2.20 (m,1H),1.98-1.99(m,1H),0.99-1.01(m,2H),0.75-0.76(m,2H); Chiral HPLC: Method Y10, 10.27 min.

[0543] Example 13 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide [ka]

[0544] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate A stirred solution of ethyl 5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate (0.40 g, 1.16 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.31 g, 1.16 mmol) in THF (4 mL) was purged with N for 10 minutes. DBU (1.2 mL, 3 vol) was added dropwise at 0 °C. The mixture was allowed to warm to room temperature and stirred at room temperature for 4 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 × 15 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (silica gel, 78% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.08 g, 0.14 mmol, 12% yield). LCMS: Method C1, 1.32 min, MS: ES+564.3.

[0545] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.08 g, 0.14 mmol) in DCM (0.8 mL) was added TFA (0.4 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 2 hours, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.09 g, quantitative yield).

[0546] LCMS: Method C1, 1.13 min, MS: ES+464.3.

[0547] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.095 g, 0.16 mmol) in THF (1 mL) was added K2CO3 (0.068 g, 0.49 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.017 g, 0.16 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 2 hours, then poured into water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse-phase preparative HPLC (Method X8) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide (0.03 g, 0.06 mmol, 41% yield over two steps).

[0548] LCMS: Method H1, 3.01 min, MS: ES+489.2; 1 H NMR(400MHz,DMSO-d6)δ9.77(d,J=6.0Hz,1H),8.19(s,1H),7.78-7.83(m,2H), 7.57(d,J=8.0Hz,1H),7.31(d,J=8.8Hz,1H),4.62-4.64(m,2H),4.35-4.38(m,2 H),3.66-3.70(m,1H),3.41-3.45(m,1H),2.67-2.69(m,1H),2.17-2.24(m,1H), 1.97-2.04(m,1H),1.05-1.07(m,2H),0.80-0.81(m,2H); Chiral HPLC: Method Y9, 4.98 min.

[0549] Example 14 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide [ka]

[0550] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxylate (0.25 g, 0.98 mmol) and tert-butyl 2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.34 g, 1.27 mmol) in THF (5 mL) was added DIPEA (2.5 mL, 2.94 mmol) and HATU (0.74 g, 1.96 mmol) at 0 °C. The mixture was stirred at room temperature for 3 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 83.6% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide)-pyrrolidine-1-carboxylate (0.47 g, quantitative yield).

[0551] LCMS: Method C1, 1.21 min, MS: ES+505.3.

[0552] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl 2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.47 g, 0.93 mmol) in DCM (3 mL) was added TFA (2.3 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.32 g, 0.62 mmol, 87% yield over three steps).

[0553] LCMS: Method H1, 2.38 min, MS: ES+405.2.

[0554] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.31 g, 0.60 mmol) in THF (5 mL) was added K2CO3 (0.41 g, 3.04 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.07 g, 0.68 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 30 minutes, then poured into water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 82% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide (0.05 g, 0.12 mmol, 17% yield over three steps), which was further purified by reverse-phase preparative HPLC (Method X10) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide (0.01 g, 0.03 mmol, 5% yield over three steps).

[0555] LCMS: Method H1, 2.55 min, MS: ES+430.2; 1 H NMR(400MHz,DMSO-d6)δppm:9.77(s,1H),8.30(s,1H),8.20(s,1H),7.9(d,J= 8.0Hz,1H),7.78(s,1H),7.32(d,J=8.0Hz,1H),4.62-4.64(m,2H),4.33-4.44 (m,2H),3.65-3.72(s,1H),3.42-3.45(m,1H),2.77-2.9(m,1H),2.16-2.25(m ,1H),1.98-2.05(s,1H),1.16-1.17(m,2H),0.93(s,2H);Chiral SFC: Method Y4, 5.15 minutes.

[0556] Example 15 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide [ka]

[0557] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxylate (1.2 g, 4.49 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (1.43 g, 4.49 mmol) in THF (12 mL) was added TBD (0.75 g, 5.38 mmol) portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 6 h, then poured into water (50 mL) and extracted with EtOAc (2 × 60 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.13 g, 0.24 mmol, 6% yield).

[0558] LCMS: Method J1, 3.90 min, MS: ES-540.1.

[0559] Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of cyclopropanol (CAS 16545-68-9, Synthonix, 0.03 g, 0.48 mmol) in THF (1.3 mL) was added NaH (60% in oil) (0.02 g, 0.48 mmol) portionwise at 0° C. and stirred for 45 min at 0° C. A solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-fluoro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamido)pyrrolidine-1-carboxylate (0.13 g, 0.24 mmol) in THF (1.3 mL) was added dropwise at 0° C. The mixture was allowed to warm to room temperature and stirred for 6 h, then poured into ice-cold water (20 mL) and extracted with EtOAc (3×40 mL). The combined organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 40% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropoxy-5-(trifluoromethoxy)-phenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.08 g, 0.14 mmol, 57% yield).

[0560] LCMS: Method J1, 3.66 min, MS: ES+580.4.

[0561] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropoxy(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide)pyrrolidine-1-carboxylate (0.08 g, 0.13 mmol) in DCM (0.8 mL) was added TFA (0.4 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.1 g, quantitative yield).

[0562] LCMS: Method J1, 2.91 min, MS: ES+480.2.

[0563] Step (iv) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide TFA salt (0.1 g, 0.16 mmol) in THF (1 mL) was added K2CO3 (0.11 g, 0.84 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.02 g, 0.24 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (20 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 96% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide (0.02 g, 0.03 mmol, 24% yield over two steps).

[0564] LCMS: Method H1, 2.88 min, MS: ES+505.2; 1 H NMR(400MHz,DMSO-d6)δppm:9.78(d,J=4.0Hz,1H),8.20(s,1H),7.87(s,1H),7. 78(s,1H),7.73-7.76(m,1H),7.67-7.69(m,1H),4.62-4.63(m,2H),4.33-4.45(m ,2H),4.07-4.13(m,1H),3.65-3.69(m,1H),3.41-3.44(m,1H),2.18-2.21(m,1H) ,1.97-2.04(m,1H),0.86-0.88(m,2H),0.72-0.77(m,2H);Chiral SFC: Method Y21, 9.32 minutes.

[0565] Example 16 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide [ka]

[0566] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-fluorophenyl)-N-cyclopropyloxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(5-cyano-2-fluorophenyl)oxazole-2-carboxylate (0.25 g, 0.81 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.28 g, 1.22 mmol) in pyridine (2.5 mL) was added POCl (0.37 g, 0.22 mL, 2.44 mmol) dropwise at 0 °C. The mixture was stirred at room temperature for 30 min, then poured into water (30 mL) and extracted with EtOAc (2 × 30 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-fluorophenyl)-N-cyclopropyloxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.15 g, 0.28 mmol, 26% yield over two steps). LCMS: Method C1, 1.25 min, MS: ES+ 522.3.

[0567] Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of oxetan-3-ol (0.02 g, 0.38 mmol) in THF (2 mL) was added NaH (60% in oil) (0.01 g, 0.38 mmol) portionwise under a N atmosphere at 0° C. After 15 min, a THF solution (1 mL) of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-fluorophenyl)-N-cyclopropyloxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.18 g, 0.34 mmol) was added dropwise at 0° C. The mixture was stirred at room temperature for 2 h, then poured into water (20 mL) and extracted with EtOAc (2×20 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.13 g, 0.22 mmol, 75% yield).

[0568] LCMS: Method C1, 1.17 min, MS: ES+476.3 (M-100).

[0569] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.13 g, 0.22 mmol) in DCM (2 mL) was added TFA (0.65 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt (0.14 g, quantitative yield).

[0570] LCMS: Method C1, 0.99 min, MS: ES+476.2.

[0571] Step (iv) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide TFA salt (0.14 g, 0.23 mmol) in THF (2 mL) was added K2CO3 (0.09 g, 0.71 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.02 g, 0.23 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (30 mL) and extracted with EtOAc (2 × 40 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase preparative HPLC (Method X9) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide (0.01 g, 0.02 mmol, 13% yield over two steps).

[0572] LCMS: Method H1, 2.43 min, MS: ES+501.2; 1 H NMR(400MHz,DMSO-d6)δppm:8.20-8.23(m,2H),7.93(s,1H),7.87(d,J=8.8Hz,1H),7.79(s,1H) ,7.01(d,J=8.8Hz,1H),5.57-5.60(m,1H),4.99-5.03(m,2H),4.75-4.78(m,2H),4.60-4.61(m, 2H),4.40(brs,1H),4.32(brs,1H),3.76-3.80(m,1H),3.61-3.65(m,1H),3.13(brs,1H),2.50- 2.54(m,1H),2.18-2.20(m,1H),0.65-0.72(m,2H),0.54-0.57(m,2H); Chiral HPLC: Method Y21, 11.44 min.

[0573] Example 17 N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide [ka]

[0574] Step (i) tert-Butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-cyanophenyl)oxazole-2-carboxylate (0.54 g, 2.24 mmol) and tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.30 g, 1.12 mmol) in THF (6 mL) was added TBD (0.31 g, 2.24 mmol) portionwise at 0 °C. The mixture was allowed to warm to room temperature, stirred for 24 h, and heated at 70 °C for 24 h. The mixture was poured into water (100 mL) and extracted with EtOAc (4 × 100 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 3% MeOH in DCM) to give tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol, 29% yield).

[0575] LCMS: Method C, 1.62 min, MS: ES+464.5.

[0576] Step (ii) N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-(5-(3-cyanophenyl)-oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.15 g, 0.32 mmol) in DCM (3 mL) was added TFA (0.75 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol, 97% yield).

[0577] LCMS: Method C, 1.33 min, MS: ES+364.5.

[0578] Step (iii) N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.31 mmol) in THF (3 mL) was added KCO (0.13 g, 0.94 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.03 g, 0.31 mmol) was added to the reaction mixture at 0° C. The mixture was stirred at room temperature for 1 h, then poured into ice-cold water (100 mL) and the solid was filtered through a Buchner funnel and washed with n-hexane (2 × 100 mL) to give N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.07 g, 0.17 mmol, 56% yield).

[0579] LCMS: Method H, 2.47 min, MS: ES+389.1; 1H NMR(400MHz,DMSO-d6)δppm:9.40(d,J=6.4Hz,1H),8.34(s,1H),8.14(d,J=8.0 Hz,1H),8.10(s,1H),7.92(d,J=8.0Hz,1H),7.86(s,2H),7.75(t,J=8.0Hz,1H) ,4.63-4.65(m,2H),4.37-4.46(m,1H),4.26-4.35(m,1H),3.61-3.65(m,1H),3 .38-3.41(m,1H),2.17-2.25(m,1H),2.01-2.08(m,1H); Chiral SFC: Method Y12A, 3.99 minutes.

[0580] Example 18 N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide [ka]

[0581] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.31 g, 1.40 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.25 g, 0.93 mmol) in pyridine (2.5 mL) was added POCl (0.43 g, 0.27 mL, 2.81 mmol) dropwise at 0 °C, and the mixture was stirred at 0 °C for 2 h. The mixture was then poured into ice-cold water (100 mL) and extracted with DCM (4 × 100 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 2% MeOH in DCM) to give tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.06 g, 0.13 mmol, 14% yield).

[0582] LCMS: Method C, 1.531 min, MS: ES+464.4.

[0583] Step (ii) N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.06 g, 0.13 mmol) in DCM (1.2 mL) was added TFA (0.3 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.07 g, quantitative yield). LCMS: Method C, 1.316 min, MS: ES+ 364.3.

[0584] Step (iii) N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.07 g, 0.15 mmol) in THF (1.4 mL) was added K2CO3 (0.06 g, 0.44 mmol) at room temperature and stirred for 5 min. Cyanogen bromide (0.01 g, 0.15 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 h, then poured into ice-cold water (100 mL) and extracted with DCM (3 × 100 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5.6% MeOH in DCM) to give N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.01 g, 0.02 mmol, 30% yield over two steps).

[0585] LCMS: Method N, 13.05 min, MS: ES+389.2; 1 H NMR(400MHz,DMSO-d6)δppm:9.40(d,J=6.4Hz,1H),8.58(s,1H),8.34(s,1H),8.10-8.15(m,2H),8.04(s,1H),7.91-7.93(m,1H),7.74 -7.77(m,1H),4.30-4.42(m,4H),3.67-3.70(m,1H),3.40-3.43(m,1H),2.16-2.23(m,1H),1.99-2.07(m,1H);Chiral SFC: Method Y12A, 4.12 minutes.

[0586] Example 19 N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide [ka]

[0587] Step (i) tert-Butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.26 g, 0.97 mmol) and lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.25 g, 1.16 mmol) in DMF (2.6 mL) was added DIPEA (0.25 g, 0.33 mL, 1.94 mmol) and T3P (50% in EtOAc) (0.46 g, 0.92 mL, 1.45 mmol) at 0 °C. The mixture was stirred at room temperature for 15 h. The mixture was poured into water (20 mL) and extracted with EtOAc (3 × 50 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by trituration with diethyl ether (2 × 10 mL) to give tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.13 g, 0.28 mmol, 29% yield).

[0588] LCMS: Method J, 3.79 min, MS: ES+464.2.

[0589] Step (ii) N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.13 g, 0.28 mmol) in DCM (2.6 mL) was added TFA (0.65 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.13 g, 0.27 mmol, 97% yield).

[0590] LCMS: Method J, 2.81 min, MS: ES+364.0.

[0591] Step (iii) N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.13 g, 0.27 mmol) in THF (5 mL) was added K2CO3 (0.11 g, 0.81 mmol) at room temperature and stirred for 5 min. Cyanogen bromide (0.028 g, 0.27 mmol) was added to the reaction mixture at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h, then poured into water (50 mL) and extracted with DCM (4 × 100 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 8% MeOH in DCM) to give N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.04 g, 0.10 mmol, 38% yield).

[0592] LCMS: Method H, 2.14 min, MS: ES-387.1; 1 H NMR(400MHz,DMSO-d6)δppm:9.38(d,J=6.8Hz,1H),8.57(s,2H),8.34(s,1H),8.14(d,J=8.0Hz,1H),8.11(s,1H),7.92(d,J=7.6Hz,1H),7.75(t,J=8 .0Hz,1H),4.38-4.48(m,1H),4.23-4.31(m,3H),3.69-3.73(m,1H),3.40- 3.43(m,1H),2.15-2.20(m,1H),1.90-1.93(m,1H); Chiral SFC: Method Y12A, 4.3 minutes.

[0593] Example 24 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide [ka]

[0594] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolinamido)pyrrolidine-1-carboxylate To a stirred solution of 4-bromopicolinic acid (0.22 g, 1.12 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.20 g, 0.74 mmol) in DCM (6.8 mL) was added DIPEA (0.28 g, 0.37 mL, 2.24 mmol) and HATU (0.42 g, 1.12 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h, then poured into water (30 mL) and extracted with DCM (2 × 30 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 11% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolinamido)pyrrolidine-1-carboxylate (0.2 g, 0.44 mmol, 59% yield).

[0595] LCMS: Method C1, 1.18 min, MS: ES+451.1, 453.1.

[0596] Step (ii) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoromethyl)phenyl)picolinamido)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolinamido)-pyrrolidine-1-carboxylate (0.27 g, 0.59 mmol) and (3-(trifluoromethyl)phenyl)boronic acid (CAS 1423-26-3, Combi-Blocks, 0.14 g, 0.72 mmol) in toluene:water (10 mL, 1:1) was added KPO (0.38 g, 1.79 mmol). The mixture was purged with N for 15 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.04 g, 0.06 mmol) and heating at 90 °C for 1 hour. The mixture was poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 56% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoromethyl)phenyl)picolinamido)-pyrrolidine-1-carboxylate (0.27 g, 0.52 mmol, 87% yield).

[0597] LCMS: Method H1, 1.33 min, MS: ES+517.4.

[0598] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoromethyl)-phenyl)picolinamide)pyrrolidine-1-carboxylate (0.27 g, 0.52 mmol) in DCM (2.7 mL) was added TFA (1.35 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide TFA salt (0.35 g, quantitative yield).

[0599] Step (iv) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide TFA salt (0.35 g, 0.66 mmol) in THF (4 mL) was added K2CO3 (0.36 g, 2.64 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.08 g, 0.79 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1.5 hours, then poured into water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide (0.03 g, 0.06 mmol, 13% yield over two steps).

[0600] LCMS: Method H1, 2.89 min, MS: ES+442.0; 1H NMR(400MHz,DMSO-d6)δppm:9.21(d,J=6.8Hz,1H),8.76(d,J=4.8Hz,1H),8 .33(s,1H),8.18-8.21(m,3H),8.06(d,J=3.2Hz,1H),7.88-7.90(m,1H),7.7 8-7.82(m,2H),4.61-4.63(m,2H),4.35-4.40(m,2H),3.65-3.69(m,1H),3. 43-3.46(m,1H),2.23-2.33(m,1H),1.96-2.02(m,1H); Chiral SFC: Method Y9, 5.07 minutes.

[0601] Example 25 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)picolinamide [ka]

[0602] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoromethoxy)phenyl)picolinamido)-pyrrolidine-1-carboxylate To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-bromopicolinamido)-pyrrolidine-1-carboxylate (0.20 g, 0.44 mmol) and (3-(trifluoromethoxy)phenyl)boronic acid (CAS#179113-90-7, Combi-Blocks, 0.11 g, 0.53 mmol) in toluene:water (3 mL, 1:1) was added KPO (0.28 g, 1.32 mmol). The mixture was purged with N for 20 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.02 g, 0.02 mmol) and heating at 80 °C for 2 hours. The mixture was poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 60% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoromethoxy)phenyl)picolinamido)-pyrrolidine-1-carboxylate (0.15 g, 0.28 mmol, 63% yield).

[0603] LCMS: Method C1, 1.33 min, MS: ES+533.3.

[0604] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)-picolinamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3-(trifluoromethoxy)phenyl)picolinamide)pyrrolidine-1-carboxylate (0.14 g, 0.27 mmol) in DCM (1.5 mL) was added TFA (0.72 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)picolinamide TFA salt (0.17 g, quantitative yield).

[0605] LCMS: Method C1, 1.11 min, MS: ES+433.3.

[0606] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethoxy)-phenyl)picolinamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)picolinamide TFA salt (0.17 g, 0.31 mmol) in THF (6 mL) was added K2CO3 (0.17 g, 1.24 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.04 g, 0.37 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 82% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)picolinamide (0.025 g, 0.05 mmol, 20% yield over two steps).

[0607] LCMS: Method H1, 2.95 min, MS: ES+458.2; 1 H NMR(400MHz,DMSO-d6)δppm:9.19(d,J=6.8Hz,1H),8.75(d,J=4.8Hz,1H),8.29(s,1 H),8.20(s,1H),8.01(d,J=4.8Hz,1H),7.88-7.93(m,2H),7.78(s,1H),7.70(t,J=8. 0Hz,1H),7.54(d,J=7.6Hz,1H),4.61-4.63(m,2H),4.36-4.38(m,2H),3.65-3.69(m, Chiral SFC: Method Y10, 8.67 minutes.

[0608] Example 26 N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide [ka]

[0609] Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.25 g, 1.13 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.30 g, 1.13 mmol) in DMF (5 mL) was added DIPEA (0.44 g, 0.58 mL, 3.41 mmol) and HATU (0.65 g, 1.70 mmol) at 0 °C. The mixture was stirred at room temperature for 3 h, then poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 85% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.08 g, 0.18 mmol, 16% yield).

[0610] LCMS: Method C1, 1.59 min, MS: ES+463.4.

[0611] Step (ii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-cyanophenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.08 g, 0.17 mmol) in DCM (3 mL) was added TFA (0.24 mL, 3 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.09 g, quantitative yield).

[0612] LCMS: Method C1, 1.33 min, MS: ES+363.2.

[0613] Step (iii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide TFA salt (0.08 g, 0.17 mmol) in THF (3 mL) was added K2CO3 (0.07 g, 0.50 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.03 g, 0.25 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 89% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.01 g, 0.02 mmol, 15% yield over two steps).

[0614] LCMS: Method H, 2.46 min, MS: ES+388.1; 1 H NMR(400MHz,DMSO-d6)δppm:9.36(d,J=6.4Hz,1H),8.35(s,1H),8.16(d,J=7.6Hz,1H),8.10(s,1H),7.93(d,J=7.2Hz,1H),7.74-7.79(m,2H),7 .51(s,1H),6.29(s,1H),4.25-4.37(m,4H),3.62-3.66(m,1H),3.40-3. 42(m,1H),2.10-2.18(m,1H),2.00-2.04(m,1H); Chiral SFC: Method Y12A, 3.99 minutes.

[0615] Example 27 N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide [ka]

[0616] Step (i) Lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate To a stirred solution of ethyl 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, 0.99 mmol) in THF:water (3:2, 5 mL) was added lithium hydroxide monohydrate (0.08 g, 1.99 mmol) in portions at 0° C. The mixture was stirred at room temperature for 2 hours and then concentrated under reduced pressure to give lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.3 g, quantitative yield).

[0617] LCMS: Method C1, 1.15 min, MS: m / z: not supportive.

[0618] Step (ii) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.30 g, 1.07 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.29 g, 1.07 mmol) in pyridine (3 mL) was added POCl (0.49 g, 0.29 mL, 3.22 mmol) dropwise at 0 °C. The mixture was stirred at room temperature for 30 min, then poured into water (50 mL) and extracted with EtOAc (2 × 30 mL). The combined organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 55% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.14 g, 5.83 mmol, 26% yield). LCMS: Method C1, 1.36 min, MS: ES+: 522.3.

[0619] Step (iii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.14 g, 0.26 mmol) in DCM (5 mL) was added TFA (1.2 mL, 8.5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.15 g, quantitative yield). LCMS: Method C1, 1.11 min, MS: ES+ 422.3.

[0620] Step (iv) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide To a stirred solution of N-(3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.15 g, 0.35 mmol) in THF (3.0 mL) was added K2CO3 (0.14 g, 1.06 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.03 g, 0.35 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 20% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.03 g, 0.33 mmol, 21% yield over two steps).

[0621] LCMS: Method H1, 2.95 min, MS: ES+447.0; 1 H NMR(400MHz,DMSO-d6)δppm:9.30(s,1H),8.07(s,1H),7.77-7.87(m,3H),7.65-7.69(m,1H),7.46-7.49(m,2H),6.28(s, 1H),4.22-4.29(m,4H),3.61-3.65(m,1H),3.38-3.40(m,1H),2.1-2.21(m,1H),1.97-2.08(m,1H);Chiral SFC: Method Y10, 7.24 minutes.

[0622] Examples 28 and 29 N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide and N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide [ka]

[0623] Step (i) tert-Butyl (2S,4R)-2-((3-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate and tert-Butyl (2S,4R)-2-((5-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of lithium 5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.29 g, 1.03 mmol) and tert-butyl (2S,4R)-4-amino-2-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate and tert-butyl (2S,4R)-4-amino-2-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate (0.29 g, 1.03 mmol) in pyridine (0.28 mL) was added POCl (0.29 mL, 3.11 mmol) dropwise at 0 °C and stirred at 0 °C for 15 min. The mixture was poured into 100 mL of saturated NaHCO solution and extracted with EtOAc (3 × 100 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30-35% EtOAc in n-hexane) to give a mixture of tert-butyl (2S,4R)-2-((3-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)-pyrrolidine-1-carboxylate and tert-butyl (2S,4R)-2-((5-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.09 g, 0.17 mmol, 17% yield). LCMS: Method H1, 3.48 min, MS: ES+536.1 and 3.59 min, MS: ES+536.0.

[0624] Step (ii) N-((3R,5S)-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)-oxazole-2-carboxamide TFA salt and N-((3R,5S)-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)-oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl 2S,4R)-2-((3-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate and tert-butyl (2S,4R)-2-((5-methyl-1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.09 g, 0.17 mmol) in DCM (2 mL) was added TFA (0.48 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 30 minutes, and then concentrated under reduced pressure to give a mixture of N-((3R,5S)-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide and N-((3R,5S)-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.11 g, quantitative yield).

[0625] LCMS: Method C1, 1.18 min, MS: ES+436.2.

[0626] Step (iii) N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide and N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide and N-((3R,5S)-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.11 g, 0.20 mmol) in THF (3 mL) was added KCO (0.13 g, 1.00 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.03 g, 0.20 mmol) was added to the reaction mixture at 0° C. The mixture was stirred at 0° C. for 30 min, then poured into ice-cold water (100 mL) and extracted with EtOAc (3×50 mL). The combined organic phases were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a mixture of N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide and N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.04 g, 0.10 mmol, 55% yield).

[0627] The two compounds were separated by chiral preparative HPLC (Method Z1, UV spectra recorded at 287 nm λ) to give N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.02 g, 0.04 mmol, 22% yield) and N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (0.01 g, 0.03 mmol, 16% yield).

[0628] The assignment of the regioisomer corresponds to the methylene bonded to the pyrazole.1 Irradiate the part of the H NMR spectrum corresponding to the methyl group 1 This was based on nOe NMR experiments that measure the effect on parts of the 1 H NMR spectrum. N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (Example 28) LCMS: Method H1, 2.97 min, MS: ES+461.0; 1 H NMR(400MHz,DMSO-d6)δppm:9.34(d,J=6.8Hz,1H),8.09(s,1H),7.87(d,J=8.0H z,1H),7.82(s,1H),7.68(t,J=8.0Hz,1H),7.62(s,1H),7.46(d,J=8.0Hz,1H),6 .04(s,1H),4.28-4.31(m,1H),4.21-4.23(m,3H),3.62-3.66(m,1H),3.2-3.3(m ,1H),2.16(s,3H),2.08-2.13(m,1H),1.91-2.03(m,1H); Chiral HPLC: Method Y30, 7.05 min.

[0629] N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide (Example 29) LCMS: Method H1, 2.95 min MS: ES-459.0; 1H NMR(400MHz,DMSO-d6)δppm:9.36(d,J=6.8Hz,1H),8.09(s,1H),7.87(d,J=7.6Hz,1H ),7.82(s,1H),7.68(t,J=8.0Hz,1H),7.46(d,J=7.6Hz,1H),7.36(s,1H),6.04(s,1H) ),4.36-4.37(m,1H),4.26-4.31(m,1H),4.19-4.20(m,2H),3.66-3.70(m,1H),3.2-3 .3(m,1H),2.28(s,3H),2.12-2.16(m,1H),2.02-2.08(m,1H); Chiral HPLC: Method Y30, 7.65 minutes.

[0630] Example 30 N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)(3(trifluoromethyl)phenyl)oxazole-2-carboxamide [ka]

[0631] Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxylate (0.5 g, 1.75 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.46 g, 1.75 mmol) in THF (5 mL) was added DBU (1.5 mL, 3 vol) dropwise at 0 °C. The mixture was allowed to warm to room temperature and heated at 65 °C for 2 h. The mixture was poured into water (30 mL) and extracted with EtOAc (2 × 50 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 30% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.21 g, 0.41 mmol, 13% yield).

[0632] LCMS: Method J1, 3.72 min, MS: ES+506.3.

[0633] Step (ii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.21 g, 0.41 mmol) in DCM (2.1 mL) was added TFA (2.1 mL, 10 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide TFA salt (0.34 g, quantitative yield).

[0634] LCMS: Method C1, 1.08 min, MS: ES+406.3.

[0635] Step (iii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide TFA salt (0.34 g, 0.65 mmol) in THF (3.4 mL) was added K2CO3 (0.27 g, 1.96 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.08 g, 0.72 mmol) was added to the reaction mixture at 0°C. The mixture was stirred at room temperature for 1.5 hours and then poured into ice-cold water (100 mL), forming a precipitate. The solid was collected by filtration through a Buchner funnel and washed with n-hexane (3 × 20 mL) to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide (0.15 g, 0.35 mmol, 82% yield over two steps).

[0636] LCMS: Method H1, 2.87 min, MS: ES+431.0; 1 H NMR(400MHz,DMSO-d6)δppm:9.39(d,J=6.4Hz,1H),8.13-8.17(m,3H),7.79-7.82(m,3H),7.52(s,1H),6.30(s,1H), 4.29-4.32(m,4H),3.63-3.66(m,1H),3.41-3.42(m,1H),2.14-2.19(m,1H),2.01-2.05(m,1H);Chiral SFC: Method Y8, 6.27 min.

[0637] Example 34 N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide [ka]

[0638] Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl-1h-indazol-5-yl)benzamido)pyrrolidine-1-carboxylate To a stirred solution of 2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid (0.3 g, 1.11 mmol) in THF (3 mL) were added DIPEA (0.43 g, 0.58 mL, 3.33 mmol) and HATU (0.84 g, 2.22 mmol) in portions at 0 °C. After 30 min, tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.32 g, 1.22 mmol) was added at 0 °C. The mixture was slowly warmed to room temperature and stirred for 3 h, then poured into ice-cold water (15 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 70% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamido)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol, 86% yield).

[0639] LCMS: Method J1, 3.90 min, MS: ES+: 519.1.

[0640] Step (ii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol) in DCM (5 mL) was added TFA (2.5 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.83 mmol, 86% yield).

[0641] LCMS: Method J1, 2.97 min, MS: ES+419.0.

[0642] Step (iii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.83 mmol) in THF (3.5 mL) was added K2CO3 (0.46 g, 3.34 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.09 g, 0.92 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 5% MeOH in DCM) to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide (0.07 g, 0.17 mmol, 29% yield).

[0643] LCMS: Method H1, 2.58 min, MS: ES+444.2; 1 H NMR(400MHz,DMSO-d6)δppm:8.71(d,J=6.0Hz,1H),8.14(d,J=10.4Hz,2H),7.75-7.82(m,3H),7.66-7.70(m,3H),7.51(s,1H) ,6.29(s,1H),4.23-4.33(m,4H),4.09(s,3H),3.61-3.65(m,1H),3.31-3.34(m,1H),1.97-2.09(m,2H);Chiral SFC: Method Y9, 5.60 minutes.

[0644] Example 35 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide [ka]

[0645] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamido)pyrrolidine-1-carboxylate To a stirred solution of 2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzoic acid (0.3 g, 1.11 mmol) in THF (3 mL) were added DIPEA (0.43 g, 0.58 mL, 3.33 mmol) and HATU (0.84 g, 2.22 mmol) in portions at 0 °C. After 30 min, tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.32 g, 1.22 mmol) was added at 0 °C. The mixture was slowly warmed to room temperature and stirred for 3 h, then poured into ice-cold water (15 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 90% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamido)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol, 86% yield).

[0646] LCMS: Method C1, 1.20 min, MS: ES+: 520.3.

[0647] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide)pyrrolidine-1-carboxylate (0.50 g, 0.96 mmol) in DCM (5 mL) was added TFA (2.5 mL, 5 volumes) dropwise at 0° C. The mixture was warmed to room temperature, stirred for 1 hour, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.65 mmol, 86% yield).

[0648] LCMS: Method C1, 0.99 min, MS: ES+420.5.

[0649] Step (iii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide To a stirred solution of N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide TFA salt (0.35 g, 0.65 mmol) in THF (3.5 mL) was added K2CO3 (0.45 g, 3.28 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.07 g, 0.72 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 10% MeOH in DCM) to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide (0.08 g, 0.18 mmol, 21% yield).

[0650] LCMS: Method H1, 2.45 min, MS: ES+445.2; 1 H NMR(400MHz,DMSO-d6)δppm:8.79(d,J=5.2Hz,1H),8.15-8.21(m,3H),7.77-7.84(m,3H),7.68-7.72(m,3H),4.64-4.66(m,2H) ),4.31-4.42(m,2H),4.10(s,3H),3.66-3.70(m,1H),3.35(s,1H),2.09-2.19(m,1H),1.97-2.01(m,1H);Chiral SFC: Method Y9, 6.07 min.

[0651] Example 36 N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide [ka]

[0652] Step (i) tert-Butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of 3-(3-(trifluoromethoxy)phenyl)pyrrolidine TFA salt (0.5 g, 2.16 mmol) and tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.57 g, 3.16 mmol) in THF (4 mL) was added TEA (0.89 mL, 6.49 mmol) at 0° C. and stirred for 10 min. To the reaction mixture was added triphosgene (0.32 g, 1.08 mmol) in portions at 0° C. The mixture was stirred at room temperature for 5 h, then poured into water (20 mL) and extracted with DCM (3×20 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 3% MeOH in DCM) to give tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamido)pyrrolidine-1-carboxylate (0.14 g, 0.34 mmol, 13% yield).

[0653] LCMS: Method C1, 1.41 min, MS: ES+524.4.

[0654] Step (ii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide TFA salt To a stirred solution of tert-butyl (2S,4R)-2-((1H-pyrazol-1-yl)methyl)-4-(3-(3-(trifluoromethoxy)-phenyl)pyrrolidine-1-carboxamide)pyrrolidine-1-carboxylate (0.14 g, 0.34 mmol) in DCM (3 mL) was added TFA (0.73 mL, 5 vol) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 1 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide TFA salt (0.1 g, 0.22 mmol, 70% yield). LCMS: Method C1, 1.17 min, MS: ES+ 424.2.

[0655] Step (iii) N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide To a stirred solution of N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide TFA salt (0.1 g, 0.22 mmol) in THF (2 mL) was added K2CO3 (0.09 g, 0.68 mmol) at room temperature and stirred for 5 minutes. Cyanogen bromide (0.04 g, 0.34 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at room temperature for 1 hour, then poured into water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 95% EtOAc in n-hexane) to give N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide (0.04 g, 0.08 mmol, 14% yield).

[0656] LCMS: Method H1, 2.90 min, MS: ES+449.0; 1H NMR(400MHz,DMSO-d6)δppm:7.77(s,1H),7.46-7.50(m,2H),7.36(d,J=7. 2Hz,1H),7.31(s,1H),7.25(d,J=7.6Hz,1H),6.28(s,2H),4.19-4.29(m,3H ),3.97-4.05(m,1H),3.69-3.77(m,1H),3.40-3.56(m,4H),3.15-3.23(m,2 H),2.20-2.30(s,1H),1.86-2.00(m,3H); Chiral SFC: Method Y31, 15.52 min and 17.04 min.

[0657] Examples 37 and 38 SN-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (R)—N-((3R,5S-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; [ka]

[0658] The diastereomers were separated by chiral preparative HPLC (Method Z2, UV spectra recorded at 220 nm λmax) to give diastereomer 1 of the title compound as the first eluting isomer (0.008 g, 0.02 mmol, 18% yield) and diastereomer 2 of the title compound as the second eluting isomer (0.009 g, 0.02 mmol, 20% yield). The absolute configurations of diastereomer 1 and diastereomer 2 are not determined. Example 37 is designated as diastereomer 1. Example 38 is designated as diastereomer 2.

[0659] Example 37 Diastereomer 1: LCMS: Method H1, 2.88 min, MS: ES+449.2; 1H NMR(400MHz,DMSO-d6)δppm:7.77(s,1H),7.46-7.50(m,2H),7.36(d,J=8.0Hz,1H),7.30(s,1H),7.25(d,J=8.0Hz,1H),6.28(s,2H),4.19-4.29( m,3H),3.97-4.05(m,1H),3.69-3.77(m,1H),3.42-3.56(m,4H),3.15-3. 23(m,2H),2.20-2.30(s,1H),1.86-2.00(m,3H); Chiral SFC: Method Y31, 15.99 minutes.

[0660] Example 38 Diastereomer 2: LCMS: Method H1, 2.88 min, MS: ES+449.2; 1 H NMR(400MHz,DMSO-d6)δppm:7.76(d,J=4.0Hz,1H),7.46-7.50(m,2H),7.36(d,J=8.0Hz,1H),7.30(s,1H),7.25(d,J=8.0Hz,1H),6.28(s,2H),4.19-4 .29(m,3H),3.97-4.05(m,1H),3.71-3.77(m,1H),3.42-3.56(m,4H),3.14- 3.23(m,2H),2.20-2.28(s,1H),1.86-2.00(m,3H); Chiral SFC: Method Y31, 16.99 minutes.

[0661] Example 39 N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide [ka]

[0662] Step (i) tert-Butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxylate (0.50 g, 1.56 mmol) and tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-aminopyrrolidine-1-carboxylate (0.49 g, 1.87 mmol) in THF (5 mL) was added TBD (0.26 g, 1.87 mmol) portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 6 h. The mixture was poured into water (100 mL) and extracted with EtOAc (2 × 150 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 80% EtOAc in n-hexane) to give tert-butyl (2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamido)pyrrolidine-1-carboxylate (0.23 g, 0.42 mmol, 27% yield).

[0663] LCMS: Method J1, 3.99 min, MS: ES+541.0.

[0664] Step (ii) N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt To a stirred solution of tert-butyl 2S,4R)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-(5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide)pyrrolidine-1-carboxylate (0.23 g, 0.42 mmol) in DCM (5 mL) was added TFA (1.15 mL, 5 volumes) dropwise at 0° C. The mixture was allowed to warm to room temperature, stirred for 0.5 h, and then concentrated under reduced pressure to give N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)pyrrolidin-3-yl)-5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide TFA salt (0.40 g, quantitative ...

Claims

1. Compounds of formula (I): [Case 1] A tautomer thereof or a pharma- ceutically acceptable salt of said compound or tautomer, wherein (a) X 1 is N; X 2 , X 3 and X 4 is CR 6 or (b) X 1 is N; X 2 , X 3 and X 4 is N; X 2 , X 3 and X 4 Two of them are CR 6 or (c) X 1 and X 4 is CR 6 and X 2 and X 3 is N; Ring A is (i) a 5-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N and O; (ii) a 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N, O, and S; (iii) a 4-6 membered saturated or partially saturated monocyclic heterocyclyl ring containing 1 to 3 heteroatoms each independently selected from N, O and S; and (iv) selected from phenyl or naphthyl; Ring A is unsubstituted or contains 1 or 2 R 7 substituted by a substituent; Ring B is (i) phenyl or naphthyl; (ii) a 5-6 membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N, O and S; and (iii) a 9- to 10-membered bicyclic heteroaryl ring containing 1 to 4 heteroatoms each independently selected from N, O, and S. Selected from: Ring B is unsubstituted or each independently represents halo, CN, hydroxy, oxo, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, halo (C 1 ~C 6 ) alkyl, halo (C 1 ~C 6 ) alkoxy, (C 3 ~C 6 ) cycloalkyl, O(C 3 ~C 6 ) cycloalkyl, (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl, piperidinyl, NH(C 1 ~C 6 ) alkyl, N((C 1 ~C 6 ) alkyl) 2 , C(O)NH(C 1 ~C 6 ) alkyl, C(O)N((C 1 ~C 6 ) alkyl) 2 , NHC(O)(C 1 ~C 6 ) alkyl, N(C 1 ~C 6 ) alkyl) C(O)(C 1 ~C 6 ) alkyl), C(O)(C 1 ~C 6 ) alkyl, C(O)O(C 1 ~C 6 ) alkyl, CO 2 H, C.O.N.H. 2 , S.O. 2 NH (C 1 ~C 6) alkyl and SO 2 N ((C 1 ~C 6 ) alkyl) 2 substituted with 1 to 5 substituents selected from: R 1 is hydrogen, (C 1 ~C 6 ) alkyl and (C 3 ~C 6 ) cycloalkyl; R 2 and R 3 Each independently represents hydrogen, halo, (C 1 ~C 4 ) alkyl and (C 1 ~C 4 ) alkoxy; R 4 and R 5 are each independently hydrogen and (C 1 ~C 4 ) alkyl; R 6 is hydrogen or (C 1 ~C 4 ) alkyl; Each R 7 Halo, (C 1 -C 6 ) alkyl and (C 1 -C 6 ) alkoxy; wherein ring A is unsubstituted oxazolyl or oxadiazolyl, ring B is phenyl, and R 1 , R 2 , R 3 , R 4 and R 5 are each hydrogen, and X 1 , X 2 , X 3 and X 4 When two of the rings are N, ring B is meta to ring A and is CF 3 is not replaced by A compound, a tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer.

2. The compound of claim 1 having the formula (IA): [Case 2] A tautomer thereof or a pharma- ceutically acceptable salt of said compound or tautomer, wherein Z is N or CR 11 and R 8 , R 11 and R 12 are each independently hydrogen, halo, CN, hydroxy, oxo, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, halo (C 1 ~C 6 ) alkyl, halo (C 1 ~C 6 ) alkoxy, (C 3 ~C 6 ) cycloalkyl, O(C 3 ~C 6 Cycloalkyl, (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) selected from alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl and piperidinyl; R 9 and R 10 are each independently hydrogen, halo, CN, hydroxy, oxo, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, halo (C 1 ~C 6 ) alkyl, halo (C 1 ~C 6 ) alkoxy, (C 3 ~C 6 ) cycloalkyl, O(C 3 ~C 6 ) cycloalkyl, (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) selected from alkyl, oxetanyloxy, azetidinyl, pyrrolidinyl and piperidinyl; Or R 9 and R 10 are joined together to form a 5-6 membered saturated, partially saturated or aromatic ring containing 1-2 heteroatoms each independently selected from N, O and S, said ring being unsubstituted or each independently selected from halo, CN, hydroxy, oxo, (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkoxy, halo (C 1 ~C 6 ) alkyl and halo(C 1 ~C 6 ) alkoxy; provided that ring A is unsubstituted oxazolyl or oxadiazolyl, and R 1 , R 2 , R 3 , R 4 and R 5 are each hydrogen, and X 1 , X 2 , X 3 and X 4 Two of them are N and Z is CR 11 and R 11 is hydrogen or halo, R 9 is CF 3 isn't it, 10. A compound according to claim 1, a tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer.

3. Z is CR 11 3. The compound of claim 2,

4. The compound of claim 2 wherein Z is N.

5. The compound according to any one of claims 1 to 4, wherein Ring A is a 5-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N and O.

6. The compound of claim 5, wherein Ring A is selected from oxazolyl and oxadiazolyl.

7. The compound according to any one of claims 1 to 4, wherein ring A is a 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms each independently selected from N, O and S.

8. The compound of claim 7, wherein Ring A is pyridinyl.

9. The compound according to any one of claims 1 to 4, wherein Ring A is pyrrolidinyl.

10. The compound according to any one of claims 1 to 4, wherein Ring A is phenyl.

11. R 1 The compound according to any one of claims 1 to 10, wherein is selected from hydrogen, methyl and cyclopropyl.

12. R 2 , R 3 , R 4 and R 5 The compound of any one of claims 1 to 11, wherein each is hydrogen.

13. R 6 The compound according to any one of claims 1 to 12, wherein is hydrogen or methyl.

14. The compound of any one of claims 1 to 13, wherein Ring A is unsubstituted.

15. Each R 7 The compound of any one of claims 1 to 13, wherein is independently selected from fluoro, chloro, methyl and methoxy.

16. R 8 and R 11 The compound of any one of claims 1 to 15, wherein each is independently selected from hydrogen, CN and halo.

17. R 8 and R 11 17. The compound of claim 16, wherein each is hydrogen.

18. R 9is hydrogen, halo, CN, (C 1 ~C 3 ) alkyl, (C 1 ~C 3 ) alkoxy, cyclopropyl, cyclopropoxy, CF 3 , O.C.F. 3 18. The compound according to any one of claims 1 to 17, selected from: and oxetan-3-yloxy.

19. R 9 is hydrogen, chloro, CN, ethyl, cyclopropyl, CF 3 and O.C.F. 3 20. The compound of claim 18, selected from:

20. R 10 The compound according to any one of claims 1 to 19, wherein is selected from hydrogen, fluoro and CN.

21. R 10 21. The compound of claim 20, wherein is hydrogen.

22. R 9 and R 10 are taken together to form a 5-membered partially saturated or aromatic ring containing 1 to 2 heteroatoms each independently selected from N, O and S, said ring being unsubstituted or substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl and methoxy.

23. R 12 is hydrogen, halo, CN, (C 1 ~C 3 ) alkyl, (C 1 ~C 3 ) alkoxy, cyclopropyl, cyclopropoxy, CF 3 , O.C.F. 3 23. The compound according to any one of claims 1 to 22, selected from: and oxetan-3-yloxy.

24. R 12 is hydrogen, methoxy, cyclopropyl, cyclopropoxy, OCF 3and oxetan-3-yloxy.

25. N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-chlorophenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-methoxyphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-ethylphenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyclopropylphenyl)oxazole 2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(oxetan-3-yloxy)phenyl)-N-cyclopropyloxazole-2-carboxamide; N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethyl)phenyl)picolinamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-4-(3-(trifluoromethoxy)phenyl)picolinamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((3-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((5-methyl-1H-pyrazol-1-yl)methyl)pyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)(3(trifluoromethyl)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-2-fluoro-4-(1-methyl-1H-indazol-5-yl)benzamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (S)—N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; (R)—N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)pyrrolidine-1-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(4-fluoro-3-(trifluoromethoxy)phenyl)oxazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-(azetidin-1-yl)-5-cyanopyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-(pyrrolidin-1-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-chloro-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(3-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((2H-1,2,3-triazol-2-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(5-cyano-2-cyclopropylphenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,4-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-propyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((4H-1,2,4-triazol-4-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-3-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxamide; N-((3R,5S)-5-((1H-1,2,3-triazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-5-(2-cyclopropyl-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-3-carboxamide; and N-((3R,5S)-5-((1H-pyrazol-1-yl)methyl)-1-cyanopyrrolidin-3-yl)-6-(1H-indazol-4-yl)nicotinamide The compound according to claim 1, selected from A tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer.

26. 26. A compound according to any one of claims 1 to 25, a tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer, for use as a medicament.

27. 26. A compound according to any one of claims 1 to 25, a tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer, for use in the treatment or prevention of a condition involving mitochondrial dysfunction, cancer, or fibrosis.

28. 26. Use of a compound according to any one of claims 1 to 25, or a tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer, in the manufacture of a medicament for use in the treatment or prevention of a condition involving mitochondrial dysfunction, cancer, or fibrosis.

29. 26. A method of treating or preventing a condition involving mitochondrial dysfunction, cancer, or fibrosis comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1 to 25, or a tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer.

30. The conditions involving mitochondrial dysfunction include CNS disorders; neurodegenerative diseases; Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis; Huntington's disease; ischemia; stroke; dementia with Lewy bodies; frontotemporal dementia; multiple sclerosis; mitochondrial encephalomyopathy, lactic acidosis and stroke-like episode syndromes; maternally inherited diabetes and hearing loss; Leber's hereditary optic neuropathy; cancer; neuropathy, ataxia, retinitis pigmentosa - maternally inherited Leigh's syndrome; Danon disease; diabetes; diabetic nephropathy; metabolic disorders; heart failure; ischemic heart disease leading to myocardial infarction. Diseases; Psychosis, schizophrenia; Multiple sulfatase deficiency; Mucolibidosis II; Mucolibidosis III; Mucolibidosis IV; GM1-gangliosidosis; Neuronal ceroid lipofuscinosis; Alper's disease; Barth syndrome; β-oxidation deficiency; Carnitine-acyl-carnitine deficiency; Carnitine deficiency; Creatine deficiency syndrome; Coenzyme Q10 deficiency; Complex I deficiency; Complex II deficiency; Complex III deficiency; Complex IV deficiency; Complex V deficiency; COX deficiency; Chronic progressive external ophthalmoplegia syndrome; CPT I deficiency; CPT II deficiency; glutaric acidemia type II; Kearns-Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency; Leigh's disease or syndrome; Leigh's syndrome French-Canadian variant; fatal infantile cardiomyopathy; Luft's disease; medium-chain acyl-CoA dehydrogenase deficiency; myoclonic epilepsy with ragged red fibers; mitochondrial cytopathy; mitochondrial recessive ataxia syndrome; mitochondrial DNA depletion syndrome; myoneurogastrointestinal disorders and encephalopathies; Pearson's syndrome; pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG gene mutations; medium / short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; and very long-chain acyl-CoA dehydrogenase deficiency; peroxisomal disorders; methylmalonic acidemia; mevalonate kinase deficiency; age-dependent decline in cognitive function and muscle strength; muscle structural disorders; and cognitive disorders associated with neurodegenerative and neuropsychiatric disorders.

30. A compound, use or method according to any one of claims 27 to 29.

31. 31. The compound, use or method of claim 30, wherein the neurodegenerative disease is selected from Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, ischemia, stroke, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia, Parkinson's disease associated with mutations in alpha-synuclein, parkin, PINK1, GBA and LRRK2, and autosomal recessive juvenile Parkinson's disease in which parkin is mutated.

32. 31. The compound, use or method of claim 30, wherein the neurodegenerative disease is selected from Leigh syndrome or Leigh disease, X-linked Leigh disease, Leigh syndrome French Canadian variant, and / or symptoms associated with Leigh disease.

33. 30. The compound, use or method of any one of claims 27 to 29, wherein the cancer is selected from breast cancer, ovarian cancer, prostate cancer, lung cancer, kidney cancer, stomach cancer, colon cancer, testicular cancer, head and neck cancer, pancreatic cancer, brain cancer, melanoma, bone cancer liver cancer, soft tissue cancer, cancer of tissue organs, cancer of blood cells, CML, AML, mantle cell lymphoma, neuroblastoma, melanoma, soft tissue tumour, liposarcoma, fibroblastic sarcoma, leiomyosarcoma, hepatocellular carcinoma, osteosarcoma, esophageal cancer, leukemia, lymphoma, multiple myeloma, metastatic cancer, osteosarcoma, chondrosarcoma, Ewing's sarcoma, nasopharyngeal cancer, colorectal cancer, colorectal cancer, non-small cell lung cancer, cancers in which the apoptotic pathway is dysregulated, and cancers in which the BCL-2 family of proteins is mutated or over- or under-expressed.

34. 30. The compound, use or method of claims 27-29, wherein said fibrosis is selected from fibrosis or fibrotic disorders associated with accumulation of extracellular matrix components occurring following trauma, inflammation, tissue repair, immune response, cellular hyperplasia, and neotissue formation.

35. 35. The compound, use or method of claim 34, wherein the fibrosis is selected from fibrosis, fibrotic disorders associated with major organ disease, fibroproliferative disorders, and scarring associated with trauma.

36. 36. The compound, use or method of claim 35, wherein the fibrosis is selected from interstitial lung disease, liver cirrhosis, non-alcoholic fatty liver disease, fibrosis or fibrotic disorders associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, kidney disease, acute kidney injury, chronic kidney disease, delayed kidney transplant function, heart or vascular disease, eye disease, systemic and localized scleroderma, keloids, hypertrophic scars, atherosclerosis, restenosis, Dupuytren's contracture, surgical complications, chemotherapy-induced fibrosis, radiation-induced fibrosis, accidental injury and burns, retroperitoneal fibrosis, and peritoneal fibrosis / scarring.

37. 37. The compound, use or method of claim 36, wherein the fibrosis associated with an interstitial lung disease is selected from sarcoidosis, silicosis, drug reactions, infectious diseases, collagen vascular diseases, rheumatoid arthritis, systemic sclerosis, scleroderma, pulmonary fibrosis, idiopathic pulmonary fibrosis, common interstitial pneumonia, interstitial lung disease, fibrosing alveolitis of unknown etiology, bronchiolitis obliterans, and bronchiectasis.

38. 37. The compound, use or method of claim 36, wherein the renal disease is acute kidney injury or chronic kidney disease.

39. 26. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 25, a tautomer thereof, or a pharma- ceutically acceptable salt of said compound or tautomer, together with one or more pharma- ceutically acceptable excipients.

40. A compound selected from formulas (II) and (III): [C3] In the formula, PG is a protecting group; ring A, ring B, and X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 and R 5is as defined for a compound of formula (I) according to any one of claims 1 to 25, a tautomer thereof or a salt of said compound or tautomer; said protecting group is preferably selected from tert-butyloxycarbonyl, benzyloxycarbonyl, p-methoxybenzylcarbonyl, 9-fluorenylmethyloxycarbonyl, acetyl, benzoyl, benzyl, carbamate, p-methoxybenzyl, 3,4-dimethoxybenzyl, p-methoxyphenyl, tosyl, trichloroethoxycarbonyl, 4-nitrobenzenesulfonyl and 2-nitrophenylsulfenyl.

Citation Information

Patent Citations

  • 1-Cyano-pyrrolidine compounds as USP30 inhibitor

    JP2018510183A

  • Substituted cyanopyrrolidines with activity as USP30 inhibitors

    WO2020212350A1

  • Substituted cyanopyrrolidines with activity as USP30 inhibitors

    WO2020212351A1